title,url,time_published,summary,ticker,relevance_score,ticker_sentiment_score,ticker_sentiment_label
"Stocks making the biggest moves midday: Bed Bath & Beyond, Coinbase, Virgin Orbit and more",https://www.cnbc.com/2023/01/10/stocks-making-the-biggest-moves-midday-virgin-orbit-bed-bath-beyond-coinbase-and-more.html,2023-01-10 17:43:40,These are the stocks posting the largest moves midday.,REGN,0.054732,0.03388,Neutral
Check Out What Whales Are Doing With REGN - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/01/30357184/check-out-what-whales-are-doing-with-regn,2023-01-10 16:48:19,A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 15 strange trades.,REGN,0.802374,0.228994,Somewhat-Bullish
Regeneron  ( REGN )  Down on Ophthalmology Drug Eylea Sales Update,https://www.zacks.com/stock/news/2037409/regeneron-regn-down-on-ophthalmology-drug-eylea-sales-update,2023-01-10 14:46:00,Regeneron's (REGN) lead drug Eylea's sales decline in the fourth quarter due to a short-term shift to off-label use of Avastin.,REGN,0.294446,0.280652,Somewhat-Bullish
"Company News for Jan 10, 2023",https://www.zacks.com/stock/news/2037351/company-news-for-jan-10-2023,2023-01-10 14:32:00,"Companies In The News Are: REGN, LULU, DCT, BAX.",REGN,0.601928,0.0,Neutral
"Dow Jones, S&P 500 Reverse Lower; A Few Stocks Break Out But Volume Mixed",https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-new-data-shows-strong-economy-in-2023-retailers-fall-but-bed-bath-beyond-pops/,2023-01-09 21:33:00,"Dow Jones, S&P Reverse Lower As Nasdaq Pares Gains Investor's Business Daily ...",REGN,0.112008,-0.150196,Somewhat-Bearish
Check Out What Whales Are Doing With REGN - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/01/30339228/check-out-what-whales-are-doing-with-regn,2023-01-09 19:49:39,A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 30 strange trades.,REGN,0.718897,0.057628,Neutral
Dow Jones Rises; Retailers Fall But Bed Bath & Beyond Pops,https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-retailers-fall-but-bed-bath-beyond-pops/,2023-01-09 18:53:00,Dow Jones Rises. Retailers Fall But Bed Bath & Beyond Pops Investor's Business Daily ...,REGN,0.143843,-0.186162,Somewhat-Bearish
Regeneron Stock Sinks on Disappointing Sales of Eylea Vaccine,https://www.barrons.com/articles/regeneron-stock-eylea-vaccine-sales-51673283975,2023-01-09 17:07:00,"Regeneron Pharmaceuticals stock was tumbling after the medicine maker reported lower sales of its Eylea vaccine than Wall Street was anticipating for the fourth quarter. In a preliminary update on its fourth quarter on Monday, Regeneron ( REGN ) said fourth-quarter sales of Eylea were $1.5 ...",REGN,0.866386,-0.311833,Somewhat-Bearish
Regeneron Stock Sinks,https://www.investors.com/news/technology/regn-stock-sinks-as-eylea-sales-suffer/,2023-01-09 16:51:00,REGN Stock Sinks As Eylea Sales Suffer| Investor's Business Daily Investor's Business Daily ...,REGN,0.550532,-0.306757,Somewhat-Bearish
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma,https://www.globenewswire.com/news-release/2023/01/09/2585235/33333/en/Coherus-Agrees-to-Acquire-Exclusive-U-S-Commercial-Rights-to-Eylea-Biosimilar-FYB203-from-Klinge-Biopharma.html,2023-01-09 13:20:00,Additional Growth Driver Projected to Significantly Increase Mid-to-Long Term Revenue Potential Additional Growth Driver Projected to Significantly Increase Mid-to-Long Term Revenue Potential ...,REGN,0.032825,0.0,Neutral
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma - Coherus BioSciences  ( NASDAQ:CHRS ) ,https://www.benzinga.com/pressreleases/23/01/g30331669/coherus-agrees-to-acquire-exclusive-u-s-commercial-rights-to-eylea-biosimilar-fyb203-from-klinge-b,2023-01-09 13:20:00,"REDWOOD CITY, Calif., Jan. 09, 2023 ( GLOBE NEWSWIRE ) -- Coherus BioSciences, Inc. ( ( Coherus or Coherus BioSciences, NASDAQ:CHRS ) announced today that it has executed a binding term sheet with Klinge Biopharma GmbH ( Klinge Biopharma ) for the exclusive commercialization rights to FYB203, a ...",REGN,0.031992,0.0,Neutral
What This Drug News Could Mean for Sanofi Shareholders,https://www.fool.com/investing/2023/01/08/what-this-drug-news-could-mean-for-sanofis-stock/,2023-01-08 14:00:00,This star drug for Sanofi is one step closer to approval in the European Union for another chronic inflammatory disease.,REGN,0.111488,0.228907,Somewhat-Bullish
Why CytomX Therapeutics  ( CTMX )  Shares Are Soaring Today - CytomX Therapeutics  ( NASDAQ:CTMX ) ,https://www.benzinga.com/general/biotech/23/01/30310896/cytomx-shares-move-higher-on-collaborating-pact-with-this-famed-covid-19-vaccine-maker,2023-01-06 15:30:29,Moderna Inc MRNA and CytomX Therapeutics Inc CTMX announced a collaboration and licensing agreement to create mRNA-based conditionally activated therapies utilizing Moderna's mRNA technologies and CytomX's Probody therapeutic platform.,REGN,0.382925,-0.17108,Somewhat-Bearish
3 Growth Stocks That Could Rocket Higher in 2023,https://www.fool.com/investing/2023/01/06/3-growth-stocks-that-could-rocket-higher-in-2023/,2023-01-06 10:39:00,Upcoming binary events could push these stocks to new all-time highs.,REGN,0.108958,0.176285,Somewhat-Bullish
"Jim Cramer Says He's 'Still Feeling Good' About These 5 Stocks From 'Mutilated' Nasdaq - T-Mobile US  ( NASDAQ:TMUS ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/01/30305723/jim-cramer-says-hes-still-feeling-good-about-these-5-stocks-from-mutilated-nasdaq,2023-01-06 02:42:40,"Prominent market commentator Jim Cramer has recommended five stocks from the Nasdaq Index that he believes could be decent additions to investors' portfolios. ""In an index that's been folded, spindled and mutilated, I am still feeling good about a few of these stocks,"" Cramer said according to a ...",REGN,0.271274,-0.294272,Somewhat-Bearish
VERA Dips Despite Positive Data From IgA Nephropathy Study,https://www.zacks.com/stock/news/2035300/vera-dips-despite-positive-data-from-iga-nephropathy-study,2023-01-04 17:20:00,VERA posts positive top-line data from the phase IIb ORIGIN study evaluating atacicept for the treatment of IgA nephropathy.,REGN,0.287762,0.066164,Neutral
What's in Store for Regeneron Pharmaceuticals  ( REGN )  in 2023?,https://www.zacks.com/stock/news/2034721/whats-in-store-for-regeneron-pharmaceuticals-regn-in-2023,2023-01-03 17:13:00,Regeneron Pharmaceuticals (REGN) had a good run in 2022 and the momentum should continue in 2023 on the back of growth in Eylea and Dupixent.,REGN,0.221481,0.400269,Bullish
ZielBio Appoints Alan Bash CEO as Company Advances Oncology Therapeutics,https://www.prnewswire.com/news-releases/zielbio-appoints-alan-bash-ceo-as-company-advances-oncology-therapeutics-301712159.html,2023-01-03 13:00:00,ZielBio Appoints Alan Bash CEO as Company Advances Oncology ... PR ...,REGN,0.064973,-0.077664,Neutral
Should Invesco S&P 500 GARP ETF  ( SPGP )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2034288/should-invesco-sp-500-garp-etf-spgp-be-on-your-investing-radar,2023-01-02 11:20:06,Style Box ETF report for ...,REGN,0.124164,0.068777,Neutral
Futures Fall Ahead Of Housing Data,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-rise-ahead-of-housing-data-netflix-surges-on-subscriber-growth/,2023-01-20 13:56:00,"Dow Jones futures fell modestly Friday morning ahead of housing data, threatening to extend a three-day losing streak. China's markets rallied heading into their Lunar New Year break, giving a boost to global markets. Netflix ( NFLX ) stock surged more than 6% after the company's ...",REGN,0.050359,-0.062917,Neutral
"Stocks making the biggest moves premarket: Netflix, Alphabet, Nordstrom, PagerDuty and more",https://www.cnbc.com/2023/01/20/stocks-making-the-biggest-moves-premarket-netflix-alphabet-nordstrom-pagerduty-and-more.html,2023-01-20 12:43:22,These are the stocks posting the largest moves in early trading.,REGN,0.088472,0.083425,Neutral
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years,https://www.benzinga.com/news/earnings/23/01/30490765/heres-how-much-you-would-have-made-owning-regeneron-pharmaceuticals-stock-in-the-last-15-years,2023-01-19 19:33:28,"Regeneron Pharmaceuticals REGN has outperformed the market over the past 15 years by 18.8% on an annualized basis producing an average annual return of 26.24%. Currently, Regeneron Pharmaceuticals has a market capitalization of $78.59 billion.",REGN,0.980595,0.386944,Bullish
"Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence",https://www.globenewswire.com/news-release/2023/01/19/2591759/0/en/Outlook-Therapeutics-Strengthens-Medical-Affairs-and-Commercial-Expertise-with-Appointments-of-Surendra-Sharma-MD-Senior-Vice-President-of-Medical-Affairs-and-Glen-Olsheim-Executiv.html,2023-01-19 13:05:00,Dr. Sharma and Mr. Olsheim bring more than 30 years of combined experience in the global pharmaceutical and biotechnology industry from their various roles launching and commercializing ophthalmic products Dr. Sharma and Mr. Olsheim bring more than 30 years of combined experience in the global ...,REGN,0.029078,0.07201,Neutral
Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2039887/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now,2023-01-17 11:20:08,Smart Beta ETF report for ...,REGN,0.12013,0.062124,Neutral
"Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More",https://www.zacks.com/stock/news/2037977/biotech-stock-roundup-regn-down-on-eylea-data-cinc-surges-on-azn-offer-more,2023-01-11 16:10:00,Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week.,REGN,0.129052,-0.014112,Neutral
Will Eylea and Dupixent Fuel Regeneron's  ( REGN )  Q4 Earnings?,https://www.zacks.com/stock/news/2046381/will-eylea-and-dupixent-fuel-regenerons-regn-q4-earnings,2023-01-30 16:03:00,Regeneron's (REGN) fourth-quarter earnings are likely to have gotten a boost from the solid performances of Eylea and Dupixent.,REGN,0.27432,0.150979,Somewhat-Bullish
Europe Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic Esophagitis,https://www.benzinga.com/general/biotech/23/01/30621825/europe-approves-regeneron-sanofis-dupixent-for-expanded-use-in-eosinophilic-esophagitis,2023-01-30 14:04:05,The European Commission approved Regeneron Pharmaceuticals Inc REGN and Sanofi SA's SNY Dupixent ( dupilumab ) for expanded use in eosinophilic esophagitis ( EoE ) in adults and adolescents 12 years and older.,REGN,0.388879,0.30691,Somewhat-Bullish
Dupixent®  ( dupilumab )  Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis,https://www.globenewswire.com/news-release/2023/01/30/2597237/0/en/Dupixent-dupilumab-Approved-by-European-Commission-as-the-First-and-Only-Targeted-Medicine-Indicated-for-Eosinophilic-Esophagitis.html,2023-01-30 06:00:00,Approximately 60% of patients aged 12 years and older treated with Dupixent 300 mg weekly in the pivotal trial experienced histological disease remission. patients also significantly improved their ability to swallow compared to placebo ...,REGN,0.036407,0.038168,Neutral
Press Release: Dupixent®  ( dupilumab )  approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis,https://www.globenewswire.com/news-release/2023/01/30/2597236/0/en/Press-Release-Dupixent-dupilumab-approved-by-European-Commission-as-the-first-and-only-targeted-medicine-indicated-for-eosinophilic-esophagitis.html,2023-01-30 06:00:00,Dupixent® ( dupilumab ) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis ...,REGN,0.025873,0.035697,Neutral
Press Release: Dupixent®  ( dupilumab )  approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis,https://www.benzinga.com/pressreleases/23/01/g30617210/press-release-dupixent-dupilumab-approved-by-european-commission-as-the-first-and-only-targeted-me,2023-01-30 06:00:00,Dupixent® ( dupilumab ) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis Approximately 60% of patients aged 12 years and older treated with Dupixent 300 mg weekly in the pivotal trial experienced histological disease remission.,REGN,0.025325,0.035467,Neutral
"Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch",https://www.benzinga.com/news/earnings/23/01/30616031/can-market-sustain-upward-momentum-in-tech-heavy-earnings-week-apple-amazon-amd-alphabet-ford-among,2023-01-29 22:25:32,"With a full week of earnings behind us, it's time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed. Some of the big tech names that fell short are Intel Corp. INTC and Texas Instruments, Inc.",REGN,0.054114,0.0,Neutral
"Apple, Amazon earnings, jobs data and Fed decision top week ahead",https://www.foxbusiness.com/markets/apple-amazon-earnings-jobs-data-fed-decision-top-week-ahead,2023-01-29 21:12:17,Mega Cap earnings and Fed decision top week ahead Fox Business ...,REGN,0.04912,0.0,Neutral
"Investing Action Plan - January Wrap: Apple, OPEC, Exxon And The Fed",https://www.investors.com/research/investing-action-plan/stock-market-investing-action-plan-january-wrap-apple-opec-exxon-and-the-fed/,2023-01-27 23:20:00,"Investing Action Plan - January Wrap: Apple, OPEC, Exxon And ... Investor's Business Daily ...",REGN,0.032916,0.047876,Neutral
Press Release: Dupixent®  ( dupilumab )  recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis,https://www.globenewswire.com/news-release/2023/01/27/2596599/0/en/Press-Release-Dupixent-dupilumab-recommended-for-expanded-EU-approval-by-the-CHMP-to-treat-children-as-young-as-six-months-old-with-severe-atopic-dermatitis.html,2023-01-27 06:00:00,Dupixent® ( dupilumab ) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis ...,REGN,0.031529,0.044292,Neutral
Press Release: Dupixent®  ( dupilumab )  recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis,https://www.benzinga.com/pressreleases/23/01/g30598142/press-release-dupixent-dupilumab-recommended-for-expanded-eu-approval-by-the-chmp-to-treat-childre,2023-01-27 06:00:00,"Dupixent® ( dupilumab ) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis If approved, Dupixent would be the first and only targeted medicine in the EU for these young children",REGN,0.030858,0.042203,Neutral
Dupixent®  ( dupilumab )  Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis,https://www.benzinga.com/pressreleases/23/01/g30598138/dupixent-dupilumab-recommended-for-expanded-eu-approval-by-the-chmp-to-treat-children-as-young-as-,2023-01-27 05:59:00,"TARRYTOWN, N.Y. and PARIS, Jan. 27, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.",REGN,0.043011,0.046596,Neutral
Dupixent®  ( dupilumab )  Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis,https://www.globenewswire.com/news-release/2023/01/27/2596596/0/en/Dupixent-dupilumab-Recommended-for-Expanded-EU-Approval-by-the-CHMP-to-Treat-Children-as-Young-as-Six-Months-Old-with-Severe-Atopic-Dermatitis.html,2023-01-27 05:59:00,"If approved, Dupixent would be the first and only targeted medicine in the EU for these young children ...",REGN,0.041993,0.048523,Neutral
"Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition",https://www.benzinga.com/pressreleases/23/01/g30552825/top-40-high-school-scientists-selected-as-finalists-in-the-regeneron-science-talent-search-the-nat,2023-01-24 17:00:00,"Nation's Most Innovative Teens will Showcase Research with Prizes of Over $1.8 million TARRYTOWN, N.Y. and WASHINGTON, D.C., Jan. 24, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.",REGN,0.083541,0.130262,Neutral
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO,https://www.globenewswire.com/news-release/2023/01/24/2594040/0/en/Decibel-Therapeutics-Announces-Approval-of-Clinical-Trial-Application-by-the-U-K-Medicines-and-Healthcare-Products-Regulatory-Agency-for-Lead-Gene-Therapy-Candidate-DB-OTO.html,2023-01-24 12:00:00,The CTA authorization for DB-OTO provides approval for the Company to expand its planned Phase 1/2 clinical trial to the U.K. in patients two years of age and younger ...,REGN,0.036983,0.113543,Neutral
Regeneron's  ( REGN )  Eylea Gets FDA Nod for ROP in Infants,https://www.zacks.com/stock/news/2052527/regenerons-regn-eylea-gets-fda-nod-for-rop-in-infants,2023-02-09 18:35:00,Regeneron's (REGN) Eylea gets FDA approval for the treatment of preterm infants with retinopathy of prematurity (ROP).,REGN,0.144275,0.159013,Somewhat-Bullish
EYLEA®  ( aflibercept )  Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity  ( ROP )  by the FDA,https://www.globenewswire.com/news-release/2023/02/08/2604539/0/en/EYLEA-aflibercept-Injection-Approved-as-the-First-Pharmacologic-Treatment-for-Preterm-Infants-with-Retinopathy-of-Prematurity-ROP-by-the-FDA.html,2023-02-08 23:45:00,ROP is a leading cause of childhood blindness worldwide ...,REGN,0.070362,0.057686,Neutral
"Tom Gayner's Firm Buys Brookfield Asset Management, Dumps Texas Pacific Land",https://www.forbes.com/sites/gurufocus/2023/02/08/tom-gayners-firm-buys-brookfield-asset-management-dumps-texas-pacific-land/,2023-02-08 22:42:42,Markel Gayner reveals 4th-quarter portfolio ...,REGN,0.124486,0.044413,Neutral
Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Upgraded by StockNews.com to Buy,https://www.defenseworld.net/2023/02/08/regeneron-pharmaceuticals-nasdaqregn-upgraded-by-stocknews-com-to-buy.html,2023-02-07 12:00:00,Regeneron Pharmaceuticals ( NASDAQ:REGN ) Upgraded by ... Defense World ...,REGN,0.740604,0.376251,Bullish
Futures Fall: Market Rally Strong; Don't Get Complacent,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-stock-market-rally-signals-its-not-a-bear-run-what-to-do-now/,2023-02-06 00:07:00,Dow Jones Futures Fall: Stock Market Rally Signals It's No Bear Run ... Investor's Business Daily ...,REGN,0.04143,0.159731,Somewhat-Bullish
Market Rally Shows It's Not A Bear Run; Here's What To Do,https://www.investors.com/market-trend/stock-market-today/stock-market-rally-signals-its-not-a-bear-run-what-to-do-now/,2023-02-03 22:17:00,Market Rally Shows It's Not A Bear Run. Here's What To Do Investor's Business Daily ...,REGN,0.047797,0.161732,Somewhat-Bullish
"Drug, Chip Stocks Hit 52-Week Highs As One Breaks Out Of Bullish Chart Pattern",https://www.investors.com/stock-lists/new-highs/new-highs-drug-and-chip-stocks-hit-52-week-highs-break-out-on-strong-earnings-record/,2023-02-03 21:20:00,"Drug, Chip Stocks Hit 52-Week Highs As One Breaks Out Of Bullish ... Investor's Business Daily ...",REGN,0.256989,-0.031283,Neutral
"Regeneron  ( REGN )  Q4 Earnings & Sales Beat, Eylea Sales Decline",https://www.zacks.com/stock/news/2049666/regeneron-regn-q4-earnings-sales-beat-eylea-sales-decline,2023-02-03 16:35:00,"Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year.",REGN,0.156207,0.197065,Somewhat-Bullish
"Regeneron Outplays Fourth-Quarter Decline, But Sanofi Topples",https://www.investors.com/news/technology/regeneron-stock-regeneron-earnings-sny-stock-sanofi-earnings-q4-2022/,2023-02-03 14:02:00,"Regeneron Stock Outplays Fourth-Quarter Decline, But SNY Stock ... Investor's Business Daily ...",REGN,0.310843,-0.331362,Somewhat-Bearish
Regeneron Pharmaceuticals Q4 Earnings: Revenue Falls As COVID-19-Related Sales Dwindle - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/general/biotech/23/02/30705910/regeneron-pharmaceuticals-q4-earnings-revenue-falls-as-covid-19-related-sales-dwindle,2023-02-03 13:33:27,"Regeneron Pharmaceuticals Inc REGN earned $12.56 per share for Q4 FY22, down 46% Y/Y, beating the $10.03 Street estimate. Revenues decreased 31% Y/Y to $3.41 billion; excluding REGEN-COV and Ronapreve, revenues increased 14%, slightly ahead of the analyst consensus of $3.13 billion.",REGN,0.498188,0.148495,Neutral
"Regeneron's Earnings Beat Forecasts, With No Sales of Covid-19 Treatment",https://www.barrons.com/articles/regeneron-stock-earnings-covid-19-antibody-51675430047,2023-02-03 13:15:00,"Regeneron Pharmaceuticals delivered higher fourth-quarter profit and sales than expected, though it made no sales of its Covid-19 antibody cocktail. The pharmaceuticals company reported adjusted earnings of $12.56 per share for the quarter that ended in December, while analysts tracked by FactSet ...",REGN,0.546745,0.105954,Neutral
"Nasdaq Futures Deflate As Apple Leads Tech Disappointments - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",https://www.benzinga.com/news/earnings/23/02/30704099/nasdaq-futures-deflate-as-apple-leads-tech-disappointments-traders-look-to-jobs-data-for-mitigating,2023-02-03 12:00:04,"Trading in the U.S. index futures suggests stocks may end a solidly positive week on a negative note. That said, the data-dependency of the Fed places the onus of providing trading cues to each incoming economic data.",REGN,0.101582,0.0,Neutral
Regeneron quarterly profit plunges as COVID drug sales dry up,https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-quarterly-profit-drops-46-2023-02-03/,2023-02-03 11:51:00,"Feb 3 ( Reuters ) - Regeneron Pharmaceuticals Inc ( REGN.O ) reported an about 46% plunge in its fourth-quarter profit on Friday, hurt by a drop in U.S. sales of its blockbuster eye drug, Eylea, and drying up of its COVID-19 antibody cocktail sales.",REGN,0.245339,0.055013,Neutral
Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results,https://www.globenewswire.com/news-release/2023/02/03/2601193/0/en/Regeneron-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-and-Operating-Results.html,2023-02-03 11:30:00,"TARRYTOWN, N.Y., Feb. 03, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced financial results for the fourth quarter and full year 2022 and provided a business update.",REGN,0.032946,0.049912,Neutral
Why Regeneron  ( REGN )  Might Surprise This Earnings Season,https://www.zacks.com/stock/news/2048263/why-regeneron-regn-might-surprise-this-earnings-season,2023-02-02 13:32:00,Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.,REGN,0.812724,0.583932,Bullish
Time to Buy Cigna or Regeneron Stock Before Earnings?,https://www.zacks.com/commentary/2048006/time-to-buy-cigna-or-regeneron-stock-before-earnings,2023-02-02 00:00:00,"Among the Finance and Medical sector, Cigna (CI) and Regeneron Pharmaceuticals (REGN) are both leaders in their respective industries and have had strong performances over the last year as the broader market and economy declined.",REGN,0.113062,0.128573,Neutral
"$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today",https://www.benzinga.com/news/earnings/23/02/30669060/1000-invested-in-this-stock-5-years-ago-would-be-worth-2-300-today,2023-02-01 15:04:18,"Regeneron Pharmaceuticals REGN has outperformed the market over the past 5 years by 8.86% on an annualized basis producing an average annual return of 17.41%. Currently, Regeneron Pharmaceuticals has a market capitalization of $82.31 billion.",REGN,0.980595,0.386944,Bullish
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS,https://investingnews.com/amgen-reports-fourth-quarter-and-full-year-2022-financial-results/,2023-01-31 21:29:41,Amgen ( NASDAQ: AMGN ) today announced financial results for the fourth quarter and full year 2022 versus comparable periods in 2021.,REGN,0.014384,0.0,Neutral
"February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More",https://www.benzinga.com/general/biotech/23/01/30648889/february-pdufa-catalysts-biotech-investors-must-know-sanofis-bleeding-disorder-drug-regenerons-tw,2023-01-31 19:33:01,"The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new molecular entities for the year. NME approvals assume importance as the metric is an indicator of ...",REGN,0.067727,0.051103,Neutral
Ophthalmic Disease Therapeutics Market Exhibits 6.4% CAGR and to Hit USD 54.87 billion by 2030,https://www.benzinga.com/pressreleases/23/02/g30956403/ophthalmic-disease-therapeutics-market-exhibits-6-4-cagr-and-to-hit-usd-54-87-billion-by-2030,2023-02-17 09:02:28,"Pune, India, Feb. 17, 2023 ( GLOBE NEWSWIRE ) -- The global Ophthalmic Disease Therapeutics Market size was valued at USD 33.56 billion in 2022 and is projected to reach a valuation of USD 35.57 billion in 2023. The market is expected to reach USD 54.87 billion by 2030 with a CAGR of 6.4% during ...",REGN,0.099752,0.062523,Neutral
4 Healthcare Mutual Funds to Buy in the Post-Pandemic Period,https://www.zacks.com/stock/news/2054428/4-healthcare-mutual-funds-to-buy-in-the-post-pandemic-period,2023-02-15 10:34:00,"FBTIX, PHSYX, JNGLX and VGHCX are four healthcare mutual funds that can lend solidity to one's portfolio today and provide big returns in the foreseeable future.",REGN,0.050572,0.064481,Neutral
Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Stock Rating Lowered by StockNews.com,https://www.defenseworld.net/2023/02/15/regeneron-pharmaceuticals-nasdaqregn-stock-rating-lowered-by-stocknews-com.html,2023-02-15 08:22:44,Regeneron Pharmaceuticals ( NASDAQ:REGN ) Stock Rating ... Defense World ...,REGN,0.806045,0.490756,Bullish
"Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Cut to ""Hold"" at StockNews.com",https://www.etfdailynews.com/2023/02/15/regeneron-pharmaceuticals-nasdaqregn-cut-to-hold-at-stocknews-com/,2023-02-15 08:22:44,"Regeneron Pharmaceuticals ( NASDAQ:REGN ) Cut to ""Hold"" at ... ETF Daily News ...",REGN,0.763021,0.322298,Somewhat-Bullish
2 Biotech Stocks That Could Help Set You Up for Life,https://www.fool.com/investing/2023/02/11/2-biotech-stocks-that-could-help-set-up-for-life/,2023-02-11 18:13:00,The two companies have seen similar share growth over the past year.,REGN,0.098054,0.200652,Somewhat-Bullish
"New Data Shows Roche's Vabysmo Improves Vision, Retinal Fluid In Retinal Disorder - Roche Holding  ( OTC:RHHBF ) , Roche Holding  ( OTC:RHHVF ) , Roche Holding  ( OTC:RHHBY ) ",https://www.benzinga.com/general/biotech/23/02/30855683/new-data-shows-roches-vabysmo-improves-vision-retinal-fluid-in-retinal-disorder,2023-02-10 15:26:29,"Roche Holdings AG RHHBY announced new data from two global phase 3 studies, BALATON and COMINO, evaluating Vabysmo ( faricimab ) in macular edema due to branch and central retinal vein occlusion ( BRVO and CRVO ) at 24 weeks.",REGN,0.350564,0.443066,Bullish
"Biotech Stock Roundup: MRNA Q4 Earnings, REGN's Updates, CYTK Receives Setback",https://www.zacks.com/stock/news/2060596/biotech-stock-roundup-mrna-q4-earnings-regns-updates-cytk-receives-setback,2023-03-01 17:24:00,Earnings from Moderna (BIIB) and updates from Regeneron (REGN) are the key highlights from the biotech sector during the past week.,REGN,0.116631,-0.001182,Neutral
"FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Sanofi  ( NASDAQ:SNY ) ",https://www.benzinga.com/general/biotech/23/03/31123522/fda-approves-regeneron-sanofis-sarilumab-as-first-biologic-for-stiffness-pain-in-muscles,2023-03-01 15:28:34,"The FDA approved Regeneron Pharmaceuticals Inc's REGN and Sanofi SA's SNY Kevzara ( sarilumab ) for polymyalgia rheumatica ( PMR ) , an inflammatory rheumatic disease, The approval covers adult patients who have had an inadequate response to corticosteroids or cannot tolerate ...",REGN,0.550532,0.127877,Neutral
Kevzara®  ( sarilumab )  Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/02/g31109773/kevzara-sarilumab-approved-by-fda-as-first-and-only-biologic-indicated-for-patients-with-polymyalg,2023-03-01 01:00:00,"TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Feb. 28, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN and Sanofi today announced that the U.S.",REGN,0.052977,0.039999,Neutral
Kevzara®  ( sarilumab )  Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica,https://www.globenewswire.com/news-release/2023/03/01/2617778/0/en/Kevzara-sarilumab-Approved-by-FDA-as-First-and-Only-Biologic-Indicated-for-Patients-with-Polymyalgia-Rheumatica.html,2023-03-01 01:00:00,Three times more patients treated with Kevzara achieved sustained remission compared to placebo in Phase 3 trial ...,REGN,0.046028,0.041818,Neutral
Get Ready For The Holy Grail In Cancer Treatment,https://www.investors.com/news/technology/moderna-stock-may-usher-in-new-cancer-vaccines-whats-in-it-for-biotech-stocks/,2023-02-24 16:57:00,Moderna Stock May Usher In A New Generation Of Cancer Vaccines ... Investor's Business Daily ...,REGN,0.032056,-0.218111,Somewhat-Bearish
"Intellia's  ( NTLA )  Q4 Loss Matches Estimates, Revenues Up Y/Y",https://www.zacks.com/stock/news/2058858/intellias-ntla-q4-loss-matches-estimates-revenues-up-yy,2023-02-24 16:36:00,"Intellia Therapeutics (NTLA) reports loss for fourth-quarter 2022, in line with estimates.",REGN,0.128822,0.171105,Somewhat-Bullish
StockNews.com has raised its rating on Regeneron Pharmaceuticals  ( NASDAQ:REGN ) .,https://beststocks.com/stocknews-com-has-raised-its-rating-on-regeneron-p/,2023-02-24 15:20:14,StockNews.com has raised its rating on Regeneron ... Best Stocks ...,REGN,0.681957,0.275303,Somewhat-Bullish
Libtayo®  ( cemiplimab )  in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer  ( NSCLC ) ,https://www.globenewswire.com/news-release/2023/02/24/2615182/0/en/Libtayo-cemiplimab-in-Combination-with-Chemotherapy-Receives-Positive-CHMP-Opinion-for-the-Treatment-of-Advanced-PD-L1-Positive-Non-small-Cell-Lung-Cancer-NSCLC.html,2023-02-24 12:45:00,Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy alone Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy alone ...,REGN,0.044949,0.031826,Neutral
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress,https://www.globenewswire.com/news-release/2023/02/23/2614167/0/en/Intellia-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Highlights-Recent-Company-Progress.html,2023-02-23 12:30:00,"CAMBRIDGE, Mass., Feb. 23, 2023 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial ...",REGN,0.040923,0.04723,Neutral
Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/02/g31024435/aflibercept-8-mg-bla-for-treatment-of-wet-age-related-macular-degeneration-and-diabetic-macular-ed,2023-02-23 12:00:00,"BLA supported by two pivotal trials demonstrating non-inferior vision gains to EYLEA® ( aflibercept ) Injection, with vast majority of patients maintaining extended dosing regimens through 48 weeks TARRYTOWN, N.Y., Feb. 23, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.",REGN,0.080819,-0.011405,Neutral
Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Stock Rating Upgraded by StockNews.com,https://www.defenseworld.net/2023/02/23/regeneron-pharmaceuticals-nasdaqregn-stock-rating-upgraded-by-stocknews-com.html,2023-02-23 08:54:42,Regeneron Pharmaceuticals ( NASDAQ:REGN ) Stock Rating ... Defense World ...,REGN,0.726989,0.329292,Somewhat-Bullish
"$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/news/earnings/23/02/31012424/1000-invested-in-this-stock-5-years-ago-would-be-worth-2-300-today,2023-02-22 18:04:22,"Regeneron Pharmaceuticals REGN has outperformed the market over the past 5 years by 10.76% on an annualized basis producing an average annual return of 18.62%. Currently, Regeneron Pharmaceuticals has a market capitalization of $82.40 billion.",REGN,0.980595,0.386944,Bullish
"Biotech Rivals Apellis, Iveric Diverge - Why One Soared As The Other Toppled",https://www.investors.com/news/technology/apls-stock-rockets-after-winning-a-first-ever-approval-in-geographic-atrophy/,2023-02-21 16:53:00,APLS Stock Rockets After Winning A First-Ever Approval In ... Investor's Business Daily ...,REGN,0.117774,0.0,Neutral
Regeneron  ( REGN )  Rare Disease Drug Gets FDA's Priority Review,https://www.zacks.com/stock/news/2056975/regeneron-regn-rare-disease-drug-gets-fdas-priority-review,2023-02-21 16:36:00,Regeneron's (REGN) application seeking approval of pozelimab for the ultra-rare hereditary immune disease CHAPLE gets Priority Review by the FDA.,REGN,0.171485,0.070352,Neutral
Pozelimab  ( C5 Antibody )  BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/02/g30982945/pozelimab-c5-antibody-bla-for-treatment-of-children-and-adults-with-ultra-rare-chaple-disease-acce,2023-02-21 12:00:00,"TARRYTOWN, N.Y., Feb. 21, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced the U.S.",REGN,0.069194,-0.017247,Neutral
Pozelimab  ( C5 Antibody )  BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review,https://www.globenewswire.com/news-release/2023/02/21/2611922/0/en/Pozelimab-C5-Antibody-BLA-for-Treatment-of-Children-and-Adults-with-Ultra-rare-CHAPLE-Disease-Accepted-for-FDA-Priority-Review.html,2023-02-21 12:00:00,"If approved, pozelimab would be the first and only treatment for those living with CHAPLE ...",REGN,0.057674,0.04803,Neutral
5 Best ETFs Tracking CRISPR Gene Editing,https://www.fool.com/investing/stock-market/market-sectors/healthcare/genomics-stocks/crispr-etfs/,2023-03-10 20:45:33,These exchange-traded funds track companies in this biotech space.,REGN,0.087503,0.136786,Neutral
"Top Analyst Reports for NVIDIA, McDonald's & Intuit",https://www.zacks.com/research-daily/2064075/top-analyst-reports-for-nvidia-mcdonalds-intuit,2023-03-10 18:09:00,"Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), McDonald's Corporation (MCD) and Intuit Inc. (INTU).",REGN,0.132368,0.151858,Somewhat-Bullish
"Top Analyst Reports for NVIDIA, McDonald's & Intuit",https://www.zacks.com/research-daily/2064075/top-analyst-reports-for-nvidia-mcdonalds-intuit,2023-03-10 17:09:00,"Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), McDonald's Corporation (MCD) and Intuit Inc. (INTU).",REGN,0.132368,0.15183,Somewhat-Bullish
Anti-Viral Therapies Market Growth  ( $82.92 Billion by 2028 )  Driven by Branded Drugs Segment during  ( 2022-2028 )  - Global Report by The Insight Partners,https://www.benzinga.com/pressreleases/23/03/g31276388/anti-viral-therapies-market-growth-82-92-billion-by-2028-driven-by-branded-drugs-segment-during-20,2023-03-09 13:46:17,"New York, March 09, 2023 ( GLOBE NEWSWIRE ) -- According to The Insight Partners, ""Anti-Viral Therapies Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global Analysis by Type ( Generic Drugs and Branded Drugs ) , Mechanism of Action ( Nucleotide Polymerase ...",REGN,0.02493,-0.003819,Neutral
2 Biotech Stocks You Can Buy and Hold for the Next Decade,https://www.fool.com/investing/2023/03/09/2-biotech-stocks-you-can-buy-and-hold-for-the-next/,2023-03-09 13:30:00,Regeneron and Sarepta Therapeutics have been on fire so far this year.,REGN,0.112269,0.0,Neutral
2 Cathie Wood Stocks That Have Tripled Since the 2020 Market Crash,https://www.fool.com/investing/2023/03/09/2-cathie-wood-stocks-that-tripled-since-2020-crash/,2023-03-09 12:45:00,Are these stocks still good buys today?,REGN,0.066784,0.08449,Neutral
How Is The Market Feeling About Regeneron Pharmaceuticals? - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/short-sellers/23/03/31239936/how-is-the-market-feeling-about-regeneron-pharmaceuticals,2023-03-07 15:15:25,"Regeneron Pharmaceuticals's REGN short percent of float has fallen 8.45% since its last report. The company recently reported that it has 1.34 million shares sold short, which is 1.3% of all regular shares that are available for trading.",REGN,0.221819,0.083071,Neutral
Press Release: Dupixent®  ( dupilumab )  application for treatment of chronic spontaneous urticaria  ( CSU )  in adults and adolescents accepted for FDA review,https://www.globenewswire.com/news-release/2023/03/07/2621670/0/en/Press-Release-Dupixent-dupilumab-application-for-treatment-of-chronic-spontaneous-urticaria-CSU-in-adults-and-adolescents-accepted-for-FDA-review.html,2023-03-07 06:00:00,Dupixent® ( dupilumab ) application for treatment of chronic spontaneous urticaria ( CSU ) in adults and adolescents accepted for FDA review ...,REGN,0.03319,0.039704,Neutral
Dupixent®  ( dupilumab )  Application for Treatment of Chronic Spontaneous Urticaria  ( CSU )  in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/03/g31230817/dupixent-dupilumab-application-for-treatment-of-chronic-spontaneous-urticaria-csu-in-adults-and-ad,2023-03-07 06:00:00,"TARRYTOWN, N.Y. and PARIS, March 07, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN and Sanofi today announced that the U.S.",REGN,0.032676,0.045198,Neutral
Dupixent®  ( dupilumab )  Application for Treatment of Chronic Spontaneous Urticaria  ( CSU )  in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review,https://www.globenewswire.com/news-release/2023/03/07/2621674/0/en/Dupixent-dupilumab-Application-for-Treatment-of-Chronic-Spontaneous-Urticaria-CSU-in-Adults-and-Adolescents-Aged-12-Years-and-Older-Accepted-for-FDA-Review.html,2023-03-07 06:00:00,"More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines ...",REGN,0.032617,0.048158,Neutral
Press Release: Dupixent®  ( dupilumab )  application for treatment of chronic spontaneous urticaria  ( CSU )  in adults and adolescents accepted for FDA review - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/03/g31230818/press-release-dupixent-dupilumab-application-for-treatment-of-chronic-spontaneous-urticaria-csu-in,2023-03-07 06:00:00,"Dupixent® ( dupilumab ) application for treatment of chronic spontaneous urticaria ( CSU ) in adults and adolescents accepted for FDA review More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines Paris and Tarrytown, N.Y. March 7, 2023.",REGN,0.032338,0.037598,Neutral
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 5 Years - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/news/earnings/23/03/31217002/heres-how-much-you-would-have-made-owning-regeneron-pharmaceuticals-stock-in-the-last-5-years,2023-03-06 14:00:40,"Regeneron Pharmaceuticals REGN has outperformed the market over the past 5 years by 10.14% on an annualized basis producing an average annual return of 17.93%. Currently, Regeneron Pharmaceuticals has a market capitalization of $85.20 billion.",REGN,0.980595,0.386944,Bullish
Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA Approval,https://www.fool.com/investing/2023/03/06/sanofi-could-be-on-a-roll-with-a-strong-performanc/,2023-03-06 12:05:00,The French drug company got the nod for a hemophilia treatment.,REGN,0.091335,0.121585,Neutral
Press Release: Dupixent®  ( dupilumab )  approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis,https://www.globenewswire.com/news-release/2023/03/21/2630956/0/en/Press-Release-Dupixent-dupilumab-approved-by-European-Commission-as-first-and-only-targeted-medicine-for-children-as-young-as-six-months-old-with-severe-atopic-dermatitis.html,2023-03-21 06:00:00,Dupixent® ( dupilumab ) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis ...,REGN,0.025831,0.031993,Neutral
Press Release: Dupixent®  ( dupilumab )  approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/03/g31431265/press-release-dupixent-dupilumab-approved-by-european-commission-as-first-and-only-targeted-medici,2023-03-21 06:00:00,Dupixent® ( dupilumab ) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis,REGN,0.025352,0.0318,Neutral
Dupixent®  ( dupilumab )  Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/03/g31431264/dupixent-dupilumab-approved-by-european-commission-as-first-and-only-targeted-medicine-for-childre,2023-03-21 05:59:00,"Dupixent is now a treatment option for the approximately 80,000 infants and young children living with uncontrolled severe atopic dermatitis in Europe TARRYTOWN, N.Y. and PARIS, March 21, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.",REGN,0.037213,0.037233,Neutral
Dupixent®  ( dupilumab )  Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis,https://www.globenewswire.com/news-release/2023/03/21/2630953/0/en/Dupixent-dupilumab-Approved-by-European-Commission-as-First-and-Only-Targeted-Medicine-for-Children-as-Young-as-Six-Months-Old-with-Severe-Atopic-Dermatitis.html,2023-03-21 05:59:00,Approximately seven times as many patients aged 6 months to 5 years with severe atopic dermatitis treated with Dupixent experienced clear or almost clear skin and reduced overall disease severity compared to placebo ...,REGN,0.036351,0.038167,Neutral
Dupixent®  ( dupilumab )  Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis,https://www.globenewswire.com/news-release/2023/03/18/2629820/0/en/Dupixent-dupilumab-Late-Breaking-Data-at-AAD-Show-Significant-Improvements-in-Signs-and-Symptoms-of-Moderate-to-severe-Atopic-Hand-and-Foot-Dermatitis.html,2023-03-18 14:00:00,More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks ...,REGN,0.039112,0.041354,Neutral
Press Release: Dupixent®  ( dupilumab )  late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis,https://www.globenewswire.com/news-release/2023/03/18/2629819/0/en/Press-Release-Dupixent-dupilumab-late-breaking-data-at-AAD-show-significant-improvements-in-signs-and-symptoms-of-moderate-to-severe-atopic-hand-and-foot-dermatitis.html,2023-03-18 14:00:00,Dupixent® ( dupilumab ) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis ...,REGN,0.02849,0.039026,Neutral
Press Release: Dupixent®  ( dupilumab )  late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/03/g31409769/press-release-dupixent-dupilumab-late-breaking-data-at-aad-show-significant-improvements-in-signs-,2023-03-18 14:00:00,Dupixent® ( dupilumab ) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks,REGN,0.028039,0.037939,Neutral
Regeneron  ( REGN )  Gains 9.3% in a Year: Will the Uptrend Last?,https://www.zacks.com/stock/news/2067509/regeneron-regn-gains-93-in-a-year-will-the-uptrend-last,2023-03-17 16:17:00,"Regeneron (REGN) has had a good run in the past 12 months and the momentum should continue in 2023 on the back of growth in Dupixent, as Eylea faces challenges.",REGN,0.2872,0.131802,Neutral
Two Biotech Stocks Hit In Medicare Negotiation Crossfire,https://www.investors.com/research/ibd-industry-themes/regn-stock-halo-stock-tumble-on-cms-negotiation-confusion/,2023-03-17 14:50:45,"REGN Stock, HALO Stock Tumble On CMS Negotiation Confusion ... Investor's Business Daily ...",REGN,0.426567,-0.072737,Neutral
2 Biotech Stocks To Watch In March 2022,https://stockmarket.com/featured/2-biotech-stocks-to-watch-in-march-2022-2023-03-16,2023-03-16 21:52:41,"The biotech industry is a rapidly growing sector. The sector focuses on the development and commercialization of novel therapies, drugs, and medical technologies. Biotech companies often utilize advanced scientific techniques. These include techniques such as gene editing and immunotherapy.",REGN,0.398781,0.296377,Somewhat-Bullish
2 Biotech Stocks To Watch In March 2023,https://stockmarket.com/featured/2-biotech-stocks-to-watch-in-march-2023-2023-03-16,2023-03-16 21:52:41,"The biotech industry is a rapidly growing sector. The sector focuses on the development and commercialization of novel therapies, drugs, and medical technologies. Biotech companies often utilize advanced scientific techniques. These include techniques such as gene editing and immunotherapy.",REGN,0.398781,0.296377,Somewhat-Bullish
Dow Jones Rises Even As Fed's Pivot Remains Uncertain; Health Care Stocks Fall On New Medicare Plan,https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-even-as-fed-powells-pivot-remains-uncertain-health-care-stocks-fall-on-new-medicare-plan-news/,2023-03-16 17:56:06,Dow Jones Rises Even As Fed's Pivot Remains Uncertain. Health ... Investor's Business Daily ...,REGN,0.108466,-0.121041,Neutral
Two Biotech Stocks Hit In Medicare Negotiation Crossfire,https://www.investors.com/news/technology/regn-stock-halo-stock-tumble-on-cms-negotiation-confusion/,2023-03-16 16:05:45,"REGN Stock, HALO Stock Tumble On CMS Negotiation Confusion Investor's Business Daily ...",REGN,0.442522,-0.077151,Neutral
"$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,200 Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/news/earnings/23/03/31383718/1000-invested-in-this-stock-5-years-ago-would-be-worth-2-200-today,2023-03-16 16:00:40,"Regeneron Pharmaceuticals REGN has outperformed the market over the past 5 years by 9.56% on an annualized basis producing an average annual return of 17.3%. Currently, Regeneron Pharmaceuticals has a market capitalization of $81.07 billion.",REGN,0.980595,0.386944,Bullish
"Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease",https://www.globenewswire.com/news-release/2023/03/15/2627323/0/en/Students-Win-More-Than-1-8-Million-at-2023-Regeneron-Science-Talent-Search-for-Remarkable-Scientific-Research-on-RNA-Molecule-Structure-Media-Bias-and-Diagnostics-for-Pediatric-Hea.html,2023-03-15 01:30:00,"$250,000 top award goes to Neel Moudgal in the nation's oldest and most prestigious science and math competition for high school seniors $250,000 top award goes to Neel Moudgal in the nation's oldest and most prestigious science and math competition for high school seniors ...",REGN,0.072876,0.102028,Neutral
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/03/31348658/looking-at-regeneron-pharmaceuticalss-recent-unusual-options-activity,2023-03-14 19:45:59,"Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...",REGN,0.832645,0.219471,Somewhat-Bullish
Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?,https://www.zacks.com/stock/news/2065154/should-you-invest-in-the-ishares-biotechnology-etf-ibb,2023-03-14 10:20:11,Sector ETF report for ...,REGN,0.135347,0.071708,Neutral
"Dow Jones Rises With Gold, Bitcoin Amid Bank Sell-Off; Analysts See Rate Freeze In March",https://www.investors.com/market-trend/stock-market-today/dow-jones-falls-as-gold-bitcoin-rise-amidst-bank-run-fears-analysts-see-rate-hike-pause-as-banks-crater/,2023-03-13 17:10:31,"Dow Jones Rises With Gold, Bitcoin Amid Bank Sell-Off. Analysts ... Investor's Business Daily ...",REGN,0.109705,0.110602,Neutral
"The Zacks Analyst Blog Highlights NVIDIA, McDonald's, Intuit, AT&T and Regeneron Pharmaceuticals",https://www.zacks.com/stock/news/2064866/the-zacks-analyst-blog-highlights-nvidia-mcdonalds-intuit-att-and-regeneron-pharmaceuticals,2023-03-13 14:57:00,"NVIDIA, McDonald's, Intuit, AT&T and Regeneron Pharmaceuticals are part of the Zacks top Analyst ...",REGN,0.733479,0.0,Neutral
"NVIDIA To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday - Braze  ( NASDAQ:BRZE ) , Conagra Brands  ( NYSE:CAG ) ",https://www.benzinga.com/news/23/03/31607802/nvidia-to-rally-around-18-here-are-10-other-analyst-forecasts-for-friday,2023-03-31 12:44:20,"Benchmark cut the price target for CuriosityStream Inc. CURI from $8 to $4. Benchmark analyst Daniel Kurnos maintained a Buy rating. CuriosityStream shares dropped 22.5% to $1.24 in pre-market trading. Morgan Stanley lowered the price target for Hudson Pacific Properties, Inc. HPP from $10 to $6.",REGN,0.283323,-0.079611,Neutral
"Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback",https://www.zacks.com/stock/news/2072025/biotech-stock-roundup-vktx-bmea-itci-soar-on-study-data-incy-faces-setback,2023-03-29 15:24:00,Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector.,REGN,0.0686,0.0385,Neutral
Libtayo®  ( cemiplimab )  in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer  ( NSCLC )  - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/03/g31544436/libtayo-cemiplimab-in-combination-with-chemotherapy-approved-by-european-commission-for-the-first-,2023-03-29 11:00:00,"TARRYTOWN, N.Y., March 29, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced that the European Commission ( EC ) approved Libtayo® ( cemiplimab ) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small ...",REGN,0.042876,-0.121701,Neutral
Libtayo®  ( cemiplimab )  in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer  ( NSCLC ) ,https://www.globenewswire.com/news-release/2023/03/29/2636521/0/en/Libtayo-cemiplimab-in-Combination-with-Chemotherapy-Approved-by-European-Commission-for-the-First-line-Treatment-of-Advanced-PD-L1-Positive-Non-small-Cell-Lung-Cancer-NSCLC.html,2023-03-29 11:00:00,Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed to include patients with varied disease presentations seen in everyday clinical practice ...,REGN,0.041901,0.020793,Neutral
Regeneron Pharmaceuticals Unusual Options Activity For March 28 - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/03/31539094/regeneron-pharmaceuticals-unusual-options-activity-for-march-28,2023-03-28 20:45:52,"Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...",REGN,0.706282,0.16512,Somewhat-Bullish
"Regeneron Pharmaceuticals, Hess And 1 Of World's Biggest Bank: CNBC's 'Final Trades' - Bank of America  ( NYSE:BAC ) , Hess  ( NYSE:HES ) ",https://www.benzinga.com/news/23/03/31523538/regeneron-pharmaceuticals-hess-and-1-of-worlds-biggest-bank-cnbcs-final-trades,2023-03-28 12:29:04,"On CNBC's ""Halftime Report Final Trades,"" Bryn Talkington of Requisite Capital Management said she is sticking with Regeneron Pharmaceuticals, Inc. REGN. SVB Leerink analyst David Risinger upgraded Regeneron Pharmaceuticals from Market Perform to Outperform and raised the price target from $834 ...",REGN,0.737032,0.512508,Bullish
Immuneering Appoints Harold E. Brakewood as Chief Business Officer - Immuneering  ( NASDAQ:IMRX ) ,https://www.benzinga.com/pressreleases/23/03/g31527142/immuneering-appoints-harold-e-brakewood-as-chief-business-officer,2023-03-28 12:00:00,"CAMBRIDGE, Mass., March 28, 2023 ( GLOBE NEWSWIRE ) -- Immuneering Corporation IMRX, a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, announced today that it has appointed Harold E.",REGN,0.050679,0.003976,Neutral
"Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases",https://www.globenewswire.com/news-release/2023/03/28/2635542/0/en/Regeneron-and-Sonoma-Biotherapeutics-Announce-Collaboration-to-Discover-Develop-and-Commercialize-Treg-Cell-Therapies-for-Autoimmune-Diseases.html,2023-03-28 11:30:00,"Sonoma Biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment. potential for an additional $45 million development milestone payment Sonoma Biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity ...",REGN,0.091162,0.053808,Neutral
"Pinterest To Rally Over 27%? Here Are 10 Other Analyst Forecasts For Monday - Caterpillar  ( NYSE:CAT ) , Coinbase Glb  ( NASDAQ:COIN ) ",https://www.benzinga.com/news/23/03/31508425/pinterest-to-rally-over-27-here-are-10-other-analyst-forecasts-for-monday,2023-03-27 11:38:55,"UBS cut the price target for DISH Network Corporation DISH from $27 to $10. UBS analyst John Hodulik downgraded the stock from Buy to Neutral. DISH Network shares fell 2.1% to $8.57 in pre-market trading. Piper Sandler raised the price target for Victory Capital Holdings, Inc. VCTR from $27 to ...",REGN,0.28442,0.585361,Bullish
Futures Rise; Bank Stocks Jump As Silicon Valley Bank Sold,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-banks-jump-first-citizens-buys-silicon-valley-bank/,2023-03-27 10:57:00,"Dow Jones Futures Rise, First Citizens Buys Silicon Valley Bank ... Investor's Business Daily ...",REGN,0.084201,0.120384,Neutral
Amgen bid to revive cholesterol drug patents comes to U.S. Supreme Court,https://www.reuters.com/business/healthcare-pharmaceuticals/amgen-bid-revive-cholesterol-drug-patents-comes-us-supreme-court-2023-03-27/,2023-03-27 10:04:00,Amgen bid to revive cholesterol drug patents comes to U.S. ... ...,REGN,0.072435,0.034654,Neutral
Futures Rise With No Big Bank News,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-bank-news-for-market-rally-microsoft-tesla-near-buy-points/,2023-03-26 21:49:00,"Dow Jones Futures Due With No Big Bank News. Microsoft, Tesla ... Investor's Business Daily ...",REGN,0.085706,0.120761,Neutral
Market Rally Still Hasn't Done This; What To Do Now,https://www.investors.com/market-trend/stock-market-today/market-rally-still-hasnt-done-this-microsoft-tesla-near-buy-points/,2023-03-24 21:40:48,"Market Rally Still Hasn't Done This. Microsoft, Tesla Lead 6 Nasdaq ... Investor's Business Daily ...",REGN,0.093744,0.12307,Neutral
Investor Action Plan: Can The Market Bootstrap Itself To A Strong March Finish?,https://www.investors.com/research/investing-action-plan/stock-trading-action-plan-can-the-market-bootstrap-itself-to-a-strong-march-finish/,2023-03-24 21:10:48,Investor Action Plan: Can The Market Bootstrap Itself To A Strong ... Investor's Business Daily ...,REGN,0.05381,0.135992,Neutral
"Regeneron's  ( REGN )  Dupixent Meets Pivotal COPD Study Goal, Up 7%",https://www.zacks.com/stock/news/2070359/regenerons-regn-dupixent-meets-pivotal-copd-study-goal-up-7,2023-03-24 18:29:00,Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations.,REGN,0.160277,0.12023,Neutral
Biotech Growth Stock Soars To New Highs On Lung Disease Breakthrough,https://www.investors.com/stock-lists/new-highs/growth-stock-regeneron-pharmaceuticals-is-hitting-new-highs-after-news-of-clinical-trial-breakthrough-for-its-drug-to-treat-a-fatal-lung-disease-analysts-upgrade-sales-outlook/,2023-03-24 18:17:54,Biotech Growth Stock Soars To New Highs On Lung Disease ... Investor's Business Daily ...,REGN,0.269776,0.223083,Somewhat-Bullish
Stock Market Feeling Gloomy As Banks Are Back In The Hot Seat; Drug Stock Pops,https://www.investors.com/market-trend/stock-market-today/stock-market-overcomes-bank-gloom-as-s-drug-stock-pops/,2023-03-24 17:52:07,Stock Market Overcomes Bank Gloom As S&P 500 Turns Positive ... Investor's Business Daily ...,REGN,0.103109,0.0,Neutral
"Dow Jones, Financial Stocks Climb Off Lows Despite Economic Jitters; Baidu, ELF Beauty Show Strength",https://www.investors.com/market-trend/stock-market-today/dow-jones-financial-stocks-take-more-heat-amid-economic-worries-sellers-hit-coinbase/,2023-03-24 16:10:54,"Dow Jones, Financial Stocks Climb Off Lows Despite Economic ... Investor's Business Daily ...",REGN,0.117774,0.122363,Neutral
Wall Street Has High Hopes for These 2 Nasdaq Stocks,https://www.fool.com/investing/2023/03/24/wall-street-has-high-hopes-for-these-2-nasdaq-stoc/,2023-03-24 16:02:33,"Even in choppy markets, there are smart investments you can make.",REGN,0.22421,0.349168,Somewhat-Bullish
"Stock Market Split As Fed Hikes, Banks Keep Tumbling; Weekly Review",https://www.investors.com/news/stock-market-split-as-fed-hikes-rates-banks-tumble-nvidia-on-holding-in-focus/,2023-03-24 15:59:27,"Stock Market Split As Fed Hikes, Banks Keep Tumbling. Weekly ... Investor's Business Daily ...",REGN,0.052056,0.141019,Neutral
This Is What Whales Are Betting On Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/03/31492664/this-is-what-whales-are-betting-on-regeneron-pharmaceuticals,2023-03-24 14:46:31,A whale with a lot of money to spend has taken a noticeably bullish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 10 strange trades.,REGN,0.819522,0.190976,Somewhat-Bullish
"Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Sanofi  ( NASDAQ:SNY ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/03/31490991/regeneron-pharmaceuticals-analysts-react-to-drug-trial-results-why-whales-are-divin,2023-03-24 14:09:48,"Regeneron Pharmaceuticals Inc REGN announced the Phase 3 trial of Dupixent ( dupilumab ) , developed with Sanofi SNY, for uncontrolled chronic obstructive pulmonary disease ( COPD ) met its primary and secondary endpoints, which attracted investments from whales.",REGN,0.582526,0.063066,Neutral
Regeneron's Asthma Drug Results Were 'Stellar.' Analyst Sees a Sales Bonanza.,https://www.barrons.com/articles/regeneron-asthma-stock-drug-buy-sanofi-8d75c18a,2023-03-24 13:19:22,"Buy Regeneron. Asthma Drug Could Add Billions, Analyst Says. ...",REGN,0.733479,-0.067082,Neutral
"Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Sanofi  ( NASDAQ:SNY ) ",https://www.benzinga.com/news/23/03/31487106/regeneron-pharmaceuticals-options-traders-betting-on-stock-falling-this-much-by-april-expiration,2023-03-24 12:43:08,"Sanofi SNY and Regeneron Pharmaceuticals, Inc. REGN shares surged on Thursday after the companies announced primary and all key secondary endpoints were met in a Phase 3 trial evaluating Dupixent in COPD.",REGN,0.721785,0.547659,Bullish
"US Stocks On Track For Weak Start Friday Amid Renewed Banking Concerns And Contagion Fears - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",https://www.benzinga.com/news/23/03/31488619/us-stocks-on-track-for-weak-start-friday-amid-renewed-banking-concerns-and-contagion-fears,2023-03-24 11:12:25,"Renewed concerns about the banking system appear to weigh on stocks, as the major index futures point to a sharply lower opening on Friday. Contagion fears have continued to weigh on banking stocks in Europe and the worries could aggravate following a spike in German financial services giant ...",REGN,0.115787,0.0,Neutral
"KB Home, Worthington rise; MillerKnoll, Trupanion fall",https://apnews.com/article/financial-markets-stocks-wall-street-59e1010a4b8afcdc0cc86f01927eaf77,2023-03-23 20:18:23,"KB Home, Worthington rise. MillerKnoll, Trupanion fall The Associated Press ...",REGN,0.428632,0.0,Neutral
"Dow Jones Pares Gains As Homebuilders Outperform; Cathie Wood Stocks Sell Off, But Apple Makes Big Move",https://www.investors.com/market-trend/stock-market-today/dow-jones-rises-as-homebuilders-outperform-apple-makes-big-move/,2023-03-23 17:51:38,Dow Jones Pares Gains As Homebuilders Outperform. Cathie Wood ... Investor's Business Daily ...,REGN,0.158519,0.122073,Neutral
"Stocks making the biggest moves midday: Netflix, Block, Snap, KB Home and more",https://www.cnbc.com/2023/03/23/stocks-making-the-biggest-moves-midday-nflx-sq-snap-kbh.html,2023-03-23 17:24:35,Block fell after Hindenburg Research unveiled its latest short position on the stock. KB Home popped on earnings.,REGN,0.069495,0.084924,Neutral
"Coinbase's stock tumbles after SEC warning, Regeneron shares rally, and other stocks on the move",https://www.marketwatch.com/story/coinbase-stock-tumbles-on-sec-warning-while-first-republic-and-regeneron-shares-rally-and-other-stocks-on-the-move-24240264,2023-03-23 16:55:00,"Coinbase, Chewy, Regeneron, Accenture and First Republic were some of the most active shares on Thursday.",REGN,0.716023,0.102888,Neutral
Why Shares of Regeneron Are Rising Thursday,https://www.fool.com/investing/2023/03/23/why-shares-of-regeneron-are-rising-thursday/,2023-03-23 16:08:33,Regeneron released positive phase 3 trial results for its therapy Dupixent.,REGN,0.268294,0.185902,Somewhat-Bullish
 ( REGN )  - Analyzing Regeneron Pharmaceuticals's Short Interest - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/short-sellers/23/03/31476445/regn-analyzing-regeneron-pharmaceuticalss-short-interest,2023-03-23 14:45:26,"Regeneron Pharmaceuticals's REGN short percent of float has fallen 10.0% since its last report. The company recently reported that it has 1.20 million shares sold short, which is 1.17% of all regular shares that are available for trading.",REGN,0.221819,0.083071,Neutral
This Is What Whales Are Betting On Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/03/31475168/this-is-what-whales-are-betting-on-regeneron-pharmaceuticals,2023-03-23 13:45:56,"Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...",REGN,0.77735,0.307291,Somewhat-Bullish
"Top Stories Thursday, Mar. 23: Apple, In A Cinema Near You Soon, Elon Musk Seeks Funding For SpaceX From Middle-Eastern Fund - Manchester United  ( NYSE:MANU ) ",https://www.benzinga.com/general/biotech/23/03/31474197/apple-jumps-movie-production-bandwagon-billionaire-jim-ratcliffe-bids-for-manchester-united-elon-,2023-03-23 13:23:40,Apple Inc AAPL eyes splurging $1 billion annually to produce movies likely for theatrical release to draw subscribers to its streaming service. Apple has approached movie studios about partnering to release a few titles in theaters this year and a slate of more films in the future.,REGN,0.064536,-0.12515,Neutral
"Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung'",https://www.investors.com/news/technology/regn-stock-sny-stock-rocket-on-blow-out-results-in-copd/,2023-03-23 13:03:59,REGN Stock And SNY Stock Rocket On Blow-Out Results In COPD Investor's Business Daily ...,REGN,0.720339,0.372717,Bullish
"S&P 500 Futures Rise in Premarket Trading; Coinbase Global, Apellis Pharmaceuticals Lag",https://www.barrons.com/articles/s-p-500-futures-rise-in-premarket-trading-coinbase-global-apellis-pharmaceuticals-lag-ea4f4d5e,2023-03-23 11:32:14,"S&P 500 Futures Rise in Premarket Trading. Coinbase Global, Apellis Pharmaceuticals Lag ...",REGN,0.7887,0.0,Neutral
"Why Regeneron Pharmaceuticals  ( REGN )  And Sanofi  ( SNY )  Shares Are Trading Higher Today? - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Sanofi  ( NASDAQ:SNY ) ",https://www.benzinga.com/general/biotech/23/03/31470443/why-regeneron-pharmaceuticals-and-sanofi-shares-are-trading-higher-today,2023-03-23 11:20:07,Sanofi-Regeneron stocks are trading higher today after their blockbuster drug aced the pivotal COPD trial. Sanofi SA SNY and Regeneron Pharmaceuticals Inc's REGN Phase 3 trial of Dupixent ( dupilumab ) for uncontrolled chronic obstructive pulmonary disease ( COPD ) met its primary and secondary ...,REGN,0.371523,-0.079964,Neutral
Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2069416/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now,2023-03-23 10:20:07,Smart Beta ETF report for ...,REGN,0.122894,0.068464,Neutral
Dupixent®  ( dupilumab )  Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial,https://www.globenewswire.com/news-release/2023/03/23/2632823/0/en/Dupixent-dupilumab-Demonstrates-Potential-to-Become-First-Biologic-to-Treat-COPD-by-Showing-Significant-Reduction-in-Exacerbations-in-Pivotal-Trial.html,2023-03-23 06:00:00,First and only biologic to demonstrate clinically meaningful and statistically significant reduction ( 30% ) in exacerbations compared to placebo ...,REGN,0.035048,0.023425,Neutral
Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial,https://www.globenewswire.com/news-release/2023/03/23/2632822/0/en/Press-Release-Dupixent-demonstrates-potential-to-become-first-biologic-to-treat-COPD-by-showing-significant-reduction-in-exacerbations-in-pivotal-trial.html,2023-03-23 06:00:00,Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial ...,REGN,0.024471,0.036376,Neutral
Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/03/g31468934/press-release-dupixent-demonstrates-potential-to-become-first-biologic-to-treat-copd-by-showing-si,2023-03-23 06:00:00,Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial First and only biologic to demonstrate clinically meaningful and statistically significant reduction ( 30% ) in exacerbations compared to placebo,REGN,0.024029,0.03529,Neutral
Regeneron  ( REGN )  Gets Label Extension for Cholesterol Drug,https://www.zacks.com/stock/news/2069254/regeneron-regn-gets-label-extension-for-cholesterol-drug,2023-03-22 18:15:00,Regeneron (REGN) gets FDA approval for Evkeeza to treat children aged 5 to 11 with homozygous familial hypercholesterolemia.,REGN,0.264658,0.209672,Somewhat-Bullish
US FDA expands use of Regeneron's cholesterol drug in young children,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-expands-use-regenerons-cholesterol-drug-young-children-2023-03-22/,2023-03-22 11:35:00,US FDA expands use of Regeneron's cholesterol drug in young ... ...,REGN,0.272788,0.260869,Somewhat-Bullish
"Here's one for the battered bulls: the second-largest sector in the S&P 500 is stirring to life, says this strategist.",https://www.marketwatch.com/story/heres-one-for-the-battered-bulls-the-second-largest-sector-in-the-s-p-500-is-stirring-to-life-says-this-strategist-5e179744,2023-03-22 10:52:00,"Everyone is watching the banks, but what about healthcare. It's breaking out, says this strategist.",REGN,0.077593,0.0,Neutral
Regeneron Pharmaceuticals Unusual Options Activity For April 05 - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/04/31682495/regeneron-pharmaceuticals-unusual-options-activity-for-april-05,2023-04-05 15:31:09,"Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...",REGN,0.708701,0.347106,Somewhat-Bullish
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/news/earnings/23/04/31634455/100-invested-in-this-stock-5-years-ago-would-be-worth-200-today,2023-04-03 14:00:42,"Regeneron Pharmaceuticals REGN has outperformed the market over the past 5 years by 11.14% on an annualized basis producing an average annual return of 20.69%. Currently, Regeneron Pharmaceuticals has a market capitalization of $89.47 billion.",REGN,0.980595,0.386944,Bullish
Regeneron Pharmaceuticals Unusual Options Activity For April 20 - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/04/31923088/regeneron-pharmaceuticals-unusual-options-activity-for-april-20,2023-04-20 19:16:08,"Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...",REGN,0.77688,0.283971,Somewhat-Bullish
"With 13.87% CAGR, Atopic Dermatitis Market Size to Surpass USD 16.23 Billion by 2028 Says Brandessence Market Research",https://www.prnewswire.com/news-releases/with-13-87-cagr-atopic-dermatitis-market-size-to-surpass-usd-16-23-billion-by-2028-says-brandessence-market-research-301799955.html,2023-04-18 07:07:00,"With 13.87% CAGR, Atopic Dermatitis Market Size to Surpass USD ... PR ...",REGN,0.029654,0.080721,Neutral
"Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary",https://www.globenewswire.com/news-release/2023/04/17/2647803/0/en/Regeneron-Announces-Retirement-of-Board-Chair-Dr-P-Roy-Vagelos-Accomplished-Physician-Businessman-and-Industry-Luminary.html,2023-04-17 11:30:00,Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos to become Co-Chairs of the Board and Christine A. Poon to be named Lead Independent Director Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos to become Co-Chairs of the Board and Christine A. Poon to be named Lead Independent ...,REGN,0.205807,0.074563,Neutral
"Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/pressreleases/23/04/g31826057/regeneron-announces-retirement-of-board-chair-dr-p-roy-vagelos-accomplished-physician-businessman-,2023-04-17 11:30:00,"TARRYTOWN, N.Y., April 17, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced that P. Roy Vagelos, M.D., will retire from his role as Chair of the Company's Board of Directors and will not stand for reelection at the Company's 2023 Annual Meeting of Shareholders.",REGN,0.201244,0.073268,Neutral
Aflibercept 8 mg and EYLEA®  ( aflibercept )  Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases,https://www.globenewswire.com/news-release/2023/04/17/2647753/0/en/Aflibercept-8-mg-and-EYLEA-aflibercept-Injection-Presentations-at-ARVO-Provide-New-Insights-into-the-Treatment-of-Serious-Retinal-Diseases.html,2023-04-17 11:00:00,"New subgroup data and further analyses of the aflibercept 8 mg clinical trial program to highlight durability results of extended dosing intervals, patient characteristics, and efficacy and safety in wet age-related macular degeneration and diabetic macular edema ...",REGN,0.062271,0.046145,Neutral
Futures: 7 Stocks Near Buy Points,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-tesla-apple-stock-near-buy-points-in-market-rally/,2023-04-16 20:38:00,"Dow Jones Futures Loom: Tesla, Apple Lead 7 Stocks Near Buy ... Investor's Business Daily ...",REGN,0.060541,-0.04513,Neutral
How To Handle This Rally; Seven Stocks Near Buy Points,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-how-to-handle-volatile-market-rally-tesla-netflix-earnings-on-tap-apple-stock/,2023-04-15 12:56:00,"Dow Jones Futures: How To Handle This Market. Tesla, Netflix Near ... Investor's Business Daily ...",REGN,0.065987,-0.04536,Neutral
Regeneron Pharmaceuticals Unusual Options Activity - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/04/31776143/regeneron-pharmaceuticals-unusual-options-activity,2023-04-12 19:15:47,"Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...",REGN,0.781591,0.28462,Somewhat-Bullish
MAIA Biotechnology Touts Positive Data From Healthy Volunteer Study Of Potential Lung Cancer Candidate - MAIA Biotechnology  ( AMEX:MAIA ) ,https://www.benzinga.com/general/biotech/23/04/31749899/maia-biotechnology-touts-positive-data-from-healthy-volunteer-study-of-potential-lung-cancer-cand,2023-04-11 16:43:56,MAIA Biotechnology Inc MAIA released topline data from the completed Part A safety lead-in of its THIO-101 Phase 2 go-to-market trial in advanced Non-Small Cell Lung Cancer ( NSCLC ) and has commenced recruitment in Part B randomized efficacy/dose selection.,REGN,0.345674,0.0,Neutral
"Sports Medicine Devices Market to Witness 5.6% CAGR during 2021 - 2028, Reaching USD 13.85 Bn: TMR Study",https://www.benzinga.com/pressreleases/23/04/g32092403/sports-medicine-devices-market-to-witness-5-6-cagr-during-2021-2028-reaching-usd-13-85-bn-tmr-stud,2023-04-28 19:30:00,"Wilmington, Delaware, United States, April 29, 2023 ( GLOBE NEWSWIRE ) -- Increase in preference for minimally invasive surgeries and surge in adoption of arthroscopic surgery for the treatment of common sports injuries are propelling market growth.",REGN,0.038592,0.071758,Neutral
"Stock Charts Strategy May 1-5: Fed Policy, April Payrolls, Apple Earnings",https://www.investors.com/all-categories/stock-charts-action-plan-may-1-5-fed-policy-april-payrolls-apple-earnings/,2023-04-28 17:12:00,"Stock Charts Strategy May 1-5: Fed Policy, April Payrolls, Apple ... Investor's Business Daily ...",REGN,0.047371,0.066605,Neutral
Government Drug Price Curbs Could Sound A Death Knell For Industry,https://www.investors.com/news/technology/biotech-stocks-brace-for-the-worst-as-government-drug-price-negotiations-loom/,2023-04-28 12:00:00,Biotech Stocks Brace For The Worst As Government Drug Price ... Investor's Business Daily ...,REGN,0.027118,0.0,Neutral
AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS,https://investingnews.com/amgen-reports-first-quarter-financial-results/,2023-04-27 20:43:13,Amgen ( NASDAQ:AMGN ) today announced financial results for the first quarter of 2023.,REGN,0.015675,0.0,Neutral
AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS,https://investingnews.com/amgen-reports-first-quarter-financial-results-2659922399/,2023-04-27 20:43:13,Amgen ( NASDAQ:AMGN ) today announced financial results for the first quarter of 2023.,REGN,0.015675,0.0,Neutral
AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS,https://www.prnewswire.com/news-releases/amgen-reports-first-quarter-financial-results-301810090.html,2023-04-27 20:01:00,"THOUSAND OAKS, Calif., April 27, 2023 /PRNewswire/ -- Amgen ( NASDAQ:AMGN ) today announced financial results for the first quarter of 2023.",REGN,0.006681,0.0,Neutral
REGN: A Prescription for Success: Check Out This Strong Pharmaceutical Stock This Week,https://stocknews.com/news/regn-biib-gild-vnda-a-prescription-for-success-check-out-this-strong-pharmaceutical-stock/,2023-04-27 15:54:46,REGN: A Prescription for Success: Check Out This Strong ... ...,REGN,0.552443,0.362894,Bullish
"Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says - Alnylam Pharmaceuticals  ( NASDAQ:ALNY ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/general/biotech/23/04/32048648/alnylam-regeneron-partnered-alzheimers-candidates-initial-data-sounds-promising-analyst-says,2023-04-27 15:52:05,Alnylam Pharmaceuticals Inc ALNY and its partner Regeneron Pharmaceuticals Inc REGN announced preliminary data from their Phase I study of their experimental drug dubbed ALN-APP.,REGN,0.38489,0.248511,Somewhat-Bullish
EXCLUSIVE: SAB Biotherapeutics Releases Topline Data From Discontinued COVID Antibody Trial - SAB Biotherapeutics  ( NASDAQ:SABS ) ,https://www.benzinga.com/general/biotech/23/04/32004894/exclusive-sab-biotherapeutics-releases-topline-data-from-discontinued-covid-antibody-trial,2023-04-26 12:00:13,SAB Biotherapeutics Inc SABS has revealed topline results from the Phase 3 National Institutes of Health's ( NIH ) ACTIV-2 trial that assessed SAB-185 in non-hospitalized COVID-19 patients at high risk for severe outcomes.,REGN,0.211191,0.045143,Neutral
Regeneron Pharmaceuticals Unusual Options Activity For April 25 - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/04/31992883/regeneron-pharmaceuticals-unusual-options-activity-for-april-25,2023-04-25 15:45:51,A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 11 strange trades.,REGN,0.71032,0.057325,Neutral
"4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates",https://www.zacks.com/stock/news/2083259/4-pharma-biotech-stocks-poised-to-beat-q1-earnings-estimates,2023-04-24 12:38:00,"We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.",REGN,0.306963,0.190761,Somewhat-Bullish
"Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Upgraded to ""Strong-Buy"" by StockNews.com",https://www.defenseworld.net/2023/05/09/regeneron-pharmaceuticals-nasdaqregn-upgraded-to-strong-buy-by-stocknews-com.html,2023-05-09 09:30:55,"Regeneron Pharmaceuticals ( NASDAQ:REGN ) Upgraded to ""Strong ... Defense World ...",REGN,0.763362,0.444403,Bullish
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/05/32274966/looking-at-regeneron-pharmaceuticalss-recent-unusual-options-activity,2023-05-08 20:46:16,"Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...",REGN,0.846873,0.303176,Somewhat-Bullish
"If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/news/earnings/23/05/32240272/if-you-invested-100-in-this-stock-10-years-ago-you-would-have-300-today,2023-05-05 14:30:22,"Regeneron Pharmaceuticals REGN has outperformed the market over the past 10 years by 1.49% on an annualized basis producing an average annual return of 11.18%. Currently, Regeneron Pharmaceuticals has a market capitalization of $82.95 billion.",REGN,0.980595,0.386944,Bullish
"Intellia  ( NTLA )  Beats on Q1 Earnings, Gives Pipeline Update",https://www.zacks.com/stock/news/2090934/intellia-ntla-beats-on-q1-earnings-gives-pipeline-update,2023-05-05 13:15:00,Intellia's (NTLA) first-quarter earnings beat estimates. The company provides updates on its gene-editing pipeline.,REGN,0.261818,0.272985,Somewhat-Bullish
Ultragenyx  ( RARE )  Q1 Earnings and Revenues Miss Estimates,https://www.zacks.com/stock/news/2090844/ultragenyx-rare-q1-earnings-and-revenues-miss-estimates,2023-05-05 12:27:00,Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.,REGN,0.09239,0.137782,Neutral
Stock Market Off Heading Back To Day's Lows. Medical Diagnostics Stock Jumps 15% After Earnings.,https://www.investors.com/market-trend/stock-market-today/stock-market-off-lows-prostate-cancer-stock-jumps/,2023-05-04 19:27:00,Stock Market Off Lows Ahead Of Apple And Jobs. Prostate Cancer ... Investor's Business Daily ...,REGN,0.08197,-0.039639,Neutral
Why Regeneron Pharmaceuticals  ( REGN )  Shares Are Trading Lower Today? - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/general/biotech/23/05/32216673/why-regeneron-pharmaceuticals-shares-are-trading-lower-today,2023-05-04 17:50:24,"Regeneron Pharmaceuticals Inc REGN earned adjusted EPS of $10.09, down 12% Y/Y, beating the $9.60 Street estimate. Revenues decreased 6% Y/Y to $3.16 billion, down from $3.41 billion in Q4 FY22, beating the consensus of $3.00 billion.",REGN,0.479683,-0.078038,Neutral
Why Regeneron Pharmaceuticals Stock Is Tanking Today,https://www.fool.com/investing/2023/05/04/why-regeneron-pharmaceuticals-stock-is-tanking-tod/,2023-05-04 17:23:55,Investors are worried about Eylea's falling sales.,REGN,0.28387,-0.145033,Neutral
"Regeneron  ( REGN )  Q1 Earnings & Sales Top, Eylea Sales Decline",https://www.zacks.com/stock/news/2090283/regeneron-regn-q1-earnings-sales-top-eylea-sales-decline,2023-05-04 16:03:00,"Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.",REGN,0.187463,0.191405,Somewhat-Bullish
Regeneron Dives As Competition Undercuts Its Biggest Moneymaker,https://www.investors.com/news/technology/regn-stock-regeneron-earnings-q1-2023/,2023-05-04 12:50:00,REGN Stock Dives As Competition Hammers Away At Eylea Investor's Business Daily ...,REGN,0.779232,0.091344,Neutral
Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress,https://www.globenewswire.com/news-release/2023/05/04/2661383/0/en/Intellia-Therapeutics-Announces-First-Quarter-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html,2023-05-04 11:30:00,"CAMBRIDGE, Mass., May 04, 2023 ( GLOBE NEWSWIRE ) -- Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) , a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial ...",REGN,0.044496,0.070367,Neutral
Regeneron beats quarterly profit estimates,https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-beats-quarterly-profit-estimates-eylea-strength-2023-05-04/,2023-05-04 10:39:00,"May 4 ( Reuters ) - Regeneron Pharmaceuticals Inc ( REGN.O ) beat Wall Street estimates for first-quarter profit on Thursday, driven by strong demand for eczema treatment Dupixent. Excluding items, the company reported a profit of $10.09 per share for the quarter, above analysts' estimates of ...",REGN,0.495015,0.51181,Bullish
Regeneron Pharmaceuticals Unusual Options Activity - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/05/32196053/regeneron-pharmaceuticals-unusual-options-activity,2023-05-03 19:16:27,"Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...",REGN,0.753462,0.375938,Bullish
"Drug, Biotech Stocks' Q1 Earnings on May 4: REGN, ZTS & More",https://www.zacks.com/stock/news/2089198/drug-biotech-stocks-q1-earnings-on-may-4-regn-zts-more,2023-05-03 15:46:00,"Let us look at four big drug and biotech companies, REGN, ZTS, MRNA and NVO, which are gearing up for their earnings release.",REGN,0.18967,0.0,Neutral
Why Earnings Season Could Be Great for Regeneron  ( REGN ) ,https://www.zacks.com/stock/news/2088882/why-earnings-season-could-be-great-for-regeneron-regn,2023-05-03 12:36:00,Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.,REGN,0.812724,0.693705,Bullish
Cerevel Therapeutics Appoints Ron Renaud as President and Chief Executive Officer and Reports First Quarter 2023 Financial Results,https://www.globenewswire.com/news-release/2023/05/03/2660120/0/en/Cerevel-Therapeutics-Appoints-Ron-Renaud-as-President-and-Chief-Executive-Officer-and-Reports-First-Quarter-2023-Financial-Results.html,2023-05-03 10:30:00,"Ron Renaud to succeed Tony Coles, M.D. as CEO, effective June 12, 2023. Dr. Coles will continue as chairperson of the board ...",REGN,0.014541,0.053412,Neutral
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF  ( PBE ) ?,https://www.zacks.com/stock/news/2088704/should-you-invest-in-the-invesco-dynamic-biotechnology-genome-etf-pbe,2023-05-03 10:20:07,Sector ETF report for ...,REGN,0.130571,0.07042,Neutral
Kiniksa Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Portfolio Execution,https://www.globenewswire.com/news-release/2023/05/02/2659011/0/en/Kiniksa-Pharmaceuticals-Reports-First-Quarter-2023-Financial-Results-and-Recent-Portfolio-Execution.html,2023-05-02 11:30:00,"- ARCALYST® ( rilonacept ) Q1 2023 net product revenue of $42.7 million -- ARCALYST full-year 2023 net product revenue guidance increased to $200 - $215 million, representing ~69% year-over-year growth at the midpoint -- Final cohort of KPL-404 Phase 2 rheumatoid arthritis trial now enrolling ...",REGN,0.020615,-0.169486,Somewhat-Bearish
Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/05/g32152354/regeneron-to-highlight-new-and-updated-clinical-data-at-asco-showcasing-breadth-of-cancer-research,2023-05-02 11:00:45,Oral presentations include interim results from pivotal trial of linvoseltamab ( BCMAxCD3 ) in relapsed/refractory multiple myeloma and three cohorts of fianlimab ( LAG-3 inhibitor ) combined with Libtayo® ( cemiplimab-rwlc ) in advanced melanoma,REGN,0.055837,-0.098997,Neutral
Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research,https://www.globenewswire.com/news-release/2023/05/02/2658982/0/en/Regeneron-to-Highlight-New-and-Updated-Clinical-Data-at-ASCO-Showcasing-Breadth-of-Cancer-Research.html,2023-05-02 11:00:00,Oral presentations include interim results from pivotal trial of linvoseltamab ( BCMAxCD3 ) in relapsed/refractory multiple myeloma and three cohorts of fianlimab ( LAG-3 inhibitor ) combined with Libtayo® ( cemiplimab-rwlc ) in advanced melanoma ...,REGN,0.049706,0.029966,Neutral
Is a Beat on the Cards for Regeneron's  ( REGN )  Q1 Earnings?,https://www.zacks.com/stock/news/2087388/is-a-beat-on-the-cards-for-regenerons-regn-q1-earnings,2023-05-01 12:02:00,Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent.,REGN,0.238913,0.228333,Somewhat-Bullish
"Autoimmune Drugs Market size to grow by USD 29,314.5 million between 2022 and 2027; AbbVie Inc., and AdvaCare Pharma among others, identified as key vendors - Technavio",https://www.prnewswire.com/news-releases/autoimmune-drugs-market-size-to-grow-by-usd-29-314-5-million-between-2022-and-2027-abbvie-inc-and-advacare-pharma-among-others-identified-as-key-vendors--technavio-301828870.html,2023-05-19 23:15:00,"Autoimmune Drugs Market size to grow by USD 29,314.5 million ... PR ...",REGN,0.075161,0.137715,Neutral
Regeneron  ( REGN )  Faces Challenges as Eylea Sales Decline,https://www.zacks.com/stock/news/2097627/regeneron-regn-faces-challenges-as-eylea-sales-decline,2023-05-19 17:42:00,"Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.",REGN,0.142144,-0.306968,Somewhat-Bearish
This Is What Whales Are Betting On Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/05/32486814/this-is-what-whales-are-betting-on-regeneron-pharmaceuticals,2023-05-19 14:46:17,"Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...",REGN,0.766141,0.344161,Somewhat-Bullish
Is First Trust NYSE Arca Biotechnology ETF  ( FBT )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2097186/is-first-trust-nyse-arca-biotechnology-etf-fbt-a-strong-etf-right-now,2023-05-19 10:20:08,Smart Beta ETF report for ...,REGN,0.116348,0.06132,Neutral
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update,https://www.globenewswire.com/news-release/2023/05/19/2672401/0/en/Alvotech-Reports-Financial-Results-for-First-three-Months-of-2023-and-Provides-Business-Update.html,2023-05-19 09:00:00,"• Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same period in 2022 • Confirmatory patient study for AVT05, a proposed biosimilar for Simponi® and Simponi Aria® ( golimumab ) initiated, marking the fifth internally developed portfolio ...",REGN,0.012545,0.0,Neutral
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update,https://www.globenewswire.com/news-release/2023/05/19/2672402/0/en/Alvotech-Reports-Financial-Results-for-First-three-Months-of-2023-and-Provides-Business-Update.html,2023-05-19 09:00:00,"REYKJAVIK, Iceland, May 19, 2023 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the ""Company"" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first three months of ...",REGN,0.012512,0.0,Neutral
Regeneron Applauds Supreme Court's Unanimous Opinion Striking Down Amgen's PCSK9 Patent Claims and Supporting Scientific Innovation,https://www.globenewswire.com/news-release/2023/05/18/2672107/0/en/Regeneron-Applauds-Supreme-Court-s-Unanimous-Opinion-Striking-Down-Amgen-s-PCSK9-Patent-Claims-and-Supporting-Scientific-Innovation.html,2023-05-18 15:45:00,Decision ends nearly decade-long patent dispute related to ...,REGN,0.116631,0.056512,Neutral
Regeneron Applauds Supreme Court's Unanimous Opinion Striking Down Amgen's PCSK9 Patent Claims and Supporting Scientific Innovation - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/05/g32470164/regeneron-applauds-supreme-courts-unanimous-opinion-striking-down-amgens-pcsk9-patent-claims-and-s,2023-05-18 15:45:00,"Decision ends nearly decade-long patent dispute related to Regeneron-invented Praluent® ( alirocumab ) TARRYTOWN, N.Y., May 18, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.",REGN,0.113731,0.053555,Neutral
"Top CEOs Earned Less In 2022 Compared To 2021: Discover Their Earnings And The Highest-Paid Leaders - Apple  ( NASDAQ:AAPL ) , Amazon.com  ( NASDAQ:AMZN ) ",https://www.benzinga.com/news/23/05/32404282/top-ceos-earned-less-in-2022-compared-to-2021-discover-their-earnings-and-the-highest-paid-leaders,2023-05-15 20:57:22,"The issue of executive compensation remains a highly debated subject among shareholders of publicly traded corporations. This discussion is fueled by instances where job and cost reductions are implemented, while some executives continue to receive substantial rewards.",REGN,0.063594,0.297777,Somewhat-Bullish
How Is The Market Feeling About Regeneron Pharmaceuticals? - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/short-sellers/23/05/32400918/how-is-the-market-feeling-about-regeneron-pharmaceuticals,2023-05-15 17:15:45,"Regeneron Pharmaceuticals's REGN short percent of float has risen 11.97% since its last report. The company recently reported that it has 1.21 million shares sold short, which is 1.31% of all regular shares that are available for trading.",REGN,0.221819,0.155473,Somewhat-Bullish
Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update,https://www.globenewswire.com/news-release/2023/05/15/2668677/0/en/Decibel-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Corporate-Update.html,2023-05-15 11:45:00,"- Initiated CHORD™, a global Phase 1/2 dose escalation clinical trial of lead gene therapy product candidate, ...",REGN,0.045012,0.029736,Neutral
Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?,https://www.zacks.com/stock/news/2095065/should-you-invest-in-the-ishares-biotechnology-etf-ibb,2023-05-15 10:20:09,Sector ETF report for ...,REGN,0.137671,0.072354,Neutral
"AI-Run ETF Dumps Apple In Favor Of This Chip Stock And Hints At New Opportunity Brewing In Market - Meta Platforms  ( NASDAQ:META ) , NVIDIA  ( NASDAQ:NVDA ) , Apple  ( NASDAQ:AAPL ) , TJX Companies  ( NYSE:TJX ) , Monster Beverage  ( NASDAQ:MNST ) , Vertex Pharmaceuticals  ( NASDAQ:VRTX ) , QRAFT AI-Enhanced U.S. Large Cap Momentum ETF  ( ARCA:AMOM ) , Starbucks  ( NASDAQ:SBUX ) , Lowe's Companies  ( NYSE:LOW ) , O'Reilly Automotive  ( NASDAQ:ORLY ) , AutoZone  ( NYSE:AZO ) , Eli Lilly  ( NYSE:LLY ) , Home Depot  ( NYSE:HD ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Walmart  ( NYSE:WMT ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/05/32366764/ai-run-etf-dumps-apple-in-favor-of-this-chip-stock-and-hints-at-new-opportunity-bre,2023-05-12 15:11:24,"Apple, Inc. AAPL is often touted as an all-weather stock but one exchange-traded fund, powered by artificial intelligence, has deemed it fit to dump its entire Apple holdings and switched its allegiance to a chipmaker. What Happened: QRAFT AI-Enhanced U.S.",REGN,0.249106,0.194412,Somewhat-Bullish
"CAGR of 5.6%, Red Biotechnology Market Expected to Surpass USD 609.6 Billion by 2031 - Exclusive Study by TMR",https://www.benzinga.com/pressreleases/23/05/g32362861/cagr-of-5-6-red-biotechnology-market-expected-to-surpass-usd-609-6-billion-by-2031-exclusive-study,2023-05-12 12:30:00,"Wilmington, Delaware, United States, May 12, 2023 ( GLOBE NEWSWIRE ) -- The global red biotechnology market size stood at USD 357.2 Bn in 2021 and is anticipated to surpass value of USD 609.6 Bn by 2031. The global industry is anticipated to expand at a CAGR of 5.6% between 2022 and 2031.",REGN,0.044551,-0.157838,Somewhat-Bearish
Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices  ( AEMPS )  to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO - Decibel Therapeutics  ( NASDAQ:DBTX ) ,https://www.benzinga.com/pressreleases/23/05/g32360731/decibel-therapeutics-announces-approval-of-clinical-trial-application-by-the-spanish-agency-of-med,2023-05-12 11:00:00,"BOSTON, May 12, 2023 ( GLOBE NEWSWIRE ) -- Decibel Therapeutics DBTX, a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced approval of its Clinical Trial Application ( CTA ) by the ...",REGN,0.037681,0.107697,Neutral
Regeneron Pharmaceuticals Unusual Options Activity - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/05/32632128/regeneron-pharmaceuticals-unusual-options-activity,2023-05-30 18:30:59,A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 12 strange trades.,REGN,0.784481,0.090916,Neutral
Diabetic Retinopathy Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 50 Key Companies Working in the Domain | DelveInsight,https://www.prnewswire.com/news-releases/diabetic-retinopathy-clinical-trial-pipeline-space-brims-with-novel-emerging-therapies-with-over-50-key-companies-working-in-the-domain--delveinsight-301836337.html,2023-05-29 15:00:00,Diabetic Retinopathy Clinical Trial Pipeline Space Brims With Novel ... PR ...,REGN,0.021106,0.002652,Neutral
Regeneron  ( REGN )  Posts Upbeat Data From Multiple Myeloma Study,https://www.zacks.com/stock/news/2100449/regeneron-regn-posts-upbeat-data-from-multiple-myeloma-study,2023-05-26 15:04:00,A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.,REGN,0.148121,0.0,Neutral
"Regeneron Reveals Updated Data From Multiple Myeloma Study, Showing Response Rate Of 71% - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/general/biotech/23/05/32590555/regeneron-reveals-updated-data-from-multiple-myeloma-study-showing-response-rate-of-71,2023-05-26 10:40:22,"Regeneron Pharmaceuticals Inc REGN announced updated data from two Phase 2 expansion dose cohorts of linvoseltamab ( formerly REGN5458 ) in patients with heavily pre-treated, relapsed/refractory multiple myeloma.",REGN,0.40348,0.163141,Somewhat-Bullish
Should You Invest in the First Trust NYSE Arca Biotechnology ETF  ( FBT ) ?,https://www.zacks.com/stock/news/2100032/should-you-invest-in-the-first-trust-nyse-arca-biotechnology-etf-fbt,2023-05-26 10:20:05,Sector ETF report for ...,REGN,0.130926,0.070514,Neutral
"Updated Linvoseltamab  ( BCMAxCD3 )  Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma",https://www.globenewswire.com/news-release/2023/05/25/2676777/0/en/Updated-Linvoseltamab-BCMAxCD3-Data-from-Pivotal-Trial-Demonstrates-Early-Deep-and-Durable-Responses-in-Patients-with-Heavily-Pre-treated-Multiple-Myeloma.html,2023-05-25 21:05:00,"71% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200 mg dose, per new data to be shared in an oral session at ...",REGN,0.046969,0.048733,Neutral
Fianlimab  ( LAG-3 inhibitor )  Combined with Libtayo®  ( cemiplimab )  Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/05/g32585791/fianlimab-lag-3-inhibitor-combined-with-libtayo-cemiplimab-shows-clinically-meaningful-and-durable,2023-05-25 21:00:04,"TARRYTOWN, N.Y., May 25, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced positive data from three independent cohorts evaluating an investigational combination of LAG-3 inhibitor fianlimab and PD-1 inhibitor Libtayo® ( cemiplimab ) in adults with advanced melanoma.",REGN,0.043918,0.034726,Neutral
Regeneron Pharmaceuticals Unusual Options Activity For May 25 - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/05/32584357/regeneron-pharmaceuticals-unusual-options-activity-for-may-25,2023-05-25 20:19:26,A whale with a lot of money to spend has taken a noticeably bullish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 16 strange trades.,REGN,0.823417,0.179594,Somewhat-Bullish
"The Zacks Analyst Blog Highlights AbbVie, Intel, Qualcomm, Regeneron and CME Group",https://www.zacks.com/stock/news/2099438/the-zacks-analyst-blog-highlights-abbvie-intel-qualcomm-regeneron-and-cme-group,2023-05-25 10:38:00,"AbbVie, Intel, Qualcomm, Regeneron and CME Group are included in this Analyst Blog.",REGN,0.724687,0.0,Neutral
"Top Research Reports for AbbVie, Intel & Qualcomm",https://www.zacks.com/research-daily/2099100/top-research-reports-for-abbvie-intel-qualcomm,2023-05-24 20:26:00,"Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Intel Corporation (INTC) and Qualcomm Inc. (QCOM).",REGN,0.125789,0.093205,Neutral
AMGN: 4 Best Biotech Stocks According to POWR Ratings,https://stocknews.com/news/amgn-regn-uthr-vnda-4-best-biotech-stocks-according-to-powr-ratings/,2023-05-23 14:31:04,"The biotech industry has diversified and thrived, especially during the pandemic, owing to the advanced innovations and incessant efforts to curb the deadly virus. Moreover, the inelastic demand enjoyed by the industry makes it well-grounded to maintain its buoyancy in the upcoming times.",REGN,0.149966,0.086737,Neutral
Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2098310/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now,2023-05-23 10:20:08,Smart Beta ETF report for ...,REGN,0.123526,0.068619,Neutral
Should First Trust NASDAQ-100 Equal Weighted ETF  ( QQEW )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2098304/should-first-trust-nasdaq-100-equal-weighted-etf-qqew-be-on-your-investing-radar,2023-05-23 10:20:05,Style Box ETF report for ...,REGN,0.116914,0.060317,Neutral
Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/news/earnings/23/05/32520783/heres-how-much-100-invested-in-regeneron-pharmaceuticals-20-years-ago-would-be-worth-today,2023-05-22 21:33:03,"Regeneron Pharmaceuticals REGN has outperformed the market over the past 20 years by 14.78% on an annualized basis producing an average annual return of 22.45%. Currently, Regeneron Pharmaceuticals has a market capitalization of $82.45 billion.",REGN,0.980595,0.386944,Bullish
"Sanofi-Regeneron Highlight Dupixent Data, Say Drug Benefit Was Swift, Sustained - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Sanofi  ( NASDAQ:SNY ) ",https://www.benzinga.com/general/biotech/23/05/32508995/sanofi-regeneron-highlight-dupixent-data-say-drug-benefit-was-swift-sustained,2023-05-22 15:50:54,Regeneron Pharmaceuticals Inc REGN and Sanofi SA SNY presented results from a Phase 3 study of Dupixent ( dupilumab ) in adults currently on maximal standard-of-care inhaled therapy ( triple therapy ) with uncontrolled chronic obstructive pulmonary disease ( COPD ) and evidence of type 2 ...,REGN,0.448842,-0.104184,Neutral
Dupixent®  ( dupilumab )  Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/05/g32501095/dupixent-dupilumab-late-breaking-phase-3-copd-results-presented-at-ats-and-simultaneously-publishe,2023-05-21 18:18:51,"TARRYTOWN, N.Y. and PARIS, May 21, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.",REGN,0.03746,0.028366,Neutral
Dupixent®  ( dupilumab )  Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine,https://www.globenewswire.com/news-release/2023/05/21/2672905/0/en/Dupixent-dupilumab-Late-breaking-Phase-3-COPD-Results-Presented-at-ATS-and-Simultaneously-Published-in-the-New-England-Journal-of-Medicine.html,2023-05-21 18:18:00,Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo ...,REGN,0.035621,0.02922,Neutral
Press Release: Dupixent®  ( dupilumab )  late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/05/g32501090/press-release-dupixent-dupilumab-late-breaking-phase-3-copd-results-presented-at-ats-and-simultane,2023-05-21 18:17:07,Dupixent® ( dupilumab ) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute ...,REGN,0.025352,0.037274,Neutral
Press Release: Dupixent®  ( dupilumab )  late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine,https://www.globenewswire.com/news-release/2023/05/21/2672904/0/en/Press-Release-Dupixent-dupilumab-late-breaking-Phase-3-COPD-results-presented-at-ATS-and-simultaneously-published-in-the-New-England-Journal-of-Medicine.html,2023-05-21 18:17:00,Dupixent® ( dupilumab ) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine ...,REGN,0.025073,0.037357,Neutral
Can This Gene-Editing Stock Deliver 10X Returns?,https://www.fool.com/investing/2023/06/08/can-this-gene-editing-stock-deliver-10x-returns/,2023-06-08 15:30:00,Buying shares of Intellia Therapeutics might be a smart move.,REGN,0.05749,0.0,Neutral
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/news/earnings/23/06/32758841/heres-how-much-you-would-have-made-owning-regeneron-pharmaceuticals-stock-in-the-last-10-years,2023-06-07 14:00:42,"Regeneron Pharmaceuticals REGN has outperformed the market over the past 10 years by 1.42% on an annualized basis producing an average annual return of 11.59%. Currently, Regeneron Pharmaceuticals has a market capitalization of $81.62 billion.",REGN,0.980595,0.386944,Bullish
Is Invesco Dynamic Biotechnology & Genome ETF  ( PBE )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2104843/is-invesco-dynamic-biotechnology-genome-etf-pbe-a-strong-etf-right-now,2023-06-07 10:20:06,Smart Beta ETF report for ...,REGN,0.11894,0.061867,Neutral
Regeneron Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark,https://www.investors.com/ibd-data-stories/regeneron-pharmaceuticals-hits-80-plus-relative-strength-rating-benchmark/,2023-06-06 07:00:00,Regeneron Pharmaceuticals Hits 80-Plus Relative Strength Rating ... Investor's Business Daily ...,REGN,0.470894,0.201379,Somewhat-Bullish
Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays.,https://www.marketwatch.com/story/biotech-stocks-could-soon-get-a-m-a-boost-here-are-3-likely-takeover-plays-206b79c3,2023-06-05 19:05:00,Big pharma will be looking to acquire companies with promsing new medicines.,REGN,0.064885,-0.178347,Somewhat-Bearish
Regeneron Pharmaceuticals Unusual Options Activity For June 05 - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/06/32722765/regeneron-pharmaceuticals-unusual-options-activity-for-june-05,2023-06-05 19:01:33,"Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...",REGN,0.722509,0.308927,Somewhat-Bullish
"Alopecia Areata Market to Show Positive Growth at a CAGR of 26.3% During the Study Period  ( 2019-2032 ) , Estimates DelveInsight",https://www.prnewswire.com/news-releases/alopecia-areata-market-to-show-positive-growth-at-a-cagr-of-26-3-during-the-study-period-20192032-estimates-delveinsight-301853907.html,2023-06-19 20:00:00,"Alopecia Areata Market to Show Positive Growth at a CAGR of 26.3% During the Study Period ( 2019-2032 ) , Estimates ... PR ...",REGN,0.026474,0.074709,Neutral
2 Short-Squeeze Candidates That Could Go Parabolic,https://www.fool.com/investing/2023/06/15/2-short-squeeze-candidates-that-could-go-parabolic/,2023-06-15 14:00:00,Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately.,REGN,0.050148,0.212308,Somewhat-Bullish
"EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035 - EyePoint Pharmaceuticals  ( NASDAQ:EYPT ) ",https://www.benzinga.com/general/biotech/23/06/32861319/eyepoints-eyp-1901-tipped-to-transform-wet-amd-market-analyst-predicts-potential-870m-sales-by-20,2023-06-14 19:14:32,JonesResearch has initiated coverage of ophthalmic biopharmaceutical company EyePoint Pharmaceuticals Inc EYPT with a Buy rating and a $26 price target.,REGN,0.258351,0.172124,Somewhat-Bullish
2 Stocks to Buy No Matter What Happens in June and Beyond,https://www.fool.com/investing/2023/06/14/2-stocks-to-buy-no-matter-what-happens-in-june-and/,2023-06-14 14:00:00,"A lot could go wrong in the next few months, but investors should largely ignore all that noise.",REGN,0.112797,-0.04725,Neutral
"GILD: 2 Game-Changing Biotech Stocks, 1 to Sell Now",https://stocknews.com/news/gild-regn-ttnp-rcus-2-game-changing-biotech-stocks-1-to-sell-now/,2023-06-12 15:23:55,"Progress in the personalized medicines sector and the adoption of new avenues for biotechnology applications are boosting the biotech industry. However, concerns such as economic slowdowns and geopolitical risks might hamper its growth.",REGN,0.243585,0.16252,Somewhat-Bullish
"Melanoma Market to Witness Promising Growth, Predicts DelveInsight | Key Companies To Watch - IO Biotech, Merck, Eisai, Regeneron, Genentech, Seagen, Amgen, Astellas, Galectin, MedImmune, Aivita, Linnaeus, Checkmate, OnKure",https://www.prnewswire.com/news-releases/melanoma-market-to-witness-promising-growth-predicts-delveinsight--key-companies-to-watch---io-biotech-merck-eisai-regeneron-genentech-seagen-amgen-astellas-galectin-medimmune-aivita-linnaeus-checkmate-onkure-301846881.html,2023-06-12 15:00:00,"Melanoma Market to Witness Promising Growth, Predicts ... PR ...",REGN,0.057721,0.053018,Neutral
Why Regeneron Pharmaceuticals Stock Dipped This Week,https://www.fool.com/investing/2023/06/29/why-regeneron-pharmaceuticals-stock-dipped-this-we/,2023-06-29 18:04:19,A key regulatory setback is weighing on the biotech's stock.,REGN,0.268294,-0.033506,Neutral
What Will Amgen Buy Next?,https://www.fool.com/investing/2023/06/29/what-will-amgen-buy-next/,2023-06-29 16:45:00,The biotech could pursue these two budget-friendly targets.,REGN,0.066047,-0.074103,Neutral
Catalent's  ( CTLT )  Facility Snag Linked to Regeneron's Eylea CRL,https://www.zacks.com/stock/news/2114846/catalents-ctlt-facility-snag-linked-to-regenerons-eylea-crl,2023-06-29 13:38:00,"Catalent's (CTLT) drug manufacturing facility in Indiana faces problems, which is linked to FDA's rejection of Regeneron's eye drug application. This is the latest in a string of quality control issues for Catalent.",REGN,0.117486,-0.176046,Somewhat-Bearish
"The Zacks Analyst Blog Highlights Texas Instruments, Regeneron Pharmaceuticals, Micron Technology, FedEx and Arista Networks",https://www.zacks.com/stock/news/2114560/the-zacks-analyst-blog-highlights-texas-instruments-regeneron-pharmaceuticals-micron-technology-fedex-and-arista-networks,2023-06-29 09:00:00,"Texas Instruments, Regeneron Pharmaceuticals, Micron Technology, FedEx and Arista Networks are included in this Analyst Blog.",REGN,0.70749,0.0,Neutral
Why Catalent Stock Flopped Today,https://www.fool.com/investing/2023/06/28/why-catalent-stock-flopped-today/,2023-06-28 22:40:00,The company takes the fall for a failed drug application.,REGN,0.295867,0.011551,Neutral
"Geographic Atrophy Market to Boost Significantly, Assesses DelveInsight | Key Companies Active in the Domain - Novartis, Annexon, Apellis, Ionis, Astellas, Gyroscope, Genentech, Aviceda, Iveric Bio",https://www.prnewswire.com/news-releases/geographic-atrophy-market-to-boost-significantly-assesses-delveinsight--key-companies-active-in-the-domain---novartis-annexon-apellis-ionis-astellas-gyroscope-genentech-aviceda-iveric-bio-301865699.html,2023-06-28 21:01:00,"Geographic Atrophy Market to Boost Significantly, Assesses DelveInsight | Key Companies Active in the Domain ... PR ...",REGN,0.051663,-0.087948,Neutral
Why Regeneron Stock Is Trading Lower Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/news/23/06/33049479/why-regeneron-stock-is-trading-lower-today,2023-06-28 19:53:22,"Regeneron Pharmaceuticals, Inc. REGN shares continue to fall Wednesday after news Tuesday that the FDA issued a Complete Response Letter ( CRL ) for aflibercept 8 mg Biologics License application due to an ongoing review of inspection findings at a third-party filler.",REGN,0.969227,-0.123899,Neutral
"Top Analyst Reports for Texas Instruments, Regeneron & Micron Technology",https://www.zacks.com/research-daily/2114238/top-analyst-reports-for-texas-instruments-regeneron-micron-technology,2023-06-28 15:53:00,"Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Inc. (TXN), Regeneron Pharmaceuticals, Inc. (REGN) and Micron Technology, Inc. (MU).",REGN,0.126784,0.118819,Neutral
Check Out What Whales Are Doing With REGN - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/06/33043055/check-out-what-whales-are-doing-with-regn,2023-06-28 13:51:10,"Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...",REGN,0.7868,0.184525,Somewhat-Bullish
"Amazon.com To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Wednesday - American States Water  ( NYSE:AWR ) , Amazon.com  ( NASDAQ:AMZN ) ",https://www.benzinga.com/news/23/06/33039749/amazon-com-to-rally-over-16-here-are-10-other-analyst-forecasts-for-wednesday,2023-06-28 11:53:01,"Deutsche Bank cut the price target for Walgreens Boots Alliance, Inc. WBA from $46 to $34. Deutsche Bank analyst George Hill downgraded the stock from Buy to Hold. Walgreens shares fell 0.2% to $28.59 in pre-market trading. Canaccord Genuity cut the price target for Regeneron Pharmaceuticals, Inc.",REGN,0.266828,-0.159547,Somewhat-Bearish
"Regeneron  ( REGN )  Gets CRL for Aflibercept 8 mg Drug, Shares Fall",https://www.zacks.com/stock/news/2114010/regeneron-regn-gets-crl-for-aflibercept-8-mg-drug-shares-fall,2023-06-28 10:13:00,Regeneron (REGN) receives a completed response letter for the application seeking approval of aflibercept 8 mg for treating several retinopathic indications. The stock falls 9% following the news.,REGN,0.320676,0.309563,Somewhat-Bullish
Ophthalmology therapeutics market size to increase by USD 15.72 billion from 2022 to 2027; North America will account for 44% of market growth - Technavio,https://www.prnewswire.com/news-releases/ophthalmology-therapeutics-market-size-to-increase-by-usd-15-72-billion-from-2022-to-2027-north-america-will-account-for-44-of-market-growth---technavio-301864687.html,2023-06-28 01:15:00,Ophthalmology therapeutics market size to increase by USD 15.72 billion from 2022 to 2027. North America will ... PR ...,REGN,0.026013,0.191762,Somewhat-Bullish
Why Regeneron Stock Is Falling Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/news/23/06/33032909/why-regeneron-stock-is-falling-today,2023-06-27 19:53:04,"Regeneron Pharmaceuticals, Inc. REGN shares fell after the FDA issued a Complete Response Letter ( CRL ) for aflibercept 8 mg Biologics License application due to an ongoing review of inspection findings at a third-party filler.",REGN,0.783955,0.224293,Somewhat-Bullish
Regeneron Crumbles After FDA Rejects Its Next Blockbuster Contender,https://www.investors.com/news/technology/regn-stock-crumbles-after-the-fda-rejects-its-next-possible-blockbuster/,2023-06-27 19:50:00,REGN Stock Crumbles After The FDA Rejects Its Next Possible ... Investor's Business Daily ...,REGN,0.582526,-0.320479,Somewhat-Bearish
"US FDA declines to approve Regeneron's higher-dose Eylea, shares tumble",https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-regeneron-high-dose-eylea-2023-06-27/,2023-06-27 18:59:00,US FDA declines to approve ...,REGN,0.110462,-0.026805,Neutral
Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema,https://www.globenewswire.com/news-release/2023/06/27/2695733/0/en/Two-year-Results-for-Aflibercept-8-mg-from-Pivotal-PHOTON-Trial-Demonstrate-Durable-Vision-Gains-at-Extended-Dosing-Intervals-in-Diabetic-Macular-Edema.html,2023-06-27 18:46:00,89% of all aflibercept 8 mg patients maintained ≥12-week dosing intervals through two years ...,REGN,0.054857,0.048,Neutral
FDA Issues Complete Response Letter  ( CRL )  for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/06/g33032072/fda-issues-complete-response-letter-crl-for-aflibercept-8-mg-biologics-license-application-solely-,2023-06-27 18:45:00,"TARRYTOWN, N.Y., June 27, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced that the U.S.",REGN,0.24289,0.015121,Neutral
FDA Issues Complete Response Letter  ( CRL )  for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler,https://www.globenewswire.com/news-release/2023/06/27/2695732/0/en/FDA-Issues-Complete-Response-Letter-CRL-for-Aflibercept-8-mg-Biologics-License-Application-Solely-Due-to-an-Ongoing-Review-of-Inspection-Findings-at-a-Third-party-Filler.html,2023-06-27 18:45:00,"No issues with clinical efficacy or safety, trial design, labeling or drug substance manufacturing were identified in the CRL ...",REGN,0.115094,0.05356,Neutral
"Questex's Fierce Clinical Summit Returns to Discuss All Things Clinical, Brings the Clinical Research and Trial Management Ecosystem Together September 26-28 in Philadelphia",https://www.benzinga.com/pressreleases/23/06/g33025104/questexs-fierce-clinical-summit-returns-to-discuss-all-things-clinical-brings-the-clinical-researc,2023-06-27 14:00:00,"NEW YORK, June 27, 2023 ( GLOBE NEWSWIRE ) -- Questex's Fierce Pharma today announces the Fierce Clinical Summit will take place September 26-28 in Philadelphia. The Summit is Fierce Pharma's flagship event for the clinical research and trial management ecosystem.",REGN,0.044885,0.191892,Somewhat-Bullish
Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain,https://www.prnewswire.com/news-releases/antibody-drug-conjugates-clinical-trial-pipeline-experiences-momentum-delveinsight-estimates-a-diverse-pipeline-comprising-180-companies-working-in-the-domain-301862784.html,2023-06-26 21:01:00,Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline ... PR ...,REGN,0.083468,0.037756,Neutral
"Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Lowered to ""Buy"" at StockNews.com",https://www.defenseworld.net/2023/06/23/regeneron-pharmaceuticals-nasdaqregn-lowered-to-buy-at-stocknews-com.html,2023-06-23 08:12:43,"Regeneron Pharmaceuticals ( NASDAQ:REGN ) Lowered to ""Buy"" at ... Defense World ...",REGN,0.821115,0.461679,Bullish
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/news/earnings/23/06/32977277/100-invested-in-this-stock-5-years-ago-would-be-worth-200-today,2023-06-22 21:31:59,"Regeneron Pharmaceuticals REGN has outperformed the market over the past 5 years by 9.01% on an annualized basis producing an average annual return of 18.97%. Currently, Regeneron Pharmaceuticals has a market capitalization of $85.55 billion.",REGN,0.980595,0.386944,Bullish
VRTX: 3 Biotech Stocks With 'A' POWR Ratings,https://stocknews.com/news/vrtx-regn-uthr-crsp-3-biotech-stocks-with-a-powr-ratings/,2023-06-22 17:09:33,"The biotech industry shows solid growth, mainly driven by the influx of emerging and innovative technology and government-backed investments.",REGN,0.260719,0.174042,Somewhat-Bullish
2 Biotech Stocks You Can Buy and Hold for the Next Decade,https://www.fool.com/investing/2023/06/21/2-biotech-stocks-you-can-buy-and-hold-for-the-next/,2023-06-21 12:22:00,Gilead and Regeneron Pharmaceuticals both had triple-digit percentage growth over the past decade.,REGN,0.08609,0.130467,Neutral
"SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN",https://www.benzinga.com/pressreleases/23/07/g33158526/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-regeneron-pharm,2023-07-09 16:59:51,"NEW YORK, July 09, 2023 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. ( ""Regeneron"" or the ""Company"" ) REGN. Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.",REGN,0.275867,0.0,Neutral
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/07/33150473/looking-at-regeneron-pharmaceuticalss-recent-unusual-options-activity,2023-07-07 16:49:17,"Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...",REGN,0.834422,0.323772,Somewhat-Bullish
"$1 Billion Deal For Moderna To Expand Product Pipeline In China - Gilead Sciences  ( NASDAQ:GILD ) , Moderna  ( NASDAQ:MRNA ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33145546/1-billion-deal-for-moderna-to-expand-product-pipeline-in-china,2023-07-07 12:45:17,The defensive stocks sector has been underperforming most - if not all - of the remaining cyclical sectors in the U.S. economy. These preferences come from underlying dynamics in the money markets and where investors think we are in the business cycle.,REGN,0.157141,-0.041704,Neutral
1 Cathie Wood Stock That Could Double Your Money,https://www.fool.com/investing/2023/07/06/1-cathie-wood-stock-that-could-double-your-money/,2023-07-06 13:30:00,This gene-editing pioneer stands out as a top growth stock to buy right now.,REGN,0.055492,0.108864,Neutral
"Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday - Amedisys  ( NASDAQ:AMED ) , ArcBest  ( NASDAQ:ARCB ) ",https://www.benzinga.com/news/23/07/33131758/meta-platforms-to-rally-around-14-here-are-10-other-analyst-forecasts-for-thursday,2023-07-06 12:43:35,Morgan Stanley cut the price target for ArcBest Corporation ARCB from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at $95.42 on Wednesday. Truist Securities increased the price target for Owens Corning OC from $105 to $135.,REGN,0.285526,-0.185683,Somewhat-Bearish
Is Regeneron's Stock in Trouble After This FDA Rejection?,https://www.fool.com/investing/2023/07/06/is-regenerons-stock-in-trouble-after-this-fda-reje/,2023-07-06 11:50:00,"The company's growth rate has been slowing sharply in recent quarters, and Eylea generates the bulk of its product revenue.",REGN,0.140896,-0.043867,Neutral
Prostate Cancer Global Market to Witness Upsurge in Growth at a CAGR of ~5% by 2028 | DelveInsight,https://www.prnewswire.com/news-releases/prostate-cancer-global-market-to-witness-upsurge-in-growth-at-a-cagr-of-5-by-2028--delveinsight-301869890.html,2023-07-05 21:01:00,"The prostate cancer market is anticipated to propel owing to the increasing incidence of prostate cancer around the world, the rising number of risk factors for prostate cancer, growing technological advancements in prostate cancer diagnostics, government, and non-government awareness ...",REGN,0.027195,-0.093078,Neutral
Regeneron  ( REGN )  Loses 13% in Three Months: What Lies Ahead?,https://www.zacks.com/stock/news/2116853/regeneron-regn-loses-13-in-three-months-what-lies-ahead,2023-07-05 11:58:00,Regeneron (REGN) declines 13% in the last three months due to regulatory setback for 8 mg dose strength of aflibercept and competition for lead drug.,REGN,0.200688,-0.188505,Somewhat-Bearish
Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html,2023-07-03 21:01:00,Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the ... PR ...,REGN,0.081483,0.048837,Neutral
Check Out What Whales Are Doing With REGN - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/07/33100708/check-out-what-whales-are-doing-with-regn,2023-07-03 18:32:59,A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 15 strange trades.,REGN,0.78028,0.090724,Neutral
Looking Into Regeneron Pharmaceuticals's Recent Short Interest - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/short-sellers/23/07/33096690/looking-into-regeneron-pharmaceuticalss-recent-short-interest,2023-07-03 13:46:06,"Regeneron Pharmaceuticals's REGN short percent of float has risen 7.26% since its last report. The company recently reported that it has 1.23 million shares sold short, which is 1.33% of all regular shares that are available for trading.",REGN,0.221819,0.155473,Somewhat-Bullish
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF  ( PBE ) ?,https://www.zacks.com/stock/news/2115804/should-you-invest-in-the-invesco-dynamic-biotechnology-genome-etf-pbe,2023-07-03 10:20:09,Sector ETF report for ...,REGN,0.128478,0.069872,Neutral
"Regeneron Pharmaceuticals, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/pressreleases/23/06/g33084292/regeneron-pharmaceuticals-inc-investors-please-contact-the-portnoy-law-firm-to-recover-your-losses,2023-06-30 19:33:17,"Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 30, 2023 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises Regeneron Pharmaceuticals, Inc. ( ""Regeneron"" or ""the Company"" ) REGNinvestors that the law firm has initiated an investigation ...",REGN,0.126119,0.035373,Neutral
REGN Shareholder News: Johnson Fistel Encourages Regeneron Pharmaceuticals Shareholders with Losses to Contact the Firm Regarding Investigation - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/06/g33083753/regn-shareholder-news-johnson-fistel-encourages-regeneron-pharmaceuticals-shareholders-with-losses,2023-06-30 18:49:43,"SAN DIEGO, June 30, 2023 ( GLOBE NEWSWIRE ) -- Shareholder rights law firm Johnson Fistel, LLP ( www.JohnsonFistel.com ) is investigating whether Regeneron Pharmaceuticals, Inc. ( ""Regeneron"" or ""the Company"" ) REGN, any of its executive officers or others violated securities laws by ...",REGN,0.288893,-0.125235,Neutral
Market Rally Roars Back Toward Highs: Weekly Review,https://www.investors.com/news/stock-market-rally-roars-back-toward-highs-carnival-delta-micron-nvidia-in-focus/,2023-06-30 17:48:00,"The stock market rally ran toward 2023 highs again with broad-based gains, as many of the major indexes rebound from or near their 21-day moving averages. A number of stocks flashed buy signals, either from traditional breakouts or from pullbacks or early entries.",REGN,0.054175,-0.108088,Neutral
Looking Into Regeneron Pharmaceuticals's Recent Short Interest - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/short-sellers/23/07/33289402/looking-into-regeneron-pharmaceuticalss-recent-short-interest,2023-07-19 17:00:34,"Regeneron Pharmaceuticals's REGN short percent of float has fallen 11.28% since its last report. The company recently reported that it has 1.08 million shares sold short, which is 1.18% of all regular shares that are available for trading.",REGN,0.221819,0.083071,Neutral
Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer,https://www.globenewswire.com/news-release/2023/07/19/2707172/0/en/Autolus-Therapeutics-announces-appointment-of-Robert-F-Dolski-as-Chief-Financial-Officer.html,2023-07-19 11:00:00,"- Veronica Hersberger appointed as Senior Vice President, Medical Affairs- Miranda Neville promoted to Senior Vice President, Project Management and will continue to lead the obe-cel program ...",REGN,0.024775,0.063853,Neutral
Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?,https://www.zacks.com/stock/news/2123401/should-you-invest-in-the-ishares-biotechnology-etf-ibb,2023-07-19 10:20:07,Sector ETF report for ...,REGN,0.137278,0.072244,Neutral
"Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023",https://www.globenewswire.com/news-release/2023/07/18/2705178/0/en/Kiniksa-Pharmaceuticals-to-Report-Second-Quarter-2023-Financial-Results-on-July-25-2023.html,2023-07-18 20:01:00,"HAMILTON, Bermuda, July 18, 2023 ( GLOBE NEWSWIRE ) -- Kiniksa Pharmaceuticals, Ltd. ( Nasdaq: KNSA ) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30 a.m. Eastern Time to report its second quarter 2023 financial results and recent portfolio ...",REGN,0.183895,0.0,Neutral
What's in Store for Thermo Fisher  ( TMO )  in Q2 Earnings?,https://www.zacks.com/stock/news/2123161/whats-in-store-for-thermo-fisher-tmo-in-q2-earnings,2023-07-18 15:23:00,"Thermo Fisher (TMO) is likely to have generated growth in the second quarter, driven by a favorable business mix and new launches.",REGN,0.112532,0.121519,Neutral
This Is What Whales Are Betting On Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/07/33255457/this-is-what-whales-are-betting-on-regeneron-pharmaceuticals,2023-07-17 19:46:03,A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 10 strange trades.,REGN,0.825367,0.024317,Neutral
"Alnylam Says Single Injection Of RNAi Therapy Cuts Alzheimer's-Linked Proteins By 65%, Stock Soars - Alnylam Pharmaceuticals  ( NASDAQ:ALNY ) ",https://www.benzinga.com/general/biotech/23/07/33247048/alnylam-says-single-injection-of-rnai-therapy-cuts-alzheimers-linked-proteins-by-65-stock-soars,2023-07-17 14:18:27,Alnylam Pharmaceuticals Inc ALNY announced updated interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP for Alzheimer's disease and cerebral amyloid angiopathy ( CAA ) .,REGN,0.241684,-0.125582,Neutral
Alnylam  ( ALNY )  Posts Upbeat Data From Alzheimer's Disease Study,https://www.zacks.com/stock/news/2122141/alnylam-alny-posts-upbeat-data-from-alzheimers-disease-study,2023-07-17 14:06:00,Alnylam (ALNY) announces positive interim analysis data from the Part A of its early-stage study of ALN-APP in the treatment of early-onset Alzheimer's disease and cerebral amyloid angiopathy.,REGN,0.172919,0.087479,Neutral
"Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023",https://www.globenewswire.com/news-release/2023/07/17/2705178/0/en/Kiniksa-Pharmaceuticals-to-Report-Second-Quarter-2023-Financial-Results-on-July-25-2023.html,2023-07-17 12:00:00,"HAMILTON, Bermuda, July 17, 2023 ( GLOBE NEWSWIRE ) -- Kiniksa Pharmaceuticals, Ltd. ( Nasdaq: KNSA ) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30 a.m. Eastern Time to report its second quarter 2023 financial results and recent portfolio ...",REGN,0.183895,0.0,Neutral
Fibrodysplasia Ossificans Progressiva Pipeline Research 2023: Focus on 5+ Companies and 7+ Pipeline Drugs - Analysis of the Advancements and Potential Breakthroughs,https://www.prnewswire.com/news-releases/fibrodysplasia-ossificans-progressiva-pipeline-research-2023-focus-on-5-companies-and-7-pipeline-drugs---analysis-of-the-advancements-and-potential-breakthroughs-301877547.html,2023-07-15 00:30:00,Fibrodysplasia Ossificans Progressiva Pipeline Research 2023: Focus on 5+ Companies and 7+ Pipeline Drugs ... PR ...,REGN,0.074926,0.063543,Neutral
"UnitedHealth Group  ( UNH )  Q2 Earnings Beat, Boosts '23 EPS View",https://www.zacks.com/stock/news/2121564/unitedhealth-group-unh-q2-earnings-beat-boosts-23-eps-view,2023-07-14 16:00:00,UnitedHealth Group's (UNH) Q2 results benefited on the back of solid contributions from the UnitedHealthcare and Optum segments. Management presently forecasts adjusted net EPS within $24.70-$25.00 for 2023.,REGN,0.117486,0.107743,Neutral
Gene Editing Market worth $10.6 billion | MarketsandMarkets,https://www.prnewswire.com/news-releases/gene-editing-market-worth-10-6-billion--marketsandmarkets-301877363.html,2023-07-14 14:15:00,"CHICAGO, July 14, 2023 /PRNewswire/ -- In the near future, the gene editing industry holds immense promise in revolutionizing healthcare and addressing genetic disorders.",REGN,0.023957,0.153382,Somewhat-Bullish
Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors,https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-appointment-of-christine-a-poon-to-board-of-directors-301874728.html,2023-07-11 20:05:00,"SAN DIEGO, July 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. ( Nasdaq: NBIX ) today announced that it appointed Christine A. Poon, a business leader with extensive experience in the pharmaceutical industry, to its Board of Directors.",REGN,0.07913,0.032424,Neutral
Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS,https://www.globenewswire.com/news-release/2023/07/29/2714510/0/en/Aflibercept-8-mg-Two-Year-Results-from-Pivotal-PHOTON-Trial-in-Diabetic-Macular-Edema-Presented-at-ASRS.html,2023-07-29 18:25:00,"89% and 84% of patients were maintained on ≥12- and ≥16-week dosing intervals, respectively, throughout the two-year period, while sustaining their vision and anatomic improvements ...",REGN,0.059085,0.054053,Neutral
Regeneron  ( REGN )  to Report Q2 Earnings: What's in Store?,https://www.zacks.com/stock/news/2129606/regeneron-regn-to-report-q2-earnings-whats-in-store,2023-07-28 16:42:00,Investors' focus is likely to be on the performance of lead drugs Eylea and Dupixent when Regeneron (REGN) reports its second-quarter 2023 results.,REGN,0.236205,0.26067,Somewhat-Bullish
P/E Ratio Insights for Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/news/23/07/33446204/pe-ratio-insights-for-regeneron-pharmaceuticals,2023-07-28 16:15:14,"In the current session, the stock is trading at $746.05, after a 0.19% spike. Over the past month, Regeneron Pharmaceuticals Inc. REGN stock increased by 3.83%, and in the past year, by 29.37%.",REGN,0.433523,0.060612,Neutral
"Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director - Vaxxinity  ( NASDAQ:VAXX ) ",https://www.benzinga.com/pressreleases/23/07/g33431037/vaxxinity-appoints-peter-powchik-m-d-to-executive-vice-president-global-scientific-director,2023-07-27 20:30:36,"Appointment adds Dr. Powchik's experience in the development of marketed immunotherapeutics to Vaxxinity's leadership team CAPE CANAVERAL, Fla., July 27, 2023 ( GLOBE NEWSWIRE ) -- Vaxxinity, Inc.",REGN,0.03448,0.064032,Neutral
"Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director",https://www.globenewswire.com/news-release/2023/07/27/2712750/0/en/Vaxxinity-Appoints-Peter-Powchik-M-D-to-Executive-Vice-President-Global-Scientific-Director.html,2023-07-27 20:30:00,Appointment adds Dr. Powchik's experience in the development of marketed immunotherapeutics to Vaxxinity's leadership team ...,REGN,0.034933,0.066095,Neutral
"Roche's 1H Earnings Decline On Lower COVID-19 Sales, CFO Says Late-Stage Pipeline Has Gaps That Needs To Be Filled - Roche Holding  ( OTC:RHHBF ) , Roche Holding  ( OTC:RHHVF ) , Roche Holding  ( OTC:RHHBY ) ",https://www.benzinga.com/general/biotech/23/07/33412284/roches-1h-earnings-decline-on-lower-covid-19-sales-cfo-says-late-stage-pipeline-has-gaps-that-nee,2023-07-27 14:58:25,"Roche Holding AG RHHBY said sales for 1H 2023 dropped to CHF 30.62 billion from CHF 33.9 billion in the same period last year, reflecting the expected tapering of demand for COVID-19 tests that was booming during the pandemic.",REGN,0.232439,-0.151203,Somewhat-Bearish
"Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List - Roche Holding  ( OTC:RHHBF ) , Roche Holding  ( OTC:RHHVF ) , Roche Holding  ( OTC:RHHBY ) ",https://www.benzinga.com/general/biotech/23/07/33393415/novo-nordisks-obesity-drug-saxenda-not-included-in-whos-essential-drug-list,2023-07-26 14:24:05,"The World Health Organization ( WHO ) published the new editions of the Model Lists of Essential Medicines ( EML ) and Essential Medicines for Children ( EMLc ) , which include important new medicines for multiple sclerosis, cancer, infectious diseases, and cardiovascular conditions, among ...",REGN,0.232439,0.0,Neutral
"Obesity drugs don't make WHO's essential list, but Ebola, MS drugs added",https://www.reuters.com/business/healthcare-pharmaceuticals/obesity-drugs-dont-make-whos-essential-list-ebola-ms-drugs-added-2023-07-26/,2023-07-26 12:02:00,"LONDON, July 26 ( Reuters ) - Obesity drugs will not be included in the World Health Organization's ( WHO ) latest essential medicines list, but treatments for diseases including Ebola and multiple sclerosis will, according to documents published by the U.N. agency.",REGN,0.077094,0.0,Neutral
Should First Trust NASDAQ-100 Equal Weighted ETF  ( QQEW )  Be on Your Investing Radar?,https://www.zacks.com/stock/news/2127493/should-first-trust-nasdaq-100-equal-weighted-etf-qqew-be-on-your-investing-radar,2023-07-26 10:20:08,Style Box ETF report for ...,REGN,0.116914,0.060317,Neutral
Should You Invest in the First Trust NYSE Arca Biotechnology ETF  ( FBT ) ?,https://www.zacks.com/stock/news/2127499/should-you-invest-in-the-first-trust-nyse-arca-biotechnology-etf-fbt,2023-07-26 10:20:07,Sector ETF report for ...,REGN,0.134214,0.071398,Neutral
Regeneron Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/07/g33376698/regeneron-pharmaceuticals-investigated-by-block-leviton-for-potential-securities-law-violations-in,2023-07-25 19:04:01,"BOSTON, July 25, 2023 ( GLOBE NEWSWIRE ) -- Block & Leviton is investigating Regeneron Pharmaceuticals, Inc. REGN for potential securities law violations. Investors who have lost money in their Regeneron Pharmaceuticals, Inc. investment should contact the firm to learn more about how they might ...",REGN,0.541149,-0.243446,Somewhat-Bearish
Kiniksa Pharmaceuticals Reports Second Quarter 2023 Financial Results and Recent Portfolio Execution,https://www.globenewswire.com/news-release/2023/07/25/2710316/0/en/Kiniksa-Pharmaceuticals-Reports-Second-Quarter-2023-Financial-Results-and-Recent-Portfolio-Execution.html,2023-07-25 11:30:00,"- ARCALYST® ( rilonacept ) Q2 2023 net product revenue of $54.5 million -- ARCALYST 2023 net product revenue guidance increased to $220 - $230 million, representing ~84% year-over-year growth at the midpoint -- KPL-404 Phase 2 rheumatoid arthritis data expected in 1H 2024 -- Cash reserves now ...",REGN,0.019879,-0.168969,Somewhat-Bearish
"Cutaneous Melanoma Market is Predicted to Exhibit Remarkable Growth, Predicts DelveInsight | Key Companies - Merck, Amgen, Anaveon, Eisai, Regeneron, BMS, AstraZeneca, Seagen, Novartis, Eli Lilly and Company",https://www.prnewswire.com/news-releases/cutaneous-melanoma-market-is-predicted-to-exhibit-remarkable-growth-predicts-delveinsight--key-companies---merck-amgen-anaveon-eisai-regeneron-bms-astrazeneca-seagen-novartis-eli-lilly-and-company-301883725.html,2023-07-24 21:01:00,"Cutaneous Melanoma Market is Predicted to Exhibit Remarkable Growth, Predicts DelveInsight | Key Companies ... PR ...",REGN,0.02692,0.029117,Neutral
Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors,https://www.prnewswire.com/news-releases/cadrenal-therapeutics-announces-appointment-of-robert-lisicki-to-board-of-directors-301883700.html,2023-07-24 13:00:00,"PONTE VEDRA, Fla., July 24, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ( ""Cadrenal"" or the ""Company"" ) ( Nasdaq: CVKD ) , a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant ( blood thinner ) for certain rare medical conditions, today ...",REGN,0.054483,-0.049075,Neutral
Biotech wins fail to move stock indicators ahead of earnings,https://www.financialexpress.com/healthcare/news-healthcare/biotech-wins-fail-to-move-stock-indicators-ahead-of-earnings/3184760/,2023-07-24 10:35:25,Biotech has had a pretty good year between a flurry of deals and approvals of new drugs for vexing diseases such as Alzheimer's. Yet that isn't showing up in stock performance. Two closely watched indicators lag far behind the overall market.,REGN,0.057215,0.0,Neutral
Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2125862/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now,2023-07-24 10:20:08,Smart Beta ETF report for ...,REGN,0.121959,0.061385,Neutral
Is First Trust NYSE Arca Biotechnology ETF  ( FBT )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2125864/is-first-trust-nyse-arca-biotechnology-etf-fbt-a-strong-etf-right-now,2023-07-24 10:20:07,Smart Beta ETF report for ...,REGN,0.117486,0.060435,Neutral
"Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Upgraded by StockNews.com to ""Strong-Buy""",https://www.defenseworld.net/2023/08/08/regeneron-pharmaceuticals-nasdaqregn-upgraded-by-stocknews-com-to-strong-buy.html,2023-08-08 10:14:39,StockNews.com upgraded shares of Regeneron Pharmaceuticals ( NASDAQ:REGN - Free Report ) from a buy rating to a strong-buy rating in a research report report published on Friday morning. REGN has been the topic of a number of other reports. Robert W.,REGN,0.771638,0.452932,Bullish
BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update,https://www.globenewswire.com/news-release/2023/08/07/2719502/0/en/BioNTech-Announces-Second-Quarter-2023-Financial-Results-and-Corporate-Update.html,2023-08-07 10:00:00,"Conference call and webcast scheduled for August 7, 2023, at 8:00 am EDT ( 2:00 pm CEST ...",REGN,0.00987,-0.050379,Neutral
"StockNews.com Upgrades Regeneron Pharmaceuticals  ( NASDAQ:REGN )  to ""Strong-Buy""",https://www.defenseworld.net/2023/08/06/stocknews-com-upgrades-regeneron-pharmaceuticals-nasdaqregn-to-strong-buy.html,2023-08-06 06:04:41,"Regeneron Pharmaceuticals ( NASDAQ:REGN - Get Free Report ) was upgraded by equities research analysts at StockNews.com from a ""buy"" rating to a ""strong-buy"" rating in a report issued on Friday.",REGN,0.785083,0.440703,Bullish
 ( REGN )  - Analyzing Regeneron Pharmaceuticals's Short Interest - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/short-sellers/23/08/33578514/regn-analyzing-regeneron-pharmaceuticalss-short-interest,2023-08-04 16:45:29,"Regeneron Pharmaceuticals's REGN short percent of float has risen 16.95% since its last report. The company recently reported that it has 1.27 million shares sold short, which is 1.38% of all regular shares that are available for trading.",REGN,0.221819,0.155473,Somewhat-Bullish
"Alnylam  ( ALNY )  Q2 Loss Wider Than Expected, Revenues Miss",https://www.zacks.com/stock/news/2132776/alnylam-alny-q2-loss-wider-than-expected-revenues-miss,2023-08-04 15:24:00,"Alnylam (ALNY) reports weaker-than-expected second-quarter results. The company also provides updates on its pipeline candidates, which are being developed in collaboration with other pharma bigwigs.",REGN,0.067632,-0.023153,Neutral
Market Rally Under Pressure As Yields Soar: Weekly Review,https://www.investors.com/news/market-rally-under-pressure-as-yields-soar-amazon-elf-caterpillar-are-earnings-winners/,2023-08-04 14:51:00,"The stock market rally came under pressure amid surging Treasury yields, fueled by a U.S. credit-rating downgrade as well, swelling Treasury issuance and improving U.S. economic growth. But yields pared gains following a mixed jobs report. Apple ( AAPL ) and Amazon ( AMZN ) capped a huge week of ...",REGN,0.04872,-0.016999,Neutral
"Intellia  ( NTLA )  Misses on Q2 Earnings, Gives Pipeline Update",https://www.zacks.com/stock/news/2132773/intellia-ntla-misses-on-q2-earnings-gives-pipeline-update,2023-08-04 14:19:00,Intellia's (NTLA) second-quarter earnings miss estimates. The company provides an update on its gene-editing pipeline.,REGN,0.244723,0.25911,Somewhat-Bullish
"Ultragenyx  ( RARE )  Q2 Loss Wider Than Expected, Revenues Beat",https://www.zacks.com/stock/news/2132649/ultragenyx-rare-q2-loss-wider-than-expected-revenues-beat,2023-08-04 12:12:00,"Ultragenyx (RARE) reports mixed second-quarter 2023 results, maintaining its 2023 financial guidance. The company's pipeline progress is also on track.",REGN,0.073886,0.133203,Neutral
AMGEN REPORTS SECOND QUARTER FINANCIAL RESULTS,https://www.prnewswire.com/news-releases/amgen-reports-second-quarter-financial-results-301893066.html,2023-08-03 20:01:00,"Positive Top-Line Results for LUMAKRAS® ( Sotorasib ) Plus Vectibix® ( Panitumumab ) in Metastatic Colorectal Cancer THOUSAND OAKS, Calif., Aug. 3, 2023 /PRNewswire/ -- Amgen ( NASDAQ:AMGN ) today announced financial results for the second quarter of 2023.",REGN,0.014941,-0.017107,Neutral
"Regeneron  ( REGN )  Q2 Earnings & Sales Top, Eylea Sales Decline",https://www.zacks.com/stock/news/2132167/regeneron-regn-q2-earnings-sales-top-eylea-sales-decline,2023-08-03 16:53:00,"Regeneron (REGN) beats earnings and sales estimates in second-quarter 2023 fueled by Dupixent. However, sales of the lead drug, Eylea, decline yet again.",REGN,0.22574,0.27625,Somewhat-Bullish
Dow Jones Falls As Yields Surge; Warren Buffett Loads Up On Treasuries After Fitch Downgrade,https://www.investors.com/market-trend/stock-market-today/dow-jones-falls-yields-surge-warren-buffetts-top-holding-falls-on-earnings-as-buffett-loads-up-on-treasuries-amid-fitch-downgrade/,2023-08-03 15:08:00,Dow Jones Falls As Yields Surge. Warren Buffett Loads Up On Treasuries After Fitch Downgrade Investor's Business Daily ...,REGN,0.132368,0.231892,Somewhat-Bullish
Why Is Regeneron Pharmaceuticals Moving Higher Today? - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/general/biotech/23/08/33549371/why-is-regeneron-pharmaceuticals-moving-higher-today,2023-08-03 14:35:42,"Regeneron Pharmaceuticals Inc REGN earned second-quarter adjusted EPS of $10.24, up 5% Y/Y, beating the $9.92 Street estimate. Revenues increased 11% Y/Y to $3.16 billion, beating the consensus of $3.01 billion. Dupixent global net sales ( recorded by Sanofi ) increased 33% to $2.79 billion ...",REGN,0.401331,-0.066489,Neutral
Regeneron Surmounts Its 200-Day Line On Solid Beat,https://www.investors.com/news/technology/regn-stock-regeneron-earnings-q2-2023/,2023-08-03 13:04:00,REGN Stock Surmounts Its 200-Day Line On Its Handy Second-Quarter Beat Investor's Business Daily ...,REGN,0.760593,0.250735,Somewhat-Bullish
"Regeneron expects FDA decision on high-dose eye drug this year, shares jump",https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-pharma-beats-quarterly-profit-estimates-2023-08-03/,2023-08-03 11:50:00,"The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermid/File Photo",REGN,0.241684,0.16134,Somewhat-Bullish
"Atherosclerosis Market to Witness Growth by 2032, Estimates DelveInsight | Leading Companies - CSL Behring, Novartis, Merck, Amgen, Ionis , BioMarin, AstraZeneca",https://www.prnewswire.com/news-releases/atherosclerosis-market-to-witness-growth-by-2032-estimates-delveinsight--leading-companies---csl-behring-novartis-merck-amgen-ionis--biomarin-astrazeneca-301891245.html,2023-08-02 21:01:00,"Atherosclerosis Market to Witness Growth by 2032, Estimates DelveInsight | Leading Companies - CSL Behring ... PR ...",REGN,0.028868,0.037471,Neutral
GILD: 3 Biotech Stocks to Buy for August,https://stocknews.com/news/gild-regn-uthr-3-biotech-stocks-to-buy-for-august/,2023-08-02 12:43:37,"The biotechnology industry has emerged at the forefront as a vital industry harboring potential for innovation, economic development, and enhanced healthcare deliverables.",REGN,0.162255,0.11428,Neutral
"Nucor, Stifel And 3 Other Stocks Show Both Value And Growth",https://www.forbes.com/sites/johndorfman/2023/07/31/nucor-stifel-and-3-other-stocks-show-both-value-and-growth/,2023-07-31 15:11:56,"Value and growth, the two main schools of investing, don't have to be enemies. These stocks sell for less than 15 times per-share earnings and have grown their profits by at least 12% per year over the past five years.",REGN,0.054857,0.166864,Somewhat-Bullish
"Regeneron Pharma Says Fewer Aflibercept Injections Maintains Vision, Anatomic Improvements In Diabetic Macular Edema - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/general/biotech/23/07/33464944/regeneron-pharma-says-fewer-aflibercept-injections-maintains-vision-anatomic-improvements-in-diab,2023-07-31 13:43:02,"Regeneron Pharmaceuticals Inc REGN announced the first presentation of two-year ( 96 weeks ) results from the pivotal PHOTON trial of aflibercept 8 mg with 12- and 16-week dosing regimens, compared to Eylea ( aflibercept ) injection, in diabetic macular edema ( DME ) patients.",REGN,0.34729,0.09121,Neutral
Does Nvidia's AI for Biotech Make It a Buy?,https://www.fool.com/investing/2023/07/30/does-nvidias-ai-for-biotech-make-it-a-buy/,2023-07-30 13:00:00,It's just starting to dip its toes into the biopharma waters.,REGN,0.068112,0.175726,Somewhat-Bullish
US FDA approves Regeneron's 8-mg dose of eye disease drug Eylea,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-regenerons-8-mg-dose-eye-disease-drug-eylea-2023-08-18/,2023-08-18 23:27:00,US FDA approves Regeneron's 8-mg dose of eye disease drug ...,REGN,0.468029,0.274517,Somewhat-Bullish
"EYLEA HD  ( aflibercept )  Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration  ( wAMD ) , Diabetic Macular Edema  ( DME )  and Diabetic Retinopathy  ( DR )  - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/pressreleases/23/08/g33928076/eylea-hd-aflibercept-injection-8-mg-approved-by-fda-for-treatment-of-wet-age-related-macular-degen,2023-08-18 22:35:00,"Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA ( aflibercept ) Injection 2 mg that were maintained with fewer injections TARRYTOWN, N.Y., Aug. 18, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.",REGN,0.068384,0.043345,Neutral
"EYLEA HD  ( aflibercept )  Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration  ( wAMD ) , Diabetic Macular Edema  ( DME )  and Diabetic Retinopathy  ( DR ) ",https://www.globenewswire.com/news-release/2023/08/18/2728276/0/en/EYLEA-HD-aflibercept-Injection-8-mg-Approved-by-FDA-for-Treatment-of-Wet-Age-related-Macular-Degeneration-wAMD-Diabetic-Macular-Edema-DME-and-Diabetic-Retinopathy-DR.html,2023-08-18 22:35:00,Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA ( aflibercept ) Injection 2 mg that were maintained with fewer injections ...,REGN,0.067804,0.046358,Neutral
US FDA approves Regeneron's ultra-rare blood disease drug,https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-regenerons-ultra-rare-blood-disease-drug-2023-08-18/,2023-08-18 18:05:00,"The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermid/File Photo Acquire Licensing Rights",REGN,0.485711,0.311891,Somewhat-Bullish
Veopoz™  ( pozelimab-bbfg )  Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/08/g33920844/veopoz-pozelimab-bbfg-receives-fda-approval-as-the-first-treatment-for-children-and-adults-with-ch,2023-08-18 17:43:19,"Approval represents 10th FDA-approved medicine invented by Regeneron TARRYTOWN, N.Y., Aug. 18, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced the U.S.",REGN,0.079656,0.037965,Neutral
Veopoz™  ( pozelimab-bbfg )  Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease,https://www.globenewswire.com/news-release/2023/08/18/2728227/0/en/Veopoz-pozelimab-bbfg-Receives-FDA-Approval-as-the-First-Treatment-for-Children-and-Adults-with-CHAPLE-Disease.html,2023-08-18 17:43:00,CHAPLE is an ultra-rare hereditary disease that can cause potentially life-threatening gastrointestinal and cardiovascular symptoms ...,REGN,0.066672,0.051303,Neutral
Regeneron's  ( REGN )  Application for Blood Cancer Drug Accepted,https://www.zacks.com/stock/news/2138298/regenerons-regn-application-for-blood-cancer-drug-accepted,2023-08-18 16:20:00,Regeneron's (REGN) application seeking approval of odronextamab for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma gets accepted for review in the EU.,REGN,0.169676,-0.001422,Neutral
"Pharma Stock Roundup: FDA Okays PFE & JNJ Drugs, EU Approves ABBV's Migraine Drug",https://www.zacks.com/stock/news/2138154/pharma-stock-roundup-fda-okays-pfe-jnj-drugs-eu-approves-abbvs-migraine-drug,2023-08-18 15:38:00,"FDA approves Pfizer's (PFE) Elrexfio (elranatamab) for RRMM and J&J's (JNJ) oral combination tablet, Akeega to treat BRCA-positive mCRPC. European Commission approves AbbVie's (ABBV) Aquipta for migraine.",REGN,0.110209,0.075832,Neutral
2 Biotech Stocks That Could Make You Richer,https://www.fool.com/investing/2023/08/18/2-biotech-stocks-that-could-make-you-richer/,2023-08-18 14:00:00,"Neither is performing particularly well this year compared to the broader market, but don't let that chase you away.",REGN,0.046999,-0.015826,Neutral
Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/08/g33893875/odronextamab-receives-ema-filing-acceptance-for-treatment-of-relapsedrefractory-follicular-lymphom,2023-08-17 12:30:11,"TARRYTOWN, N.Y., Aug. 17, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.",REGN,0.208914,0.023548,Neutral
Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma,https://www.globenewswire.com/news-release/2023/08/17/2727249/0/en/Odronextamab-Receives-EMA-Filing-Acceptance-for-Treatment-of-Relapsed-Refractory-Follicular-Lymphoma-and-Diffuse-Large-B-cell-Lymphoma.html,2023-08-17 12:30:00,"TARRYTOWN, N.Y., Aug. 17, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that the European Medicines Agency ( EMA ) has accepted for review the Marketing Authorization Application ( MAA ) for odronextamab to treat adult patients with ...",REGN,0.127321,0.053798,Neutral
"Macular Degeneration Treatment Market to Expand USD 21.1 Bn by 2031, Registering at a CAGR of 8.8% | Exclusive Report by Transparency Market Research",https://www.benzinga.com/pressreleases/23/08/g33892714/macular-degeneration-treatment-market-to-expand-usd-21-1-bn-by-2031-registering-at-a-cagr-of-8-8-e,2023-08-17 11:30:00,"Wilmington, Delaware, United States, Aug. 17, 2023 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global macular degeneration treatment market is projected to exceed US$ 21.1 Bn by 2031, up from US$ 9.0 Bn in 2021.",REGN,0.042048,-0.026846,Neutral
"IBD Screen Includes Meta, Tesla, Other Big Techs, But These Others Are In Buy Zones",https://www.investors.com/research/ibd-stock-screener-includes-meta-tesla-other-big-techs-but-these-others-are-in-buy-zones/,2023-08-16 17:39:00,"IBD Screen Includes Meta, Tesla, Other Big Techs, But These Others ... Investor's Business Daily ...",REGN,0.158868,0.215904,Somewhat-Bullish
"""Motley Fool Money"" Mailbag: Commercial Real Estate, Personal Finance, and International Investing",https://www.fool.com/investing/2023/08/16/mailbag-commercial-real-estate-personal-finance-an/,2023-08-16 09:22:00,We answer some of the questions you've emailed us at podcasts@fool.com. We've also got a listener hotline! Leave us a voice mail with your question at 703-254-1445.,REGN,0.007408,-0.00251,Neutral
"$100 Invested In This Stock 20 Years Ago Would Be Worth $5,400 Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/news/earnings/23/08/33863985/100-invested-in-this-stock-20-years-ago-would-be-worth-5-400-today,2023-08-15 17:30:19,"Regeneron Pharmaceuticals REGN has outperformed the market over the past 20 years by 14.59% on an annualized basis producing an average annual return of 22.34%. Currently, Regeneron Pharmaceuticals has a market capitalization of $87.68 billion.",REGN,0.980595,0.386944,Bullish
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ElectraMeccanica  ( Nasdaq - SOLO ) , Computer Task Group, Incorporated  ( Nasdaq - CTG ) , Decibel Therapeutics, Inc.  ( Nasdaq - DBTX ) ",https://www.benzinga.com/pressreleases/23/08/g33860518/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-electrameccan,2023-08-15 14:37:11,"BALA CYNWYD, Pa., Aug. 15, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",REGN,0.172097,0.223988,Somewhat-Bullish
Sandoz announces positive results from Mylight Phase lll study for biosimilar aflibercept,https://www.globenewswire.com/news-release/2023/08/15/2725167/0/en/Sandoz-announces-positive-results-from-Mylight-Phase-lll-study-for-biosimilar-aflibercept.html,2023-08-15 05:15:00,"Basel, August 15, 2023 - Sandoz, a global leader in off-patent medicines, today releases positive results from the MYLIGHT Phase III confirmatory efficacy and safety study for its biosimilar aflibercept, for patients living with wet macular degeneration - a key development in its efforts to ...",REGN,0.029876,0.0,Neutral
This Is What Whales Are Betting On Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/08/33840559/this-is-what-whales-are-betting-on-regeneron-pharmaceuticals,2023-08-14 17:46:31,A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 10 strange trades.,REGN,0.898236,0.100063,Neutral
"Vivek Ramaswamy-Founded Biotech Reports Steep Losses, Light Sales",https://www.investors.com/news/technology/roiv-stock-roivant-earnings-q2-2023/,2023-08-14 11:00:00,"ROIV Stock, A Top Biotech Stock, Misses On Both Sales And Losses Investor's Business Daily ...",REGN,0.140896,0.128011,Neutral
Regeneron Pharmaceuticals Shows Rising Price Performance With Jump To 82 RS Rating,https://www.investors.com/ibd-data-stories/regeneron-pharmaceuticals-shows-rising-price-performance-with-jump-to-82-rs-rating/,2023-08-14 07:00:00,"On Monday, Regeneron Pharmaceuticals ( REGN ) got an upgrade to its Relative Strength ( RS ) Rating, from 74 to 82. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",REGN,0.518022,0.261692,Somewhat-Bullish
"Lifshitz Law PLLC Announces Investigations of WMC, MITT, DBTX, and CTG - Computer Task Gr  ( NASDAQ:CTG ) , Decibel Therapeutics  ( NASDAQ:DBTX ) ",https://www.benzinga.com/pressreleases/23/08/g33791951/lifshitz-law-pllc-announces-investigations-of-wmc-mitt-dbtx-and-ctg,2023-08-13 00:17:00,"NEW YORK, Aug. 12, 2023 ( GLOBE NEWSWIRE ) -- Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of WMC to AG Mortgage Investment Trust, Inc.",REGN,0.082963,0.139129,Neutral
Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Stock Rating Lowered by StockNews.com,https://www.defenseworld.net/2023/08/12/regeneron-pharmaceuticals-nasdaqregn-stock-rating-lowered-by-stocknews-com.html,2023-08-12 05:40:51,"Regeneron Pharmaceuticals ( NASDAQ:REGN - Get Free Report ) was downgraded by investment analysts at StockNews.com from a ""strong-buy"" rating to a ""buy"" rating in a research report issued to clients and investors on Saturday.",REGN,0.76367,0.466694,Bullish
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, DBTX - Computer Task Gr  ( NASDAQ:CTG ) , Decibel Therapeutics  ( NASDAQ:DBTX ) ",https://www.benzinga.com/pressreleases/23/08/g33754883/shareholder-investigation-halper-sadeh-llc-investigates-ctg-dbtx,2023-08-11 16:11:37,"NEW YORK, Aug. 11, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Computer Task Group, Inc.",REGN,0.152499,0.202868,Somewhat-Bullish
's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet - Decibel Therapeutics  ( NASDAQ:DBTX ) ,https://www.benzinga.com/general/biotech/23/08/33750159/benzingas-stock-whisper-index-5-stocks-investors-are-secretly-monitoring-but-not-talking-about-ye,2023-08-11 14:54:57,"Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information.",REGN,0.122581,0.302153,Somewhat-Bullish
"Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News",https://www.zacks.com/stock/news/2135802/biotech-stock-roundup-sage-grtx-plunge-on-setback-regn-to-buy-dbtx-more-news,2023-08-11 14:34:00,Regulatory updates from SAGE and Galera (GRTX) are in focus in the biotech sector.,REGN,0.079656,0.0,Neutral
Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update,https://www.globenewswire.com/news-release/2023/08/11/2723474/0/en/Decibel-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Corporate-Update.html,2023-08-11 11:45:00,"- Activated CHORDTM clinical trial sites in U.S., U.K. and Spain and commenced patient screening activities. anticipate dosing first patient in the Phase 1/2 clinical trial in the second half of ...",REGN,0.152018,0.09331,Neutral
Regeneron's Aflibercept 8mg Shows Sustained Vision Gains At Two Years - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/general/biotech/23/08/33713936/regenerons-aflibercept-8mg-shows-sustained-vision-gains-at-two-years,2023-08-10 16:31:57,Regeneron Pharmaceuticals Inc REGN announced two-year ( 96 weeks ) topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related macular degeneration ( wAMD ) . Among those who completed the two-year follow-up: 88% were on a ≥12-week dosing ...,REGN,0.392948,-0.04595,Neutral
"Regeneron  ( REGN )  to Buy Decibel, Gains on Hearing Loss Therapies",https://www.zacks.com/stock/news/2135290/regeneron-regn-to-buy-decibel-gains-on-hearing-loss-therapies,2023-08-10 16:03:00,Regeneron (REGN) further builds upon its collaboration with Decibel by acquiring the company to expand its gene therapy programs for hearing loss.,REGN,0.196877,0.0,Neutral
This Is What Whales Are Betting On Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/08/33713203/this-is-what-whales-are-betting-on-regeneron-pharmaceuticals,2023-08-10 15:31:08,"Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...",REGN,0.845242,0.189044,Somewhat-Bullish
3 Top Biotech Stocks Defying the Bear Market,https://www.fool.com/investing/2023/08/10/3-top-biotech-stocks-defying-the-bear-market/,2023-08-10 09:21:00,"Biotech is still booming, if you pick the right biotech stocks.",REGN,0.083541,0.079729,Neutral
Regeneron Pharmaceuticals Trying To Close In On Key Technical Benchmark,https://www.investors.com/ibd-data-stories/regeneron-pharmaceuticals-trying-to-close-in-on-key-technical-benchmark/,2023-08-10 07:00:00,"On Thursday, Regeneron Pharmaceuticals ( REGN ) received a positive adjustment to its Relative Strength ( RS ) Rating, from 68 to 74. X As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.",REGN,0.827318,0.551522,Bullish
"Generalized Myasthenia Gravis Market is Expected to Expand by 2032, Assesses DelveInsight | Key Companies - Alexion, Argenx, UCB, Horizon, Roche, Janssen Bristol Myers Squibb, Biogen Pfizer, Novartis, Sanofi, Takeda",https://www.prnewswire.com/news-releases/generalized-myasthenia-gravis-market-is-expected-to-expand-by-2032-assesses-delveinsight--key-companies---alexion-argenx-ucb-horizon-roche-janssen-bristol-myers-squibb-biogen-pfizer-novartis-sanofi-takeda-301896552.html,2023-08-09 21:01:00,"Generalized Myasthenia Gravis Market is Expected to Expand by 2032, Assesses DelveInsight | Key Companies ... PR ...",REGN,0.079392,0.074093,Neutral
"Health Care Company Regeneron Pharmaceuticals Announces Acquisition of Decibel Therapeutics - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Decibel Therapeutics  ( NASDAQ:DBTX ) ",https://www.benzinga.com/m-a/23/08/33670770/health-care-company-regeneron-pharmaceuticals-announces-acquisition-of-decibel-therapeutics,2023-08-09 15:10:06,"Regeneron Pharmaceuticals REGN has announced an acquisition of Decibel Therapeutics DBTX that is expected to be completed in Q3 of 2023. Under the terms of the agreement, Regeneron Pharmaceuticals has agreed to give Decibel Therapeutics $213.00 million in cash in exchange for DBTX stock.",REGN,0.492659,-0.20842,Somewhat-Bearish
DBTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Decibel Therapeutics to Regeneron Pharmaceuticals - Decibel Therapeutics  ( NASDAQ:DBTX ) ,https://www.benzinga.com/pressreleases/23/08/g33667486/dbtx-alert-monsey-firm-of-wohl-fruchter-investigating-fairness-of-the-sale-of-decibel-therapeutics,2023-08-09 13:31:23,"MONSEY, N.Y., Aug. 09, 2023 ( GLOBE NEWSWIRE ) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the $4.00 per share in cash, plus a contingent value right ( ""CVR"" ) for up to $3.50 per share in cash, pursuant to which Decibel Therapeutics, Inc.",REGN,0.112532,0.233034,Somewhat-Bullish
Decibel Therapeutics Stock Soars on Acquisition Deal - The Details - Decibel Therapeutics  ( NASDAQ:DBTX ) ,https://www.benzinga.com/general/biotech/23/08/33664344/decibel-therapeutics-stock-soars-on-acquisition-deal-the-details,2023-08-09 13:24:14,Regeneron Pharmaceuticals Inc REGN has agreed to acquire Decibel Therapeutics Inc DBTX at $4.00 per share with an additional contingent value right of up to $3.50 per share in cash upon achievement of certain clinical development and regulatory milestones for Decibel's lead investigational ...,REGN,0.368773,0.674689,Bullish
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Computer Task Group, Incorporated  ( Nasdaq - CTG ) , Decibel Therapeutics, Inc.  ( Nasdaq - DBTX ) ",https://www.benzinga.com/pressreleases/23/08/g33666954/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-computer-task,2023-08-09 13:13:12,"BALA CYNWYD, Pa., Aug. 09, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",REGN,0.207571,0.255914,Somewhat-Bullish
"Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Decibel Therapeutics  ( NASDAQ:DBTX ) ",https://www.benzinga.com/pressreleases/23/08/g33660744/regeneron-to-acquire-decibel-therapeutics-strengthening-gene-therapy-and-hearing-loss-programs,2023-08-09 11:30:53,"Decibel's lead investigational gene therapy DB-OTO, designed to provide hearing to people with otoferlin-related hearing loss, is in its first clinical trial TARRYTOWN, N.Y. and BOSTON, Aug. 09, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN and Decibel Therapeutics, Inc.",REGN,0.05439,0.06101,Neutral
"STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - DBTX, CELL, ESTE, CPRI",https://www.benzinga.com/pressreleases/23/08/g34079898/stockholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-dbtx-cell-este-cpri,2023-08-28 21:34:27,"NEW YORK, Aug. 28, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered ...",REGN,0.068698,0.120002,Neutral
Oncology Market's Huge Potential Puts These Stocks in Focus,https://www.zacks.com/stock/news/2141307/oncology-markets-huge-potential-puts-these-stocks-in-focus,2023-08-28 12:38:00,"The oncology treatment market has been experiencing significant growth lately. Companies like Regeneron Pharmaceuticals (REGN), Merck & Co. (MRK), Novartis (NVS) and AstraZeneca (AZN) have made meaningful contributions in cancer treatment.",REGN,0.107978,0.080642,Neutral
Wall Street Thinks This Tiny Biotech Company Could Soar Soon,https://www.fool.com/investing/2023/08/28/wall-street-thinks-this-tiny-biotech-company-could/,2023-08-28 12:30:00,An upcoming regulatory decision could prove to be an inflection point in the biotech's life cycle.,REGN,0.055621,0.022997,Neutral
Check Out What Whales Are Doing With REGN - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/08/34048020/check-out-what-whales-are-doing-with-regn,2023-08-25 18:01:05,"Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...",REGN,0.755492,0.015699,Neutral
Inside Tema ETFs' New Oncology ETF  ( CANC ) ,https://www.zacks.com/stock/news/2141014/inside-tema-etfs-new-oncology-etf-canc,2023-08-25 18:00:00,Oncology treatment has witnessed remarkable progress due to the relentless efforts of pharmaceutical companies in recent times.,REGN,0.074926,0.050822,Neutral
"The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics",https://www.zacks.com/stock/news/2140807/the-zacks-analyst-blog-highlights-regeneron-pharmaceuticals-gilead-sciences-novavax-apellis-pharmaceuticals-and-fulcrum-therapeutics,2023-08-25 13:16:00,"Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog.",REGN,0.10087,0.059516,Neutral
Insmed Shows Market Leadership With Jump To 81 RS Rating,https://www.investors.com/ibd-data-stories/insmed-shows-market-leadership-with-jump-to-81-rs-rating/,2023-08-25 07:00:00,"When building your watch list, look for stocks with an 80 or higher RS Rating. Insmed ( INSM ) now meets that criteria, with a jump from 75 to 81 Friday. When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength.",REGN,0.348103,0.0,Neutral
Amicus Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Threshold,https://www.investors.com/ibd-data-stories/amicus-therapeutics-scores-relative-strength-rating-upgrade-hits-key-threshold/,2023-08-25 07:00:00,Amicus Therapeutics Scores Relative Strength Rating Upgrade. Hits ... Investor's Business Daily ...,REGN,0.343279,0.0,Neutral
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sovos Brands, Inc.  ( Nasdaq - SOVO ) , Zynerba Pharmaceuticals, Inc.  ( Nasdaq - ZYNE ) , Computer Task Group, Incorporated  ( Nasdaq - CTG ) , Decibel Therapeutics, Inc.  ( Nasdaq - DBTX ) ",https://www.benzinga.com/pressreleases/23/08/g34028240/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-sovos-brands-,2023-08-24 16:17:28,"BALA CYNWYD, Pa., Aug. 24, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",REGN,0.132004,0.19117,Somewhat-Bullish
"Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More",https://www.zacks.com/stock/news/2140318/biotech-stock-roundup-regn-up-on-approval-apls-nvax-gain-on-updates-more,2023-08-24 14:15:00,Regulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector.,REGN,0.071463,0.143951,Neutral
Regeneron Announces Investor Conference Presentations,https://www.globenewswire.com/news-release/2023/08/23/2730718/0/en/Regeneron-Announces-Investor-Conference-Presentations.html,2023-08-23 20:05:00,"TARRYTOWN, N.Y., Aug. 23, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) will webcast management participation as follows: ...",REGN,0.310843,0.0,Neutral
Regeneron Announces Investor Conference Presentations - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/08/g34012324/regeneron-announces-investor-conference-presentations,2023-08-23 20:05:00,"TARRYTOWN, N.Y., Aug. 23, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN will webcast management participation as follows: • 2023 Wells Fargo Healthcare Conference at 8:45 a.m. ET on Wednesday, September 6, 2023 • Morgan Stanley 21st Annual Global Healthcare Conference at ...",REGN,0.282234,0.0,Neutral
Mirati Therapeutics Announces Departure of Chief Financial Officer Laurie Stelzer,https://www.prnewswire.com/news-releases/mirati-therapeutics-announces-departure-of-chief-financial-officer-laurie-stelzer-301908485.html,2023-08-23 20:00:00,"SAN DIEGO, Aug. 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® ( NASDAQ: MRTX ) , a commercial stage biotechnology company, today announced that Laurie Stelzer, Chief Financial Officer, will depart the company on September 8, 2023, to pursue an external opportunity.",REGN,0.062926,-0.064015,Neutral
"Top 5 Health Care Stocks That May Fall Off A Cliff - Praxis Precision Medicine  ( NASDAQ:PRAX ) , Capricor Therapeutics  ( NASDAQ:CAPR ) ",https://www.benzinga.com/news/23/08/34001545/top-5-health-care-stocks-that-may-fall-off-a-cliff,2023-08-23 11:58:45,"The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down.",REGN,0.329551,0.102161,Neutral
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VRTV, DBTX, CPRI, AVID - Capri Holdings  ( NYSE:CPRI ) , Avid Technology  ( NASDAQ:AVID ) ",https://www.benzinga.com/pressreleases/23/08/g33998548/shareholder-investigation-halper-sadeh-llc-investigates-vrtv-dbtx-cpri-avid,2023-08-23 08:15:39,"NEW YORK, Aug. 23, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:",REGN,0.124809,0.182563,Somewhat-Bullish
Axsome Therapeutics Scores Relative Strength Rating Upgrade; Hits Key Benchmark,https://www.investors.com/ibd-data-stories/axsome-therapeutics-scores-relative-strength-rating-upgrade-hits-key-benchmark/,2023-08-23 07:00:00,Axsome Therapeutics Scores Relative Strength Rating Upgrade ... Investor's Business Daily ...,REGN,0.360752,0.0,Neutral
Regeneron Awarded $326M Government Contract For COVID-19 Antibody Therapy Development - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/news/23/08/33994166/regeneron-awarded-326m-government-contract-for-covid-19-antibody-therapy-development,2023-08-22 20:43:39,Regeneron Pharmaceuticals Inc REGN was awarded a government contract valued at up to $326 million on Tuesday. Here are the details.,REGN,0.498188,0.651361,Bullish
"US govt awards $1.4 bln for development of new COVID therapies, vaccines",https://www.reuters.com/business/healthcare-pharmaceuticals/us-govt-awards-14-bln-development-new-covid-therapies-vaccines-2023-08-22/,2023-08-22 19:45:00,"The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020. REUTERS/Brendan McDermid/File Photo Acquire Licensing Rights",REGN,0.401331,-0.010895,Neutral
Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/08/g33991392/regeneron-announces-agreement-with-barda-supporting-development-of-next-generation-antibody-therap,2023-08-22 18:15:41,"TARRYTOWN, N.Y., Aug. 22, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.",REGN,0.156461,0.134525,Neutral
Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention,https://www.globenewswire.com/news-release/2023/08/22/2729953/0/en/Regeneron-Announces-Agreement-with-BARDA-Supporting-Development-of-Next-Generation-Antibody-Therapy-for-COVID-19-Prevention.html,2023-08-22 18:15:00,Program is part of U.S. Government's 'Project NextGen' and provides partial funding for clinical development of a novel monoclonal antibody therapy Program is part of U.S. Government's 'Project NextGen' and provides partial funding for clinical development of a novel monoclonal antibody ...,REGN,0.102449,0.065335,Neutral
"Moore Kuehn Encourages DBTX, AVID, CPRI, and ARCE Investors to Contact Law Firm - Arco Platform  ( NASDAQ:ARCE ) , Avid Technology  ( NASDAQ:AVID ) ",https://www.benzinga.com/pressreleases/23/08/g33990599/moore-kuehn-encourages-dbtx-avid-cpri-and-arce-investors-to-contact-law-firm,2023-08-22 17:30:17,"NEW YORK, Aug. 22, 2023 ( GLOBE NEWSWIRE ) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.",REGN,0.107978,0.267137,Somewhat-Bullish
Peering Into Regeneron Pharmaceuticals's Recent Short Interest - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/short-sellers/23/08/33989686/peering-into-regeneron-pharmaceuticalss-recent-short-interest,2023-08-22 16:45:20,"Regeneron Pharmaceuticals's REGN short percent of float has risen 6.52% since its last report. The company recently reported that it has 1.34 million shares sold short, which is 1.47% of all regular shares that are available for trading.",REGN,0.221819,0.155473,Somewhat-Bullish
Stocks Flashing Renewed Technical Strength: ACELYRIN,https://www.investors.com/ibd-data-stories/stocks-flashing-renewed-technical-strength-acelyrin/,2023-08-22 07:00:00,"ACELYRIN ( SLRN ) had its Relative Strength ( RS ) Rating upgraded from 87 to 91 Tuesday. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",REGN,0.338582,0.129299,Neutral
"Alkermes Clears Key Benchmark, Hitting 80-Plus RS Rating",https://www.investors.com/ibd-data-stories/alkermes-clears-key-benchmark-hitting-80-plus-rs-rating-2/,2023-08-22 07:00:00,"When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is Alkermes ( ALKS ) , which had its Relative Strength ( RS ) Rating upgraded from 79 to 82 Tuesday.",REGN,0.323078,0.0,Neutral
"STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - CELL, DBTX, CPRI, ESTE",https://www.benzinga.com/pressreleases/23/08/g33973966/stockholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-cell-dbtx-cpri-este,2023-08-21 21:32:34,"NEW YORK, Aug. 21, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered ...",REGN,0.068698,0.120002,Neutral
Why Regeneron Pharmaceuticals  ( REGN )  Stock Is Trading Higher Today? - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/analyst-ratings/analyst-color/23/08/33967522/regenerons-crucial-eylea-hd-approval-a-shield-against-potential-biosimilar-competit,2023-08-21 19:04:31,"Friday, the FDA approved Regeneron Pharmaceuticals Inc's REGN approved Eylea HD ( aflibercept ) Injection 8 mg for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy ( DR ) .",REGN,0.30569,0.21245,Somewhat-Bullish
Regeneron  ( REGN )  Gets FDA Nod for Higher Dose of Eylea,https://www.zacks.com/stock/news/2138751/regeneron-regn-gets-fda-nod-for-higher-dose-of-eylea,2023-08-21 15:23:00,Regeneron (REGN) obtains FDA approval for a higher dose of aflibercept injection under the brand name Eylea HD for various ophthalmology indications. The regulatory body also approves Veopoz.,REGN,0.167322,0.046973,Neutral
FDA Approves Regeneron's Drug For Ultra Rare Immune Disorder - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/general/biotech/23/08/33959971/fda-approves-regenerons-drug-for-ultra-rare-immune-disorder,2023-08-21 14:18:09,"The FDA approved Regeneron Pharmaceuticals Inc's REGN Veopoz ( pozelimab-bbfg ) for adult and pediatric patients one year of age and older with CHAPLE disease, known as CD55-deficient protein-losing enteropathy. Veopoz is the first and only treatment indicated specifically for CHAPLE.",REGN,0.423843,0.296755,Somewhat-Bullish
Why This Regeneron Approval 'Could Not Come Soon Enough',https://www.investors.com/news/technology/regn-stock-climbs-as-fda-approves-high-dose-eylea-why-the-approval-could-not-come-soon-enough/,2023-08-21 14:01:00,REGN Stock Climbs As FDA Approves High-Dose Eylea. Why The ... Investor's Business Daily ...,REGN,0.428632,0.008689,Neutral
Regeneron's Eylea could return to growth after nod to high-dose version- analysts,https://www.reuters.com/business/healthcare-pharmaceuticals/regenerons-eylea-could-return-growth-after-nod-high-dose-version-analysts-2023-08-21/,2023-08-21 13:41:00,"The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermid/File Photo Acquire Licensing Rights",REGN,0.207571,0.279815,Somewhat-Bullish
Jim Cramer's top 10 things to watch in the stock market Monday,https://www.cnbc.com/2023/08/21/jim-cramers-top-10-things-to-watch-in-the-stock-market-monday.html,2023-08-21 13:06:37,"Stocks edge up in premarket trading Monday, following three-consecutive weeks of losses, as the market looks to Nvidia's (NVDA) quarterly report.",REGN,0.117486,0.174511,Somewhat-Bullish
FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/general/biotech/23/08/33959575/fda-approves-regeneron-pharmaceuticals-higher-dose-of-eylea-for-age-related-blindness,2023-08-21 12:37:48,"The FDA approved Regeneron Pharmaceuticals Inc's REGN approved Eylea HD ( aflibercept ) Injection 8 mg for wet age-related macular degeneration ( wAMD ) , diabetic macular edema ( DME ) , and diabetic retinopathy ( DR ) .",REGN,0.431065,0.259452,Somewhat-Bullish
Is Regeneron Pharmaceuticals Still a Top Growth Stock?,https://www.fool.com/investing/2023/08/21/is-regeneron-pharmaceuticals-still-a-top-growth-st/,2023-08-21 10:30:00,The biotech's focus on innovation could be a boon for shareholders.,REGN,0.110462,0.09317,Neutral
Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Coverage Initiated by Analysts at StockNews.com,https://www.defenseworld.net/2023/08/20/regeneron-pharmaceuticals-nasdaqregn-coverage-initiated-by-analysts-at-stocknews-com.html,2023-08-20 05:21:03,Regeneron Pharmaceuticals ( NASDAQ:REGN ) Coverage Initiated ... Defense World ...,REGN,0.752347,0.450465,Bullish
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SOVO, DBTX, DM, ZYNE - Desktop Metal  ( NYSE:DM ) , Decibel Therapeutics  ( NASDAQ:DBTX ) ",https://www.benzinga.com/pressreleases/23/09/g34321972/shareholder-investigation-halper-sadeh-llc-investigates-sovo-dbtx-dm-zyne,2023-09-07 14:36:09,"NEW YORK, Sept. 07, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Sovos Brands, Inc.",REGN,0.097854,0.167429,Somewhat-Bullish
"Moore Kuehn Encourages SOVO, DBTX, DM and ZYNE Investors to Contact Law Firm - Desktop Metal  ( NYSE:DM ) , Decibel Therapeutics  ( NASDAQ:DBTX ) ",https://www.benzinga.com/pressreleases/23/09/g34321471/moore-kuehn-encourages-sovo-dbtx-dm-and-zyne-investors-to-contact-law-firm,2023-09-07 14:15:04,"NEW YORK, Sept. 07, 2023 ( GLOBE NEWSWIRE ) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.",REGN,0.105141,0.264846,Somewhat-Bullish
Should You Invest in the Invesco Biotechnology & Genome  ( PBE ) ?,https://www.zacks.com/stock/news/2145173/should-you-invest-in-the-invesco-biotechnology-genome-pbe,2023-09-06 10:20:04,Sector ETF report for ...,REGN,0.130926,0.070514,Neutral
"ALERT: The M&A Class Action Firm Continues Investigating the Merger - NEWR, AMNB, DBTX, RETA",https://www.benzinga.com/pressreleases/23/09/g34257451/alert-the-m-a-class-action-firm-continues-investigating-the-merger-newr-amnb-dbtx-reta,2023-09-05 23:46:11,"NEW YORK, Sept. 05, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and ...",REGN,0.067919,0.119896,Neutral
"Allergic Conjunctivitis Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key Companies - Bausch & Lomb, Aldeyra, Vanda, Allakos, Regeneron, JW, Nanomerics, OKYO Pharma",https://www.prnewswire.com/news-releases/allergic-conjunctivitis-market-is-expected-to-showcase-a-significant-growth-by-2032-predicts-delveinsight--key-companies---bausch--lomb-aldeyra-vanda-allakos-regeneron-jw-nanomerics-okyo-pharma-301916685.html,2023-09-04 21:01:00,"Allergic Conjunctivitis Market is Expected to Showcase a Significant Growth by 2032, Predicts DelveInsight | Key ... PR ...",REGN,0.052685,0.012,Neutral
Regeneron  ( REGN )  Gains 13% in 1 Month on FDA Nod For Eylea HD,https://www.zacks.com/stock/news/2143243/regeneron-regn-gains-13-in-1-month-on-fda-nod-for-eylea-hd,2023-08-31 17:43:00,Regeneron (REGN) gains 13% in a month on the FDA's approval of a higher dose of Eylea and other positive updates.,REGN,0.224903,0.199463,Somewhat-Bullish
"BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Acer Therapeutics Inc.  ( Nasdaq - ACER ) , Sovos Brands, Inc.  ( Nasdaq - SOVO ) , Computer Task Group, Incorporated  ( Nasdaq - CTG ) , Decibel Therapeutics, Inc.  ( Nasdaq - DBTX ) ",https://www.benzinga.com/pressreleases/23/08/g34142398/brodsky-smith-shareholder-update-notifying-investors-of-the-following-investigations-acer-therapeu,2023-08-31 12:54:33,"BALA CYNWYD, Pa., Aug. 31, 2023 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847.",REGN,0.129516,0.189349,Somewhat-Bullish
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/08/34125693/looking-at-regeneron-pharmaceuticalss-recent-unusual-options-activity,2023-08-30 20:45:49,"Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't ...",REGN,0.83872,0.117595,Neutral
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update,https://www.globenewswire.com/news-release/2023/08/30/2734798/0/en/Alvotech-Reports-Financial-Results-for-First-Six-Months-of-2023-and-Provides-Business-Update.html,2023-08-30 20:15:00,"Alvotech ( NASDAQ: ALVO, or the ""Company"" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2023 and provided a summary of recent corporate highlights.",REGN,0.013868,0.0,Neutral
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update,https://www.globenewswire.com/news-release/2023/08/30/2734797/0/en/Alvotech-Reports-Financial-Results-for-First-Six-Months-of-2023-and-Provides-Business-Update.html,2023-08-30 20:15:00,"REYKJAVIK, Iceland, Aug. 30, 2023 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the ""Company"" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of ...",REGN,0.013819,0.0,Neutral
Allakos Appoints Neil Graham to its Board of Directors,https://www.globenewswire.com/news-release/2023/08/30/2734781/0/en/Allakos-Appoints-Neil-Graham-to-its-Board-of-Directors.html,2023-08-30 20:05:00,"SAN CARLOS, Calif., Aug. 30, 2023 ( GLOBE NEWSWIRE ) -- Allakos Inc. ( Nasdaq: ALLK ) , a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today ...",REGN,0.057767,-0.221004,Somewhat-Bearish
"10 growth stocks that are trading at bargain prices, including Delta and Cheniere Energy",https://www.marketwatch.com/story/10-growth-stocks-that-are-trading-at-bargain-prices-including-delta-and-cheniere-energy-1c407efd,2023-08-30 16:10:00,"These stocks trade at low P/E ratios, pass FTSE Russell's growth screens and are favored by analysts.",REGN,0.113329,0.177675,Somewhat-Bullish
"SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DBTX, AMED, RETA, SURF - Amedisys  ( NASDAQ:AMED ) , Decibel Therapeutics  ( NASDAQ:DBTX ) ",https://www.benzinga.com/pressreleases/23/08/g34097085/shareholder-investigation-halper-sadeh-llc-investigates-dbtx-amed-reta-surf,2023-08-29 16:34:52,"NEW YORK, Aug. 29, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Decibel Therapeutics, Inc.",REGN,0.129516,0.185732,Somewhat-Bullish
"Moore Kuehn Encourages AMED, DBTX, RETA, and SURF Investors to Contact Law Firm - Amedisys  ( NASDAQ:AMED ) , Decibel Therapeutics  ( NASDAQ:DBTX ) ",https://www.benzinga.com/pressreleases/23/08/g34095921/moore-kuehn-encourages-amed-dbtx-reta-and-surf-investors-to-contact-law-firm,2023-08-29 15:47:47,"NEW YORK, Aug. 29, 2023 ( GLOBE NEWSWIRE ) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.",REGN,0.107978,0.267137,Somewhat-Bullish
"The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca",https://www.zacks.com/stock/news/2141956/the-zacks-analyst-blog-highlights-regeneron-pharmaceuticals-merck-novartis-and-astrazeneca,2023-08-29 13:45:00,"Regeneron Pharmaceuticals, Merck, Novartis and AstraZeneca are part of the Zacks top Analyst Blog.",REGN,0.100518,0.0,Neutral
"Small Cancer Therapy Player Celularity To Provide Research Support For Regeneron's Therapy - Celularity  ( NASDAQ:CELU ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/general/biotech/23/08/34090241/small-cancer-therapy-player-celularity-to-provide-research-support-for-regenerons-therapy,2023-08-29 13:41:16,Celularity Inc CELU shares are trading higher after the company announced a multi-year Research Collaboration Services Agreement with Regeneron Pharmaceuticals Inc REGN. The pact supports the research of Regeneron's allogeneic cell therapy candidates.,REGN,0.459624,0.61915,Bullish
"Asthma Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - GlaxoSmithKline, AstraZeneca, Sanofi, Roche, Amgen, Regeneron, Incyte, Areteia, Suzhou Connect, Cumberland, Pulmatrix",https://www.prnewswire.com/news-releases/asthma-market-is-predicted-to-exhibit-remarkable-growth-by-2032-predicts-delveinsight--key-companies-to-look-out---glaxosmithkline-astrazeneca-sanofi-roche-amgen-regeneron-incyte-areteia-suzhou-connect-cumberland-pulma-301927336.html,2023-09-14 21:01:00,"Asthma Market is Predicted to Exhibit Remarkable Growth by 2032, Predicts DelveInsight | Key Companies to Look Out ... PR ...",REGN,0.025929,0.084714,Neutral
Peering Into Regeneron Pharmaceuticals's Recent Short Interest - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/short-sellers/23/09/34582720/peering-into-regeneron-pharmaceuticalss-recent-short-interest,2023-09-14 14:00:38,"Regeneron Pharmaceuticals's REGN short percent of float has risen 9.4% since its last report. The company recently reported that it has 1.48 million shares sold short, which is 1.63% of all regular shares that are available for trading.",REGN,0.221819,0.155473,Somewhat-Bullish
"SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - DBTX, CELL, CCF, AGE",https://www.benzinga.com/pressreleases/23/09/g34500135/shareholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-dbtx-cell-ccf-age,2023-09-12 18:01:36,"NEW YORK, Sept. 12, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and ...",REGN,0.068112,0.119922,Neutral
REGN: 3 Biotech Gainers to Consider,https://stocknews.com/news/regn-biib-regn-reta-3-biotech-gainers-to-consider/,2023-09-11 16:47:19,"The biotech industry is well-positioned to thrive, owing to inelastic demand, rapid advancements, and government initiatives. So, quality biotech stocks Regeneron Pharmaceuticals, Inc. ( REGN ) , Biogen Inc. ( BIIB ) , and United Therapeutics Corporation ( UTHR ) could be worth buying.",REGN,0.265217,0.381353,Bullish
"Morgan Stanley says it's a lonely bull, recommending government bonds",https://www.marketwatch.com/story/morgan-stanley-says-its-a-lonely-bull-recommending-government-bonds-78004824,2023-09-11 10:55:00,Here's why Morgan Stanley is persisting with its call to buy government bonds.,REGN,0.086556,-0.241989,Somewhat-Bearish
New to Investing? Here's How You Can Get Started With $500.,https://www.fool.com/investing/2023/09/10/new-to-investing-heres-how-you-can-get-started-wit/,2023-09-10 09:00:00,You don't have to invest a lot to start building a winning portfolio.,REGN,0.054483,0.204993,Somewhat-Bullish
3 Unstoppable Growth Stocks to Buy Right Now,https://www.fool.com/investing/2023/09/09/3-unstoppable-growth-stocks-to-buy-right-now/,2023-09-09 10:55:00,These healthcare stocks show no signs of slowing down.,REGN,0.165598,0.085386,Neutral
Regeneron Provides Update on Planned Chief Financial Officer Transition,https://www.globenewswire.com/news-release/2023/09/08/2740338/0/en/Regeneron-Provides-Update-on-Planned-Chief-Financial-Officer-Transition.html,2023-09-08 20:46:00,"Robert E. Landry to retire effective February 2024. Christopher Fenimore, long-standing Senior Vice President, Head of Accounting and Controller, to assume CFO role Robert E. Landry to retire effective February 2024.",REGN,0.211806,-0.008631,Neutral
Regeneron Provides Update on Planned Chief Financial Officer Transition - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/09/g34373268/regeneron-provides-update-on-planned-chief-financial-officer-transition,2023-09-08 20:46:00,"TARRYTOWN, N.Y., Sept. 08, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced that Robert E. Landry, Executive Vice President, Finance and Chief Financial Officer of Regeneron, will retire in February 2024.",REGN,0.20698,-0.008466,Neutral
Regeneron Announces Updates to Board of Directors,https://www.globenewswire.com/news-release/2023/09/08/2740337/0/en/Regeneron-Announces-Updates-to-Board-of-Directors.html,2023-09-08 20:45:00,"Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., join Regeneron's Board of Directors Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., join Regeneron's Board of Directors ...",REGN,0.130453,0.047984,Neutral
Regeneron Announces Updates to Board of Directors - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/09/g34373255/regeneron-announces-updates-to-board-of-directors,2023-09-08 20:45:00,"TARRYTOWN, N.Y., Sept. 08, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced that Kathryn Guarini, Ph.D., and David P. Schenkein, M.D., have joined Regeneron's Board of Directors effective September 8, 2023.",REGN,0.128592,0.046349,Neutral
Check Out What Whales Are Doing With REGN - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/09/34369351/check-out-what-whales-are-doing-with-regn,2023-09-08 19:01:17,A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 10 strange trades.,REGN,0.895116,0.14938,Neutral
2 Top Biotech Stocks to Buy in September,https://www.fool.com/investing/2023/09/08/2-top-biotech-stocks-to-buy-in-september/,2023-09-08 13:53:00,There is rarely a bad time to buy stocks with massive upside potential.,REGN,0.109956,0.216707,Somewhat-Bullish
Stocks Showing Improving Market Leadership: Regeneron Pharmaceuticals Earns 85 RS Rating,https://www.investors.com/ibd-data-stories/stocks-showing-improving-market-leadership-regeneron-pharmaceuticals-earns-85-rs-rating/,2023-09-27 07:00:00,Stocks Showing Improving Market Leadership: Regeneron ... Investor's Business Daily ...,REGN,0.625937,-0.081122,Neutral
Futures: What To Do As Stocks Sell Off; Meta's AI Push In Focus,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-correction-intensifies-what-to-do-meta-ai-push-in-focus/,2023-09-26 20:49:00,Futures: What To Do As Stocks Sell Off. Meta's AI Push In Focus Investor's Business Daily ...,REGN,0.086765,0.103975,Neutral
FDA Accepts Sanofi's  ( SNY )  sBLA for Dupixent in Pediatric EoE,https://www.zacks.com/stock/news/2155380/fda-accepts-sanofis-sny-sbla-for-dupixent-in-pediatric-eoe,2023-09-26 12:11:00,"If this filing is approved, Sanofi (SNY)/Regeneron's (REGN) Dupixent will be the first FDA-approved treatment for eosinophilic esophagitis in children aged 1 to 11. A final decision is expected in January.",REGN,0.204647,0.218257,Somewhat-Bullish
Press Release: Dupixent®  ( dupilumab )  sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review,https://www.globenewswire.com/news-release/2023/09/26/2749151/0/en/Press-Release-Dupixent-dupilumab-sBLA-for-treatment-of-eosinophilic-esophagitis-in-children-aged-1-to-11-accepted-for-FDA-Priority-Review.html,2023-09-26 05:30:00,"Dupixent® ( dupilumab ) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review • If approved, Dupixent would be the first and only treatment indicated in the U.S. for children aged 1- 11 with eosinophilic esophagitis, a disease driven by type 2 ...",REGN,0.032164,0.043115,Neutral
Press Release: Dupixent®  ( dupilumab )  sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review,https://www.benzinga.com/pressreleases/23/09/g34889029/press-release-dupixent-dupilumab-sbla-for-treatment-of-eosinophilic-esophagitis-in-children-aged-1,2023-09-26 05:30:00,"Dupixent® ( dupilumab ) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review If approved, Dupixent would be the first and only treatment indicated in the U.S. for children aged 1- 11 with eosinophilic esophagitis, a disease driven by type 2 ...",REGN,0.031446,0.041974,Neutral
Dupixent®  ( dupilumab )  sBLA for Treatment of Eosinophilic Esophagitis  ( EoE )  in Children Aged 1 to 11 Accepted for FDA Priority Review,https://www.globenewswire.com/news-release/2023/09/26/2749147/0/en/Dupixent-dupilumab-sBLA-for-Treatment-of-Eosinophilic-Esophagitis-EoE-in-Children-Aged-1-to-11-Accepted-for-FDA-Priority-Review.html,2023-09-26 05:29:00,"If approved, Dupixent would be the first and only treatment in the U.S. indicated for children aged 1 to 11 with EoE, a disease driven by type 2 inflammation that impacts the ability to eat ...",REGN,0.054162,0.047,Neutral
"Ultragenyx Launches Evkeeza®  ( evinacumab for injection )  in Canada for the Treatment of Homozygous Familial Hypercholesterolemia  ( HoFH )  - Ultragenyx Pharmaceutical  ( NASDAQ:RARE ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/pressreleases/23/09/g34882289/ultragenyx-launches-evkeeza-evinacumab-for-injection-in-canada-for-the-treatment-of-homozygous-fam,2023-09-25 21:13:21,"TORONTO, Sept. 25, 2023 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. RARE, a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare genetic diseases, today announced the approval of Evkeeza® ( evinacumab ) in Canada.",REGN,0.076847,0.013247,Neutral
Ultragenyx Launches Evkeeza®  ( evinacumab for injection )  in Canada for the Treatment of Homozygous Familial Hypercholesterolemia  ( HoFH ) ,https://www.globenewswire.com/news-release/2023/09/25/2749034/20739/en/Ultragenyx-Launches-Evkeeza-evinacumab-for-injection-in-Canada-for-the-Treatment-of-Homozygous-Familial-Hypercholesterolemia-HoFH.html,2023-09-25 21:13:00,"Evkeeza is a first-in-class medicine approved by Health Canada, the U.S. Food and Drug Administration ( FDA ) and European Commission ( EC ) to treat an ultrarare, inherited form of high cholesterol Evkeeza is a first-in-class medicine approved by Health Canada, the U.S.",REGN,0.077593,0.012251,Neutral
"CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key Companies - Cartesian, Arcellx, Novartis, Bristol-Myers Squibb, CARsgen, Poseida, Juno, CRISPR, bluebird bio",https://www.prnewswire.com/news-releases/car-t-cell-therapy-for-multiple-myeloma-market-to-observe-stunning-growth-by-2032-evaluates-delveinsight--key-companies---cartesian-arcellx-novartis-bristol-myers-squibb-carsgen-poseida-juno-crispr-bluebird-bio-301937157.html,2023-09-25 21:01:00,"CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by 2032, Evaluates DelveInsight | Key ... PR ...",REGN,0.037504,0.029512,Neutral
REGN: Investors Keeping a Close Eye on These 3 Biotech Stocks,https://stocknews.com/news/regn-incy-cort-dbtx-investors-keeping-a-close-eye-on-these-3-biotech-stocks/,2023-09-25 15:20:17,"The biotech industry is fueled by an increasing number of orphan drug formulations and increasing investment in advanced technologies. Given the industry's steady growth prospects, investors could consider quality biotech stocks Regeneron Pharmaceuticals, Inc. ( REGN ) , Corcept Therapeutics ...",REGN,0.309864,0.340321,Somewhat-Bullish
"The Zacks Analyst Blog Highlights Amazon.com, Boeing, Regeneron, Boston Scientific and Waste Management",https://www.zacks.com/stock/news/2154908/the-zacks-analyst-blog-highlights-amazoncom-boeing-regeneron-boston-scientific-and-waste-management,2023-09-25 13:07:00,"Amazon.com, Boeing, Regeneron, Boston Scientific and Waste Management are part of the Zacks top Analyst Blog.",REGN,0.218161,0.049508,Neutral
"Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/pressreleases/23/09/g34861912/regeneron-completes-acquisition-of-decibel-therapeutics-adding-promising-gene-therapy-programs-for,2023-09-25 12:34:45,"TARRYTOWN, N.Y., Sept. 25, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company's gene therapy and auditory programs.",REGN,0.067095,0.056431,Neutral
"Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss",https://www.globenewswire.com/news-release/2023/09/25/2748643/0/en/Regeneron-Completes-Acquisition-of-Decibel-Therapeutics-Adding-Promising-Gene-Therapy-Programs-for-Hearing-Loss.html,2023-09-25 12:34:00,"TARRYTOWN, N.Y., Sept. 25, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that it has successfully completed its acquisition of Decibel Therapeutics, Inc., strengthening the company's gene therapy and auditory programs.",REGN,0.068371,0.058553,Neutral
This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost,https://www.fool.com/investing/2023/09/20/this-recent-fda-approval-could-give-regenerons-top/,2023-09-20 14:07:00,A higher-dose version of Eylea will help the company fight off competition and increase revenue.,REGN,0.206392,-0.10349,Neutral
"Head and Neck Squamous Cell Carcinoma Market to Witness Upsurge in Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Pfizer, Merck, Eisai, AstraZeneca, Innate, Roche, GlaxoSmithKline, BeiGene, IO Biotech, Incyte",https://www.prnewswire.com/news-releases/head-and-neck-squamous-cell-carcinoma-market-to-witness-upsurge-in-growth-by-2032-assesses-delveinsight--key-companies-in-the-market---pfizer-merck-eisai-astrazeneca-innate-roche-glaxosmithkline-beigene-io-biotech-incyt-301930322.html,2023-09-18 21:01:00,"Head and Neck Squamous Cell Carcinoma Market to Witness Upsurge in Growth by 2032, Assesses DelveInsight | Key ... PR ...",REGN,0.023146,0.04357,Neutral
"STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - DBTX, RETA, VRTV, HCCI",https://www.benzinga.com/pressreleases/23/09/g34702887/stockholder-alert-the-m-a-class-action-firm-continues-investigating-the-merger-dbtx-reta-vrtv-hcci,2023-09-18 20:59:47,"NEW YORK, Sept. 18, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the ""M&A Class Action Firm"" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and ...",REGN,0.067727,0.119871,Neutral
Myopia and presbyopia treatment market to grow by USD 7.94 billion from 2022 to 2027 | Asia to account for 37% of ... - PR Newswire,https://www.prnewswire.com/news-releases/myopia-and-presbyopia-treatment-market-to-grow-by-usd-7-94-billion-from-2022-to-2027--asia-to-account-for-37-of-market-growth--technavio-301929564.html,2023-09-18 04:15:00,Myopia and presbyopia treatment market to grow by USD 7.94 billion from 2022 to 2027 | Asia to account for 37% of ... PR ...,REGN,0.052801,0.184679,Somewhat-Bullish
P/E Ratio Insights for Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/news/23/10/35131743/pe-ratio-insights-for-regeneron-pharmaceuticals,2023-10-06 19:30:18,"In the current market session, Regeneron Pharmaceuticals Inc. REGN stock price is at $830.00, after a 0.13% decrease. However, over the past month, the company's stock increased by 1.13%, and in the past year, by 14.93%.",REGN,0.428632,0.068711,Neutral
"The Zacks Analyst Blog Highlights Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna",https://www.zacks.com/stock/news/2161291/the-zacks-analyst-blog-highlights-novavax-alx-oncology-regeneron-pharmaceuticals-intellia-and-moderna,2023-10-06 08:59:00,"Novavax, ALX Oncology, Regeneron Pharmaceuticals, Intellia and Moderna are included in this Analyst Blog.",REGN,0.11787,0.004529,Neutral
"Diffuse Cutaneous Systemic Sclerosis Market to Proliferate at a Considerable Growth Rate by 2032, Estimates DelveInsight | Leading Companies in the Market - Kyowa Kirin Acceleron, Cumberland, Horizon, CSL Behring, Seagen, Janssen",https://www.prnewswire.com/news-releases/diffuse-cutaneous-systemic-sclerosis-market-to-proliferate-at-a-considerable-growth-rate-by-2032-estimates-delveinsight--leading-companies-in-the-market---kyowa-kirin-acceleron-cumberland-horizon-csl-behring-seagen-janssen-301947923.html,2023-10-05 21:01:00,"Diffuse Cutaneous Systemic Sclerosis Market to Proliferate at a Considerable Growth Rate by 2032, Estimates ... PR ...",REGN,0.025679,0.015133,Neutral
"Biotech Stock Roundup: NVAX Up on Updates, ALXO Gains on Study Data & More",https://www.zacks.com/stock/news/2160940/biotech-stock-roundup-nvax-up-on-updates-alxo-gains-on-study-data-more,2023-10-05 14:58:00,Regulatory and pipeline updates from Novavax (NVAX) and ALX Oncology Holdings (ALXO) are in focus in the biotech sector.,REGN,0.084423,0.008282,Neutral
EYLEA® HD  ( aflibercept )  Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA,https://www.globenewswire.com/news-release/2023/10/05/2755506/0/en/EYLEA-HD-aflibercept-Injection-8-mg-Two-year-Results-from-Pivotal-PULSAR-Trial-in-Wet-Age-related-Macular-Degeneration-Presented-at-EURETINA.html,2023-10-05 13:43:00,First presentation of long-term results demonstrated sustained visual and anatomic improvements among EYLEA HD patients through two years First presentation of long-term results demonstrated sustained visual and anatomic improvements among EYLEA HD patients through two years ...,REGN,0.072964,0.044662,Neutral
EYLEA® HD  ( aflibercept )  Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/10/g35108562/eylea-hd-aflibercept-injection-8-mg-two-year-results-from-pivotal-pulsar-trial-in-wet-age-related-,2023-10-05 13:43:00,"TARRYTOWN, N.Y., Oct. 05, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.",REGN,0.07292,0.042608,Neutral
Here's the Best Big Pharma Stock of the Decade so Far  ( and It's Not Even Close ) ,https://www.fool.com/investing/2023/10/05/heres-the-best-big-pharma-stock-of-the-decade-so-f/,2023-10-05 09:50:00,"This stock puts the ""big"" in big pharma after massive gains in recent years.",REGN,0.116348,0.285979,Somewhat-Bullish
"Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Leading Companies - Amgen, Novartis, AbbVie, BMS, Clovis Oncology, Cardiff Oncology, Roche, Daiichi Sankyo",https://www.prnewswire.com/news-releases/small-cell-lung-cancer-market-to-accelerate-substantially-during-the-study-period-20192032-assesses-delveinsight--leading-companies----amgen-novartis-abbvie-bms-clovis-oncology-cardiff-oncology-roche-daiichi-sankyo-301946615.html,2023-10-04 21:01:00,"Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period ( 2019-2032 ) , Assesses ... PR ...",REGN,0.021778,-0.02031,Neutral
Teva Hooks Immunology Powerhouse Sanofi In $1.5 Billion Deal,https://www.investors.com/news/technology/teva-stock-dives-after-inking-deal-for-inflammation-drug/,2023-10-04 14:47:00,Teva Stock Dives After Inking $1.5 Billion Deal For Inflammation Drug Investor's Business Daily ...,REGN,0.099271,0.11034,Neutral
"Intellia  ( NTLA ) , Regeneron Expand Deal for Gene-Editing Therapies",https://www.zacks.com/stock/news/2160105/intellia-ntla-regeneron-expand-deal-for-gene-editing-therapies,2023-10-04 13:27:00,"Intellia (NTLA) expands partnership with Regeneron, to develop potential treatments for neurological and muscular diseases.",REGN,0.2872,0.339345,Somewhat-Bullish
Public reimbursement for biosimilar BYOOVIZ™ to treat serious retinal disorders now secured in four provinces and two national benefits programs,https://www.newswire.ca/news-releases/public-reimbursement-for-biosimilar-byooviz-tm-to-treat-serious-retinal-disorders-now-secured-in-four-provinces-and-two-national-benefits-programs-817633984.html,2023-10-04 11:00:00,Public reimbursement for biosimilar BYOOVIZ™ to treat serious retinal disorders now secured in four provinces and two ... Canada ...,REGN,0.05749,0.0,Neutral
MAIA Secures FDA Clearance Of IND Application For THIO For Non-Small Cell Lung Cancer - MAIA Biotechnology  ( AMEX:MAIA ) ,https://www.benzinga.com/markets/equities/23/10/35066621/maia-secures-fda-clearance-of-ind-application-for-thio-for-non-small-cell-lung-cancer,2023-10-03 17:25:33,"MAIA Biotechnology, Inc. MAIA announced that the U.S. Food and Drug Administration ( FDA ) has cleared its Investigational New Drug application for THIO, a first-in-class telomere targeting agent for the treatment of non-small-cell-lung-cancer, or NSLC.",REGN,0.268294,0.012168,Neutral
Regeneron Pharmaceuticals Unusual Options Activity - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/10/35067969/regeneron-pharmaceuticals-unusual-options-activity,2023-10-03 16:01:40,A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 10 strange trades.,REGN,0.802374,0.228994,Somewhat-Bullish
"Regeneron, Intellia to make gene editing therapies in expanded collaboration",https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-intellia-therapeutics-expand-research-collaboration-make-gene-editing-2023-10-03/,2023-10-03 11:10:00,"Regeneron, Intellia Therapeutics expand research collaboration to make gene editing therapies ...",REGN,0.310843,0.0,Neutral
"Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Intellia Therapeutics  ( NASDAQ:NTLA ) ",https://www.benzinga.com/pressreleases/23/10/g35055988/regeneron-and-intellia-announce-expanded-research-collaboration-to-develop-crispr-based-therapies-,2023-10-03 11:00:00,"Collaboration combines Intellia's leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron's proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases",REGN,0.085022,0.065391,Neutral
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases,https://www.globenewswire.com/news-release/2023/10/03/2753457/0/en/Regeneron-and-Intellia-Announce-Expanded-Research-Collaboration-to-Develop-CRISPR-Based-Therapies-for-the-Treatment-of-Neurological-and-Muscular-Diseases.html,2023-10-03 11:00:00,"Collaboration combines Intellia's leading genome editing platform, including its proprietary Nme2Cas9 technology, with Regeneron's proprietary antibody-targeted viral vector delivery technologies to jointly advance in vivo programs outside of the liver for neurological and muscular diseases ...",REGN,0.069194,0.0646,Neutral
Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases,https://www.globenewswire.com/news-release/2023/10/03/2753456/0/en/Regeneron-and-Intellia-Announce-Expanded-Research-Collaboration-to-Develop-CRISPR-Based-Therapies-for-the-Treatment-of-Neurological-and-Muscular-Diseases.html,2023-10-03 11:00:00,"TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Oct. 03, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) and Intellia Therapeutics, Inc. ( NASDAQ:NTLA ) today announced an expanded research collaboration to develop additional in vivo CRISPR-based gene editing therapies focused ...",REGN,0.051961,0.063974,Neutral
Stock Split Watch: Is Regeneron Pharmaceuticals Next?,https://www.fool.com/investing/2023/09/30/stock-split-watch-is-regeneron-next/,2023-09-30 09:30:00,"If the biotech does split its stock, it will be a first for the company.",REGN,0.109455,0.049699,Neutral
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma  ( FL )  and Diffuse Large B-cell Lymphoma  ( DLBCL )  Accepted for FDA Priority Review,https://www.globenewswire.com/news-release/2023/09/29/2751977/0/en/Odronextamab-BLA-for-Treatment-of-Relapsed-Refractory-Follicular-Lymphoma-FL-and-Diffuse-Large-B-cell-Lymphoma-DLBCL-Accepted-for-FDA-Priority-Review.html,2023-09-29 12:30:00,"If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL - the two most common subtypes of non-Hodgkin lymphoma ...",REGN,0.117948,0.051846,Neutral
"Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023",https://www.globenewswire.com/news-release/2023/09/28/2751630/0/en/Regeneron-to-Report-Third-Quarter-2023-Financial-and-Operating-Results-and-Host-Conference-Call-and-Webcast-on-November-2-2023.html,2023-09-28 20:05:00,"TARRYTOWN, N.Y., Sept. 28, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that it will report its third quarter 2023 financial and operating results on Thursday, November 2, 2023, before the U.S. financial markets open.",REGN,0.25168,0.0,Neutral
Price Over Earnings Overview: Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/news/23/10/35289588/price-over-earnings-overview-regeneron-pharmaceuticals,2023-10-17 14:15:16,"In the current market session, Regeneron Pharmaceuticals Inc. REGN share price is at $844.27, after a 0.07% increase. Moreover, over the past month, the stock decreased by 0.18%, but in the past year, went up by 17.75%.",REGN,0.399204,0.046466,Neutral
Intellia's  ( NTLA )  HAE Candidate Gets EMA's PRIME Designation,https://www.zacks.com/stock/news/2166668/intellias-ntla-hae-candidate-gets-emas-prime-designation,2023-10-16 16:39:00,"The European Medicines Agency bestows a Priority Medicines (PRIME) designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema.",REGN,0.211191,0.407962,Bullish
2 Healthcare Stocks Near 52-Week Highs Still Worth Buying,https://www.fool.com/investing/2023/10/16/2-healthcare-stocks-near-52-week-highs-still-worth/,2023-10-16 13:26:00,These two large-cap biopharma companies could have more room to run.,REGN,0.349575,0.33828,Somewhat-Bullish
"Futures Rise As Netflix, Tesla Earnings Loom",https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-netflix-tesla-earnings-loom-lululemon-surges-on-sp-news/,2023-10-16 12:17:00,"Dow Jones futures rose Monday ahead of a big week of earning reports, headlined by Netflix ( NFLX ) and Tesla ( TSLA ) . Meanwhile, Lululemon Athletica ( LULU ) jumped on news that the company will join the S&P 500 index this week.",REGN,0.070207,0.175048,Somewhat-Bullish
Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/10/g35257414/regeneron-to-showcase-progress-from-innovative-oncology-portfolio-in-several-difficult-to-treat-ca,2023-10-15 22:05:23,"Event-free survival of investigational use of Libtayo® ( cemiplimab ) in neoadjuvant cutaneous squamous cell carcinoma ( CSCC ) from Phase 2 trial to be featured in oral presentation TARRYTOWN, N.Y., Oct. 15, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.",REGN,0.071357,-0.054547,Neutral
Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO,https://www.globenewswire.com/news-release/2023/10/15/2760264/0/en/Regeneron-to-Showcase-Progress-from-Innovative-Oncology-Portfolio-in-Several-Difficult-to-Treat-Cancers-at-ESMO.html,2023-10-15 22:05:00,Event-free survival of investigational use of Libtayo® ( cemiplimab ) in neoadjuvant cutaneous squamous cell carcinoma ( CSCC ) from Phase 2 trial to be featured in oral presentation ...,REGN,0.059607,0.025035,Neutral
2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years,https://www.fool.com/investing/2023/10/14/2-growth-stocks-that-could-deliver-parabolic-retur/,2023-10-14 16:20:22,These two gene-editing stocks could be diamonds in the rough.,REGN,0.109956,0.128748,Neutral
Two AI Stocks Lead 5 Resilient Names Near Buy Points,https://www.investors.com/news/ai-stocks-avgo-and-anet-lead-5-resilient-names-near-buy-points/,2023-10-14 14:44:00,"AI stocks Broadcom ( AVGO ) and Arista Networks ( ANET ) lead this weekend's watch list of five names near buy points. In addition to AVGO and ANET, the list includes Costco Wholesale ( COST ) , Regeneron Pharmaceuticals ( REGN ) , and Chinese gaming leader NetEase ( NTES ) .",REGN,0.131463,0.10146,Neutral
"Investing Action Plan: A Change Of Season As Netflix, Tesla Face Tests",https://www.investors.com/research/investing-action-plan/investing-action-plan-a-change-of-season-as-netflix-tesla-face-tests/,2023-10-13 21:45:00,"Investing Action Plan: A Change Of Season As Netflix, Tesla Face ... Investor's Business Daily ...",REGN,0.045874,0.032889,Neutral
"Regeneron Bulls, Bears Clash: Will Biotech Get Eylea Mojo Back?",https://www.investors.com/research/ibd-stock-of-the-day/regn-stock-regeneron-bulls-bears-clash-eylea-mojo/,2023-10-13 18:35:00,Regeneron Pharmaceuticals ( REGN ) is the IBD Stock of the Day as the biotech giant trades near an all-time high ahead of its earnings report due Nov. 2. The big debate for REGN stock: Will the company get its mojo back in its core eye disease treatment business?,REGN,0.590628,0.206575,Somewhat-Bullish
Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance in Aging Demographics,https://www.prnewswire.com/news-releases/growing-geriatric-population-fuels-ankylosing-spondylitis-market-management-of-pain-and-mobility-gains-importance-in-aging-demographics-301956060.html,2023-10-13 15:45:00,Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance ... PR ...,REGN,0.036643,0.067285,Neutral
Stock Market Mixed As Banks Start A New Earnings Season,https://www.investors.com/market-trend/stock-market-today/stock-market-mixed-as-banks-start-a-new-earnings-season/,2023-10-13 14:48:00,"The stock market wavered in the first hour of trading Friday with major indexes showing mixed results. Meanwhile, earnings season got underway with big banks the first to report third-quarter numbers. The Nasdaq notched down 0.3% on the stock market today.",REGN,0.145145,-0.085735,Neutral
Sanofi reaps rewards of immunology investment with eczema results,https://www.marketwatch.com/story/sanofi-reaps-rewards-of-immunology-investment-with-eczema-results-9ce642b0,2023-10-13 14:00:00,Pharmaceutical giant set to take on Amgen with atopic dermatitis treatment.,REGN,0.221819,0.151207,Somewhat-Bullish
"J&J  ( JNJ )  to Report Q3 Earnings, Its First After Unit Spin-Off",https://www.zacks.com/stock/news/2165582/jj-jnj-to-report-q3-earnings-its-first-after-unit-spin-off,2023-10-13 13:49:00,J&J's (JNJ) third-quarter results are the first quarterly update for the new company after the Consumer Health spin-off.,REGN,0.257442,0.135924,Neutral
2 Brilliant Growth Stocks to Buy and Hold Forever,https://www.fool.com/investing/2023/10/12/2-brilliant-growth-stocks-to-buy-and-hold-forever/,2023-10-12 12:57:00,These two growth stocks could be genuine wealth escalators.,REGN,0.056674,0.077922,Neutral
"Down 45%, Is Intellia a Buy?",https://www.fool.com/investing/2023/10/10/down-45-percent-is-intellia-a-buy/,2023-10-10 18:00:00,Intellia's operating in the high-growth field of gene editing.,REGN,0.058615,0.240035,Somewhat-Bullish
"This Cathie Wood Stock Is Poised to Double, Says Wall Street",https://www.fool.com/investing/2023/10/10/this-cathie-wood-stock-poised-to-double-says-wall-/,2023-10-10 14:07:00,Almost anything is possible in the volatile biotech industry.,REGN,0.052801,0.059954,Neutral
"The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand Disease | Key Analysis by DelveInsight",https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-factor-based-bleeding-disorders-hemophilia-a-hemophilia-b-and-von-willebrand-disease--key-analysis-by-delveinsight-301950491.html,2023-10-09 21:01:00,"The Evolving Market Dynamics of Factor-based Bleeding Disorders: Hemophilia A, Hemophilia B, and Von Willebrand ... PR ...",REGN,0.036338,0.029364,Neutral
"Antibody Drug Conjugates Market Revenue to Hit $29.6 Billion, Globally, by 2030 - Exclusive Study by The Insight Partners",https://www.benzinga.com/pressreleases/23/10/g35143608/antibody-drug-conjugates-market-revenue-to-hit-29-6-billion-globally-by-2030-exclusive-study-by-th,2023-10-09 12:04:10,"Pune, India, Oct. 09, 2023 ( GLOBE NEWSWIRE ) -- Antibody drug conjugates ( ADC ) are one of the fastest growing anticancer drugs. It is typically composed of a monoclonal antibody ( mAbs ) covalently attached to a cytotoxic drug via a chemical linker.",REGN,0.04406,0.047239,Neutral
Regeneron  ( REGN )  to Report Q3 Earnings: What's in the Cards?,https://www.zacks.com/stock/news/2173690/regeneron-regn-to-report-q3-earnings-whats-in-the-cards,2023-10-27 12:37:00,Investors' focus is likely to be on the performance of lead drug Eylea and the uptake of Eylea HD when Regeneron (REGN) reports its third-quarter 2023 results.,REGN,0.27676,0.246419,Somewhat-Bullish
Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/10/g35450111/regeneron-shares-preliminary-results-showing-gene-therapy-improves-auditory-responses-in-child-wit,2023-10-26 20:00:07,"TARRYTOWN, N.Y., Oct. 26, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced preliminary, positive safety and efficacy results from the first patient ( <2 years of age ) dosed in the Phase 1/2 CHORD trial investigating otoferlin gene therapy ( DB-OTO ) in children ...",REGN,0.115416,0.090525,Neutral
Intellia  ( NTLA )  Focuses on Developing Gene-Editing Therapies,https://www.zacks.com/stock/news/2170217/intellia-ntla-focuses-on-developing-gene-editing-therapies,2023-10-23 13:40:00,Intellia's (NTLA) in-vivo CRISPR-based gene-edited therapy candidate NTLA-2001 holds potential. Other pipeline candidates are in early-stage development and progressing well.,REGN,0.237358,0.478488,Bullish
Regeneron : Dupixent Phase 3 Results Show Sustained Efficacy For Up To One Year In Children With EoE,https://markets.businessinsider.com/news/stocks/regeneron-dupixent-phase-3-results-show-sustained-efficacy-for-up-to-one-year-in-children-with-eoe-1032726139,2023-10-23 02:20:12,Regeneron : Dupixent Phase 3 Results Show Sustained Efficacy For Up To One Year In Children With ...,REGN,0.499789,0.498711,Bullish
Press Release: Dupixent®  ( dupilumab )  Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis  ( EoE ) ,https://www.globenewswire.com/news-release/2023/10/22/2764338/0/en/Press-Release-Dupixent-dupilumab-Phase-3-Results-show-sustained-efficacy-for-up-to-one-year-in-children-1-to-11-years-of-age-with-eosinophilic-esophagitis-EoE.html,2023-10-22 19:00:00,Dupixent® ( dupilumab ) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis ...,REGN,0.027571,0.041305,Neutral
Press Release: Dupixent®  ( dupilumab )  Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis  ( EoE ) ,https://www.benzinga.com/pressreleases/23/10/g35365800/press-release-dupixent-dupilumab-phase-3-results-show-sustained-efficacy-for-up-to-one-year-in-chi,2023-10-22 19:00:00,Dupixent® ( dupilumab ) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis ( EoE ) Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week ...,REGN,0.026518,0.039154,Neutral
Press Release: Dupixent®  ( dupilumab )  Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis  ( EoE ) ,https://markets.businessinsider.com/news/stocks/press-release-dupixent-dupilumab-phase-3-results-show-sustained-efficacy-for-up-to-one-year-in-children-1-to-11-years-of-age-with-eosinophilic-esophagitis-eoe-1032726107,2023-10-22 19:00:00,Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis ...,REGN,0.026444,0.039139,Neutral
Dupixent®  ( dupilumab )  Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis  ( EoE ) ,https://markets.businessinsider.com/news/stocks/dupixent-dupilumab-phase-3-results-show-sustained-efficacy-for-up-to-one-year-in-children-1-to-11-years-of-age-with-eosinophilic-esophagitis-eoe-1032726106,2023-10-22 18:59:00,Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis ...,REGN,0.048839,0.04288,Neutral
Libtayo®  ( cemiplimab )  Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma  ( CSCC ) ,https://www.globenewswire.com/news-release/2023/10/21/2764294/0/en/Libtayo-cemiplimab-Neoadjuvant-Treatment-Demonstrates-Encouraging-Event-Free-Survival-in-Patients-with-Resectable-Cutaneous-Squamous-Cell-Carcinoma-CSCC.html,2023-10-21 12:48:00,89% estimated event-free survival at one year among patients with stage II to IV resectable CSCC who received Libtayo prior to surgery in a Phase 2 trial ...,REGN,0.056116,0.025006,Neutral
Regeneron and Sanofi Provide Update on Dupixent®  ( dupilumab )  sBLA for Chronic Spontaneous Urticaria,https://www.globenewswire.com/news-release/2023/10/20/2764256/0/en/Regeneron-and-Sanofi-Provide-Update-on-Dupixent-dupilumab-sBLA-for-Chronic-Spontaneous-Urticaria.html,2023-10-20 21:00:00,"TARRYTOWN, N.Y. and PARIS, Oct. 20, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) and Sanofi today announced that the U.S. Food and Drug Administration ( FDA ) has issued a Complete Response Letter ( CRL ) for the supplemental Biologics License Application ( sBLA ) ...",REGN,0.060267,0.05109,Neutral
Futures Extend Losses; This Solar Stock Crashes,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-extend-losses-from-market-sell-off-solaredge-crashes-on-warning/,2023-10-20 12:11:00,Dow Jones Futures Extend Losses From Market Sell-Off. SolarEdge ... Investor's Business Daily ...,REGN,0.101725,0.079746,Neutral
"$100 Invested In This Stock 20 Years Ago Would Be Worth $6,000 Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/news/23/10/35337733/100-invested-in-this-stock-20-years-ago-would-be-worth-6-000-today,2023-10-19 19:00:21,"Regeneron Pharmaceuticals REGN has outperformed the market over the past 20 years by 15.45% on an annualized basis producing an average annual return of 22.72%. Currently, Regeneron Pharmaceuticals has a market capitalization of $87.68 billion.",REGN,0.980595,0.386944,Bullish
Intellia's  ( NTLA )  IND for Gene-Editing Therapy Gets FDA Clearance,https://www.zacks.com/stock/news/2169049/intellias-ntla-ind-for-gene-editing-therapy-gets-fda-clearance,2023-10-19 15:46:00,"Intellia (NTLA) gets FDA nod to begin a phase III study on its gene editing candidate, NTLA-2001 to treat transthyretin amyloidosis with cardiomyopathy. The study is set to begin by 2023-end.",REGN,0.270773,0.502456,Bullish
Stocks Mixed After Jobless Claims,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fall-jobless-claims-tesla-stock-dives-elon-musk-cybertruck-warnings/,2023-10-19 14:42:00,Dow Jones Falls On Jobless Claims. Tesla Stock Dives On Elon ... Investor's Business Daily ...,REGN,0.094143,0.062249,Neutral
3 Under-the-Radar Biotech Stocks to Buy in 2023,https://www.fool.com/investing/2023/10/19/3-under-the-radar-biotech-stocks-to-buy-in-2023/,2023-10-19 12:15:00,These three lesser-known biotech companies are profitable and growing revenue.,REGN,0.051221,0.070937,Neutral
Biotech Stumbles As It Aims For A First-Ever In CRISPR Gene Editing,https://www.investors.com/news/technology/ntla-stock-stumbles-as-intellia-aims-for-a-first-ever-in-crispr-gene-editing/,2023-10-18 14:38:00,"The Food and Drug Administration gave Intellia Therapeutics ( NTLA ) the go-ahead to begin a pivotal study of its gene-editing treatment for a deadly heart disease, but NTLA stock reversed lower at the open.",REGN,0.192694,-0.034344,Neutral
"Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN",https://www.globenewswire.com/news-release/2023/10/18/2762503/0/en/Regeneron-builds-on-Together-for-CHANGE-initiative-with-five-year-5-million-commitment-to-fuel-the-STEM-talent-pipeline-in-Nashville-TN.html,2023-10-18 13:30:00,"Commitment builds on Regeneron's longstanding efforts to develop the STEM talent pipeline as lead sponsor of the premier high school competitions, the Regeneron Science Talent Search ( STS ) and Regeneron International Science and Engineering Fair ...",REGN,0.10863,0.127115,Neutral
Futures Fall Ahead Of Housing Data,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-fall-ahead-of-housing-data-netflix-tesla-earnings-next/,2023-10-18 12:16:00,"Dow Jones futures dropped Wednesday, along with S&P 500 futures and Nasdaq futures, ahead of key housing data. Up next, Netflix ( NFLX ) and Tesla ( TSLA ) will report their quarterly earnings results after the close. The Commerce Department's housing starts and building permits report is due ...",REGN,0.093897,0.062208,Neutral
Why This Potential Regeneron Rival Just Rocketed 14%,https://www.investors.com/news/technology/cldx-stock-rockets-as-it-looks-to-take-on-a-regeneron-sanofi-blockbuster/,2023-11-06 17:31:00,"CLDX Stock Rockets As It Looks To Take On A Regeneron, Sanofi ... Investor's Business Daily ...",REGN,0.165031,-0.1226,Neutral
BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update,https://www.globenewswire.com/news-release/2023/11/06/2773898/0/en/BioNTech-Announces-Third-Quarter-2023-Financial-Results-and-Corporate-Update.html,2023-11-06 11:45:00,"Conference call and webcast scheduled for November 6, 2023, at 8:00 am ET ( 2:00 pm ...",REGN,0.007918,0.004095,Neutral
"Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind - Analyst Review - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/general/biotech/23/11/35597373/regeneron-pharmaceuticals-stock-upgraded-after-q3-but-there-is-a-headwind-analyst-review,2023-11-03 19:32:25,"Thursday, Regeneron Pharmaceuticals Inc REGN reported better-than-expected Q3 earnings. Piper Sandler notes that the most significant short-term driver for Regeneron is the impending interim analysis of the Phase 3 NOTUS study in chronic obstructive pulmonary disorder, scheduled for Q4 2023.",REGN,0.592095,0.535528,Bullish
Market Rally Back In Force As Yields Plunge: Weekly Review,https://www.investors.com/news/stock-market-rally-back-in-force-as-treasury-yields-plunge-arista-palantir-are-winners/,2023-11-03 16:55:59,"The stock market rally took off this past week as Treasury yields plunged on generally weak economic data and soothing words from Fed Chief Jerome Powell Nasdaq staged a follow-through day to confirm the market rally on Wednesday, with the S&P 500 and Dow Jones following through on Thursday.",REGN,0.035476,0.043443,Neutral
Ultragenyx  ( RARE )  Q3 Earnings and Revenues Miss Estimates,https://www.zacks.com/stock/news/2178339/ultragenyx-rare-q3-earnings-and-revenues-miss-estimates,2023-11-03 15:43:00,"Ultragenyx (RARE) reports weaker-than-expected third-quarter 2023 results, missing earnings and sales estimates. Management reiterates the 2023 financial outlook.",REGN,0.127682,0.153951,Somewhat-Bullish
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/11/g35587285/regeneron-to-highlight-scientific-advancements-across-diversified-pipeline-in-difficult-to-treat-b,2023-11-03 11:00:14,"TARRYTOWN, N.Y., Nov. 03, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.",REGN,0.172713,0.048539,Neutral
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH,https://www.globenewswire.com/news-release/2023/11/03/2773090/0/en/Regeneron-to-Highlight-Scientific-Advancements-Across-Diversified-Pipeline-in-Difficult-to-Treat-Blood-Cancers-and-Disorders-at-ASH.html,2023-11-03 11:00:00,"Ten abstracts, including three oral presentations, spotlight the expanding body of evidence supporting odronextamab in follicular lymphoma and diffuse large B-cell lymphoma ...",REGN,0.08687,0.051057,Neutral
"Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/general/biotech/23/11/35569003/regenerons-skin-drugs-propel-revenue-in-q3-witnesses-strong-demand-for-higher-dose-version-of-fla,2023-11-02 17:53:54,"Regeneron Pharmaceuticals Inc REGN earned Q3 adjusted EPS of $11.59, up 4% Y/Y, beating the $10.77 Street estimate. Revenues increased 15% Y/Y to $3.36 billion, beating the consensus of $3.235 billion. Dupixent global net sales ( recorded by Sanofi ) increased 33% to $3.10 billion versus the ...",REGN,0.340915,-0.059022,Neutral
"Regeneron  ( REGN )  Q3 Earnings & Sales Top, Eylea Sales Decline",https://www.zacks.com/stock/news/2177618/regeneron-regn-q3-earnings-sales-top-eylea-sales-decline,2023-11-02 16:31:00,"Regeneron (REGN) beats earnings and sales estimates in third-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, fall yet again.",REGN,0.233108,0.283905,Somewhat-Bullish
Regeneron sees strong initial demand for higher-dose Eylea,https://www.reuters.com/business/healthcare-pharmaceuticals/regeneron-beats-quarterly-profit-estimates-eczema-treatment-strength-2023-11-02/,2023-11-02 15:59:00,Regeneron sees strong initial demand for ...,REGN,0.24289,0.100748,Neutral
Regeneron's High-Dose Eylea Is Off To A Strong Start,https://www.investors.com/news/technology/regn-stock-regeneron-earnings-q3-2023/,2023-11-02 13:38:36,Regeneron Stock Edges Higher As High-Dose Eylea Delivers A ... Investor's Business Daily ...,REGN,0.744196,0.54515,Bullish
"Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings - Roku  ( NASDAQ:ROKU ) , Wendy's  ( NASDAQ:WEN ) , Paramount Global  ( NASDAQ:PARA ) , Peloton Interactive  ( NASDAQ:PTON ) ",https://www.benzinga.com/news/earnings/23/11/35559421/us-stocks-on-track-for-solid-start-amid-lingering-fed-optimism-traders-eye-earnings-from-market-bel,2023-11-02 11:19:24,"After the Federal Reserve's decision, the stock market rally is poised to gain momentum on Thursday, with stock futures indicating an uptick. Positive earnings reports may bolster this rally, and the decline in bond yields, driven by rising rate-cut expectations, could be viewed favorably by ...",REGN,0.088635,0.0,Neutral
1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years,https://www.fool.com/investing/2023/11/02/1-supercharged-growth-stock-that-could-make-you-a/,2023-11-02 10:45:00,"Biotech may be in a slump, but this innovator holds enormous promise as a potential wealth escalator.",REGN,0.193207,0.299801,Somewhat-Bullish
Regeneron Reports Third Quarter 2023 Financial and Operating Results,https://www.globenewswire.com/news-release/2023/11/02/2772055/0/en/Regeneron-Reports-Third-Quarter-2023-Financial-and-Operating-Results.html,2023-11-02 10:30:00,"TARRYTOWN, N.Y., Nov. 02, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced financial results for the third quarter of 2023 and provided a business update.",REGN,0.046724,0.048704,Neutral
Rally Gains Steam As Powell Signals No More Rate Hikes,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-market-rally-gains-steam-as-fed-chief-powell-signals-no-more-rate-hikes/,2023-11-01 20:55:33,"Dow Jones futures were little changed hours, along with S&P 500 futures and Nasdaq futures, after Fed chief Jerome Powell signaled the rates will stay on hold into next year. Roku ( ROKU ) and MercadoLibre were among a slew of earnings Wednesday night, with Palantir Technologies ( PLTR ) , Eli ...",REGN,0.053689,-0.079734,Neutral
Regeneron Pharmaceuticals Unusual Options Activity - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/11/35548168/regeneron-pharmaceuticals-unusual-options-activity,2023-11-01 20:01:05,A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals REGN we detected 10 strange trades.,REGN,0.765728,-0.023605,Neutral
EYLEA® HD  ( aflibercept )  Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/11/g35548096/eylea-hd-aflibercept-injection-8-mg-data-presentations-at-aao-reinforce-efficacy-and-safety-profil,2023-11-01 20:00:00,"TARRYTOWN, N.Y., Nov. 01, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced long-term outcomes and new analyses of pivotal clinical data for EYLEA® HD ( aflibercept ) Injection 8 mg will be presented at the American Academy of Ophthalmology ( AAO ) annual meeting in ...",REGN,0.079026,0.043043,Neutral
REGN: Regeneron Pharmaceuticals  ( REGN )  Earnings Analysis -- Should Investors Brace for Impact?,https://stocknews.com/news/regn-otsky-gild-jazz-regeneron-pharmaceuticals-regn-earnings-analysis-should-investors-brace-for/,2023-11-01 18:02:55,REGN: Regeneron Pharmaceuticals ( REGN ) Earnings Analysis ... ...,REGN,0.52395,0.248758,Somewhat-Bullish
$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/news/23/10/35520855/100-invested-in-regeneron-pharmaceuticals-15-years-ago-would-be-worth-this-much-today,2023-10-31 17:30:15,"Regeneron Pharmaceuticals REGN has outperformed the market over the past 15 years by 18.12% on an annualized basis producing an average annual return of 28.39%. Currently, Regeneron Pharmaceuticals has a market capitalization of $84.49 billion.",REGN,0.980595,0.386944,Bullish
AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS,https://investingnews.com/amgen-reports-third-quarter-financial-results/,2023-10-31 11:39:17,"Amgen ( NASDAQ:AMGN ) today announced financial results for the third quarter of 2023 1 . References in this release to ""non-GAAP"" measures, measures presented ""on a non-GAAP basis"" and ""free cash flow"" ( computed by subtracting capital expenditures from operating cash flow ) refer to ...",REGN,0.01615,0.020913,Neutral
Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution,https://www.globenewswire.com/news-release/2023/10/31/2770046/0/en/Kiniksa-Pharmaceuticals-Reports-Third-Quarter-2023-Financial-Results-and-Recent-Portfolio-Execution.html,2023-10-31 11:30:00,"- ARCALYST® ( rilonacept ) Q3 2023 net product revenue of $64.8 million, representing ~94% year-over-year growth ...",REGN,0.020335,-0.167092,Somewhat-Bearish
AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS,https://www.prnewswire.com/news-releases/amgen-reports-third-quarter-financial-results-301972231.html,2023-10-31 11:00:00,"THOUSAND OAKS, Calif., Oct. 31, 2023 /PRNewswire/ -- Amgen ( NASDAQ:AMGN ) today announced financial results for the third quarter of 20231.",REGN,0.016053,0.021825,Neutral
"Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient",https://www.fool.com/investing/2023/10/30/gene-therapy-could-be-on-the-cusp-of-major-breakth/,2023-10-30 12:30:00,This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.,REGN,0.051999,0.081572,Neutral
"Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week - Lattice Semiconductor  ( NASDAQ:LSCC ) , Exact Sciences  ( NASDAQ:EXAS ) , Amgen  ( NASDAQ:AMGN ) , STMicroelectronics  ( NYSE:STM ) ",https://www.benzinga.com/analyst-ratings/analyst-color/23/10/35484208/apple-amd-palantir-earnings-on-deck-this-week-as-market-seeks-positive-catalysts-in,2023-10-30 07:40:15,"The third-quarter earnings season has largely been mixed so far, reflecting the impact of the economic uncertainties on profit growth. That said, data suggests S&P 500 companies may be on track to break a fourth-quarter earnings-declining streak.",REGN,0.0864,0.0,Neutral
"Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More - Target  ( NYSE:TGT ) , CVS Health  ( NYSE:CVS ) , Rite Aid  ( OTC:RADCQ ) , Novartis  ( NYSE:NVS ) ",https://www.benzinga.com/markets/equities/23/10/35478496/are-your-eyes-at-grave-risk-fda-issues-dangerous-warning-over-popular-drops-from-cvs-target-card,2023-10-28 16:49:12,"The U.S. Food and Drug Administration has recently issued a stern warning to the public, advising against the purchase and use of multiple specific over-the-counter eye drop products from prominent brands.",REGN,0.145145,0.0,Neutral
Intellia Therapeutics Will Soon Make Biotech History. Is the Stock a Buy?,https://www.fool.com/investing/2023/10/28/intellia-therapeutics-will-soon-make-biotech-histo/,2023-10-28 11:30:00,There's more to being a good investment than doing groundbreaking science.,REGN,0.045054,0.061769,Neutral
How Is The Market Feeling About Regeneron Pharmaceuticals? - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/short-sellers/23/11/35831982/how-is-the-market-feeling-about-regeneron-pharmaceuticals,2023-11-16 16:30:22,"Regeneron Pharmaceuticals's REGN short percent of float has fallen 4.67% since its last report. The company recently reported that it has 1.31 million shares sold short, which is 1.43% of all regular shares that are available for trading.",REGN,0.221819,0.083071,Neutral
Intellia  ( NTLA )  Rises on EC's Orphan Drug Tag for HAE Candidate,https://www.zacks.com/stock/news/2184720/intellia-ntla-rises-on-ecs-orphan-drug-tag-for-hae-candidate,2023-11-15 16:07:00,"The European Commission bestows orphan drug designation to Intellia's (NTLA) in vivo CRISPR-based investigational therapy, NTLA-2002, for treating hereditary angioedema. Stock rises.",REGN,0.196344,0.43873,Bullish
Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis - XBiotech  ( NASDAQ:XBIT ) ,https://www.benzinga.com/pressreleases/23/11/g35776284/dr-alan-kivitz-to-chair-xbiotechs-natrunix-program-in-rheumatoid-arthritis,2023-11-14 14:00:00,"AUSTIN, Texas, Nov. 14, 2023 ( GLOBE NEWSWIRE ) -- XBiotech XBIT today announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis. XBiotech believes Natrunix will be a breakthrough therapy for ...",REGN,0.039614,0.037048,Neutral
"Intellia  ( NTLA )  Beats on Q3 Earnings, Provides Pipeline Update",https://www.zacks.com/stock/news/2182117/intellia-ntla-beats-on-q3-earnings-provides-pipeline-update,2023-11-10 11:30:00,Intellia (NTLA) reports mixed third-quarter 2023 results. Management provides developmental and regulatory updates on its key pipeline candidates.,REGN,0.172097,0.388276,Bullish
Kiniksa Pharmaceuticals  ( KNSA )  Up 14.7% YTD: Here's How,https://www.zacks.com/stock/news/2189297/kiniksa-pharmaceuticals-knsa-up-147-ytd-heres-how,2023-11-24 19:05:00,Kiniksa Pharmaceuticals (KNSA) enjoys a good run in the year on the back of solid revenue growth and pipeline updates.,REGN,0.14131,0.179405,Somewhat-Bullish
Regeneron  ( REGN )  Stock Rallies 10% YTD: What Lies Ahead?,https://www.zacks.com/stock/news/2189105/regeneron-regn-stock-rallies-10-ytd-what-lies-ahead,2023-11-24 16:29:00,Regeneron (REGN) shares gain 10% year to date on Eylea HD's approval and Dupixent's momentum. Pipeline progress is impressive as well.,REGN,0.244109,0.201738,Somewhat-Bullish
"The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight",https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-b-cell-lymphomas-diffuse-large-b-cell-lymphoma-follicular-lymphoma-chronic-lymphocytic-leukemia-mantle-cell-lymphoma-marginal-zone-lymphoma-waldenstrom-macroglobulinemia-and-burkitt-lymphoma--301995626.html,2023-11-22 22:01:00,"The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic ... PR ...",REGN,0.039505,-0.000967,Neutral
Is CRISPR Therapeutics the Best Gene-Editing Stock?,https://www.fool.com/investing/2023/11/22/is-crispr-therapeutics-the-best-gene-editing-stock/,2023-11-22 12:30:00,The biotech's first-mover advantage bodes well for its long-term prospects.,REGN,0.037563,0.176057,Somewhat-Bullish
Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?,https://www.zacks.com/stock/news/2186419/should-you-invest-in-the-ishares-biotechnology-etf-ibb,2023-11-20 11:20:07,Sector ETF report for ...,REGN,0.135729,0.071814,Neutral
You Don't Have to Pick a Winner in Biotech. Here's Why.,https://www.fool.com/investing/2023/11/18/you-dont-have-to-pick-biotech-winner-heres-why/,2023-11-18 10:00:00,"If you invest over the long term, you'll increase your chances of victory.",REGN,0.056943,0.093937,Neutral
"If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/news/23/11/35852568/if-you-invested-100-in-this-stock-5-years-ago-you-would-have-200-today,2023-11-17 17:00:21,"Regeneron Pharmaceuticals REGN has outperformed the market over the past 5 years by 7.81% on an annualized basis producing an average annual return of 19.06%. Currently, Regeneron Pharmaceuticals has a market capitalization of $87.89 billion.",REGN,0.980595,0.386944,Bullish
Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise,https://www.investors.com/news/regeneron-pharmaceuticals-sees-relative-strength-rating-rise-to-71/,2023-12-06 20:45:00,"Regeneron Pharmaceuticals ( REGN ) had its Relative Strength ( RS ) Rating upgraded from 68 to 71 before the market opened Wednesday -- a welcome improvement, but still short of the 80 or better score you prefer to see. Was this the cause of the small gap up at the open?",REGN,0.669956,0.49969,Bullish
Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers,https://www.globenewswire.com/news-release/2023/12/05/2790782/0/en/Replimune-Shares-Initial-Primary-Analysis-Results-from-CERPASS-Clinical-Trial-in-Advanced-Cutaneous-Squamous-Cell-Carcinoma-and-Presents-New-Data-from-IGNYTE-Clinical-Trial-of-RP1-.html,2023-12-05 12:00:00,"RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary endpoints ...",REGN,0.016691,0.163105,Somewhat-Bullish
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.,https://www.fool.com/investing/2023/12/04/you-dont-have-to-pick-a-winner-in-gene-editing-do/,2023-12-04 13:30:00,"The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.",REGN,0.204072,0.239476,Somewhat-Bullish
An Important History Lesson for Gene-Editing Investors,https://www.fool.com/investing/2023/12/02/an-important-history-lesson-for-gene-editing-inves/,2023-12-02 13:30:00,Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.,REGN,0.040691,0.050122,Neutral
Laryngeal Cancer Therapeutics Market size to grow by USD 575.25 million from 2022-2027| Accord Healthcare Ltd ... - PR Newswire,https://www.prnewswire.com/news-releases/laryngeal-cancer-therapeutics-market-size-to-grow-by-usd-575-25-million-from-2022-2027-accord-healthcare-ltd-amgen-inc-astrazeneca-plc-athenex-inc-and-more-among-the-major-companies-in-the-market--technavio-302002789.html,2023-12-01 22:35:00,Laryngeal Cancer Therapeutics Market size to grow by USD 575.25 million from 2022-2027| Accord Healthcare Ltd ... PR ...,REGN,0.066414,-0.02104,Neutral
$1000 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/news/23/12/36047567/1000-invested-in-regeneron-pharmaceuticals-15-years-ago-would-be-worth-this-much-today,2023-12-01 17:00:21,"Regeneron Pharmaceuticals REGN has outperformed the market over the past 15 years by 18.44% on an annualized basis producing an average annual return of 29.82%. Currently, Regeneron Pharmaceuticals has a market capitalization of $89.41 billion.",REGN,0.980595,0.386944,Bullish
Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2191965/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now,2023-12-01 11:20:06,Smart Beta ETF report for ...,REGN,0.122269,0.068311,Neutral
3 Biotech Stocks To Watch Before December 2023,https://stockmarket.com/featured/3-biotech-stocks-to-watch-before-december-2023-2023-11-27,2023-11-27 15:38:43,"The biotechnology sector is a dynamic and innovative field that combines biological sciences with technology. It encompasses a range of companies focusing on medical research, pharmaceuticals, and genetic engineering. These companies work on groundbreaking treatments, vaccines, and technologies.",REGN,0.296582,-0.017807,Neutral
"Regeneron  ( REGN ) , Sanofi's Dupixent Succeeds in 2nd COPD Study",https://www.zacks.com/stock/news/2189807/regeneron-regn-sanofis-dupixent-succeeds-in-2nd-copd-study,2023-11-27 15:35:00,Regeneron (REGN) and partner Sanofi (SNY) post positive data from the second COPD study and plan to submit a sBLA to the FDA by the end of 2023.,REGN,0.181137,0.208896,Somewhat-Bullish
Regeneron Plots A Major Expansion That Could Add $4 Billion In Sales,https://www.investors.com/news/technology/regn-stock-rises-as-it-plans-a-major-expansion-for-blockbuster-dupixent/,2023-11-27 15:29:00,REGN Stock Rises As It Plans A Major Expansion For Blockbuster ... Investor's Business Daily ...,REGN,0.355588,0.0,Neutral
"Sanofi/Regeneron's Blockbuster Prescription Drug Dupixent Shows Additional Promise In Chronic Lung Disorder - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) , Sanofi  ( NASDAQ:SNY ) ",https://www.benzinga.com/general/biotech/23/11/35955998/sanofiregenerons-blockbuster-prescription-drug-dupixent-shows-additional-promise-in-chronic-lung-,2023-11-27 14:17:24,Regeneron Pharmaceuticals Inc REGN and Sanofi SA SNY announced the second Dupixent ( dupilumab ) Phase 3 chronic obstructive pulmonary disease ( COPD ) trial ( NOTUS ) showed that Dupixent significantly reduced exacerbations.,REGN,0.367865,0.010215,Neutral
"Dupixent®  ( dupilumab )  Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease",https://www.globenewswire.com/news-release/2023/11/27/2785840/0/en/Dupixent-dupilumab-Significantly-Reduced-COPD-Exacerbations-in-Second-Positive-Phase-3-Trial-Accelerating-FDA-Submission-and-Confirming-Potential-to-Become-First-Approved-Biologic-.html,2023-11-27 06:30:00,"NOTUS trial met its primary endpoint with overwhelming efficacy, showing Dupixent significantly reduced exacerbations by 34% compared to placebo in patients with moderate-to-severe COPD with evidence of type 2 inflammation ( i.e., blood eosinophils ≥300 cells per μL ) , confirming results from ...",REGN,0.03458,0.051254,Neutral
"Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease",https://www.globenewswire.com/news-release/2023/11/27/2785836/0/en/Press-Release-Dupixent-significantly-reduced-COPD-exacerbations-in-second-positive-Phase-3-trial-accelerating-FDA-submission-and-confirming-potential-to-become-first-approved-biolo.html,2023-11-27 06:30:00,"Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease ...",REGN,0.023418,0.041381,Neutral
"Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease",https://www.benzinga.com/pressreleases/23/11/g35953326/press-release-dupixent-significantly-reduced-copd-exacerbations-in-second-positive-phase-3-trial-a,2023-11-27 06:30:00,"Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease",REGN,0.022881,0.039327,Neutral
3 Stocks to Buy Before 2024 That Can Set You Up For Life,https://www.fool.com/investing/2023/12/14/3-stocks-to-buy-before-2024-that-can-set-you-up/,2023-12-14 14:00:00,"These stocks are still relatively cheap, but don't expect them to stay that way for long.",REGN,0.155118,0.233808,Somewhat-Bullish
Futures: What To Do As Rally Runs,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-rise-market-rally-runs-on-fed-rate-cut-shift/,2023-12-14 11:42:00,Dow Jones Futures Rise As Market Rally Runs On Fed Rate-Cut Shift. What To Do Now Investor's Business Daily ...,REGN,0.088039,0.089746,Neutral
"Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period  ( 2019-2032 ) , Evaluates DelveInsight | Key Companies to Watch Out - Octapharma, argenx, Immunovant Sciences, Sanofi, Janssen, Takeda",https://www.prnewswire.com/news-releases/chronic-inflammatory-demyelinating-polyneuropathy-market-to-register-positive-growth-during-the-study-period-20192032-evaluates-delveinsight--key-companies-to-watch-out---octapharma-argenx-immunovant-sciences-sanofi-janss-302013061.html,2023-12-12 22:01:00,Chronic Inflammatory Demyelinating Polyneuropathy Market to Register Positive Growth During the Study Period ( 2019 ... PR ...,REGN,0.026241,0.027812,Neutral
"Vanqua Bio Advances Clinical Candidate for Parkinson's Disease, Expands Leadership Team to Support Further Development",https://www.benzinga.com/pressreleases/23/12/g36194201/vanqua-bio-advances-clinical-candidate-for-parkinsons-disease-expands-leadership-team-to-support-f,2023-12-12 12:30:00,"CHICAGO, Dec. 12, 2023 ( GLOBE NEWSWIRE ) -- Vanqua Bio today announced that its development candidate VQ-101, a best-in-class brain-penetrant small molecule allosteric activator of glucocerebrosidase ( GCase ) , will enter clinical development in the first quarter of 2024, with an initial ...",REGN,0.047092,0.094795,Neutral
Could Intellia Therapeutics Become the Next CRISPR Therapeutics?,https://www.fool.com/investing/2023/12/12/could-intellia-become-the-next-crispr-therapeutics/,2023-12-12 11:00:00,Intellia is approaching the finish line.,REGN,0.051663,0.094949,Neutral
 ( REGN )  - Analyzing Regeneron Pharmaceuticals's Short Interest - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/short-sellers/23/12/36176742/regn-analyzing-regeneron-pharmaceuticalss-short-interest,2023-12-11 14:15:22,"Regeneron Pharmaceuticals's REGN short percent of float has risen 6.99% since its last report. The company recently reported that it has 1.40 million shares sold short, which is 1.53% of all regular shares that are available for trading.",REGN,0.221819,0.155473,Somewhat-Bullish
Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year,https://www.globenewswire.com/news-release/2023/12/11/2793753/0/en/Regeneron-Named-on-Dow-Jones-Sustainability-World-Index-for-Fifth-Consecutive-Year.html,2023-12-11 12:30:00,"TARRYTOWN, N.Y., Dec. 11, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced its inclusion on the Dow Jones Sustainability World Index ( DJSI World ) for the fifth consecutive year, alongside its fourth consecutive inclusion on the Dow Jones ...",REGN,0.174167,0.14098,Neutral
Latest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes,https://www.globenewswire.com/news-release/2023/12/11/2793480/0/en/Latest-Odronextamab-Data-in-Relapsed-Refractory-Follicular-Lymphoma-Showed-Compelling-Responses-and-Overall-Maintenance-of-Patient-Reported-Outcomes.html,2023-12-11 00:30:00,"Updated results presented at ASH demonstrated an 80% objective response rate and a 73% complete response ( CR ) , with a 23-month median duration of response and 24-month median duration of CR ...",REGN,0.084068,0.05084,Neutral
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes,https://www.globenewswire.com/news-release/2023/12/10/2793465/0/en/Updated-Odronextamab-Data-from-Relapsed-Refractory-Diffuse-Large-B-cell-Lymphoma-Pivotal-Trial-Showed-Deep-and-Durable-Responses-and-the-Potential-of-ctDNA-To-Predict-Long-term-Out.html,2023-12-10 17:30:00,"Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate ( ORR ) , with 31% achieving a complete response ( CR ...",REGN,0.081441,0.044342,Neutral
Regeneron  ( REGN )  Posts Positive Data on Blood Cancer Candidate,https://www.zacks.com/stock/news/2195671/regeneron-regn-posts-positive-data-on-blood-cancer-candidate,2023-12-08 17:07:00,Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.,REGN,0.158173,0.180437,Somewhat-Bullish
Could Regeneron Pharmaceuticals Stock Help You Become a Millionaire?,https://www.fool.com/investing/2023/12/08/could-regeneron-stock-help-you-become-a/,2023-12-08 12:45:00,Regeneron has been an excellent investment in recent years. Can that trend continue?,REGN,0.112532,0.253139,Somewhat-Bullish
Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/12/g36130463/updated-linvoseltamab-pivotal-data-demonstrated-strong-rates-and-depth-of-response-in-patients-wit,2023-12-07 12:00:45,"TARRYTOWN, N.Y., Dec. 07, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN today announced that the primary endpoint analysis from the pivotal trial ( LINKER-MM1 ) investigating linvoseltamab demonstrated high rates of deep and durable responses in patients with relapsed/refractory ...",REGN,0.090702,0.021905,Neutral
Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma,https://www.globenewswire.com/news-release/2023/12/07/2792394/0/en/Updated-Linvoseltamab-Pivotal-Data-Demonstrated-Strong-Rates-and-Depth-of-Response-in-Patients-with-Heavily-Pre-Treated-Multiple-Myeloma.html,2023-12-07 12:00:00,"71% objective response rate, with 46% achieving a complete response or better after 11 months of median ...",REGN,0.074287,0.050778,Neutral
Regeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO,https://www.globenewswire.com/news-release/2023/12/07/2792241/0/en/Regeneron-to-Share-Progress-of-Novel-Combination-Therapies-in-Oncology-at-ESMO-IO.html,2023-12-07 07:30:00,"First dose-escalation results for REGN5668 ( MUC16xCD28 ) , a costimulatory bispecific, in combination with Libtayo® ( cemiplimab ) showed encouraging initial activity in patients with recurrent ovarian cancer ...",REGN,0.057545,0.014011,Neutral
Unpacking the Latest Options Trading Trends in Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/markets/options/23/12/36366734/unpacking-the-latest-options-trading-trends-in-regeneron-pharmaceuticals,2023-12-22 17:32:19,"Benzinga's options scanner has just identified more than 8 option transactions on Regeneron Pharmaceuticals REGN, with a cumulative value of $289,480. Concurrently, our algorithms picked up 4 puts, worth a total of 195,130.",REGN,0.686288,0.079276,Neutral
Where Will Regeneron Pharmaceuticals Be in 1 Year?,https://www.fool.com/investing/2023/12/22/where-will-regeneron-pharmaceuticals-be-in-1-year/,2023-12-22 14:45:00,Can the stock continue its market-beating ways?,REGN,0.12645,0.167282,Somewhat-Bullish
$1000 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth This Much Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/news/23/12/36343340/1000-invested-in-regeneron-pharmaceuticals-10-years-ago-would-be-worth-this-much-today,2023-12-21 14:00:19,"Regeneron Pharmaceuticals REGN has outperformed the market over the past 10 years by 1.8% on an annualized basis producing an average annual return of 11.69%. Currently, Regeneron Pharmaceuticals has a market capitalization of $91.71 billion.",REGN,0.980595,0.386944,Bullish
Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2023/12/18/2798125/0/en/Regeneron-Announces-Presentation-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html,2023-12-18 21:05:00,"TARRYTOWN, N.Y., Dec. 18, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation is scheduled for 2:15 p.m. Pacific Time ( 5:15 p.m.",REGN,0.320974,0.0,Neutral
Regeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/23/12/g36291426/regeneron-announces-presentation-at-the-42nd-annual-j-p-morgan-healthcare-conference,2023-12-18 21:05:00,"TARRYTOWN, N.Y., Dec. 18, 2023 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation is scheduled for 2:15 p.m. Pacific Time ( 5:15 p.m.",REGN,0.299478,0.0,Neutral
"Anti-Inflammatory Therapeutics Market Analysis 2024-2028: Market Size, Growth Rate, Leading Regions And Segments As Per The Business Research Company's Anti-Inflammatory Therapeutics Global Market Report 2024",https://www.benzinga.com/pressreleases/23/12/g36286285/anti-inflammatory-therapeutics-market-analysis-2024-2028-market-size-growth-rate-leading-regions-a,2023-12-18 16:30:00,"LONDON, Dec. 18, 2023 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's anti-inflammatory therapeutics global market report 2024, the anti-inflammatory therapeutics market has experienced consistent growth, evolving from $109.88 billion in 2023 to $114.71 billion in 2024 at a ...",REGN,0.06211,0.133417,Neutral
Price Over Earnings Overview: Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/news/23/12/36284407/price-over-earnings-overview-regeneron-pharmaceuticals,2023-12-18 15:15:35,"In the current market session, Regeneron Pharmaceuticals Inc. REGN stock price is at $850.63, after a 0.99% decrease. However, over the past month, the company's stock increased by 6.48%, and in the past year, by 15.96%.",REGN,0.345674,0.058809,Neutral
It's Almost 2024: 3 Top Stocks to Buy Before the New Year,https://www.fool.com/investing/2023/12/17/its-almost-2024-3-top-stocks-to-buy-before-the-new/,2023-12-17 10:00:00,You can pick these players up for a great price right now.,REGN,0.096091,0.025951,Neutral
"Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024",https://www.globenewswire.com/news-release/2024/01/05/2804868/0/en/Regeneron-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-and-Operating-Results-and-Host-Conference-Call-and-Webcast-on-February-2-2024.html,2024-01-05 21:05:00,"TARRYTOWN, N.Y., Jan. 05, 2024 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that it will report its fourth quarter and full year 2023 financial and operating results on Friday, February 2, 2024, before the U.S. financial markets open.",REGN,0.247838,0.0,Neutral
"Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024 - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/pressreleases/24/01/g36517619/regeneron-to-report-fourth-quarter-and-full-year-2023-financial-and-operating-results-and-host-con,2024-01-05 21:05:00,"TARRYTOWN, N.Y., Jan. 05, 2024 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that it will report its fourth quarter and full year 2023 financial and operating results on Friday, February 2, 2024, before the U.S. financial markets open.",REGN,0.219809,0.0,Neutral
IBD Stock Of The Day: The Buying Opportunity In Weight Loss,https://www.investors.com/research/ibd-stock-of-the-day/novo-nordisk-stock-lingers-in-a-buy-zone-after-snagging-two-obesity-deals/,2024-01-05 18:01:00,Novo Nordisk Stock Lingers In Buy Zone After Snagging Two Obesity Deals Investor's Business Daily ...,REGN,0.120431,0.032569,Neutral
This Top 10% Stock Is Playing A Game Of Whiplash,https://www.investors.com/news/technology/kymr-stock-whiplash-shares-surge-then-topple-after-275-million-offering/,2024-01-05 15:16:00,"KYMR Stock Whiplash: Shares Surge, Then Topple After $275 Million Offering Investor's Business Daily ...",REGN,0.16171,-0.143216,Neutral
3 Top Biotech Stocks Worth Adding to Your Portfolio in 2024,https://www.zacks.com/stock/news/2206307/3-top-biotech-stocks-worth-adding-to-your-portfolio-in-2024,2024-01-05 14:49:00,"REGN, BGNE & SRPT are three biotech companies that are likely to outperform the sector on the back of strong fundamentals.",REGN,0.108958,0.175182,Somewhat-Bullish
"If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/news/24/01/36510191/if-you-invested-100-in-this-stock-10-years-ago-you-would-have-300-today,2024-01-05 14:30:18,"Regeneron Pharmaceuticals REGN has outperformed the market over the past 10 years by 3.2% on an annualized basis producing an average annual return of 12.97%. Currently, Regeneron Pharmaceuticals has a market capitalization of $99.38 billion.",REGN,0.980595,0.386944,Bullish
It's Been An Abysmal Two Years. But Biotech Is Looking Up.,https://www.investors.com/news/technology/biotech-stocks-pharma-heat-up-in-2024-as-buyouts-obesity-ai-drive-excitement/,2024-01-05 14:00:00,"Biotech Stocks, Pharma Heat Up In 2024 As Buyouts, Obesity And AI Drive Excitement Investor's Business Daily ...",REGN,0.02379,-0.042606,Neutral
Select Medical  ( SEM )  Unveils Separation Plan for Concentra,https://www.zacks.com/stock/news/2205808/select-medical-sem-unveils-separation-plan-for-concentra,2024-01-04 16:55:00,Select Medical (SEM) intends to separate its Concentra business in a bid to enhance shareholder value and boost growth prospects of strategically prioritized areas.,REGN,0.329551,0.219576,Somewhat-Bullish
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼  ( evinacumab )  for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia  ( HoFH )  - Ultragenyx Pharmaceutical  ( NASDAQ:RARE ) ,https://www.benzinga.com/pressreleases/24/01/g36488124/ultragenyx-receives-positive-recommendation-from-nice-in-the-u-k-for-evkeeza-evinacumab-for-adoles,2024-01-04 13:00:29,"NOVATO, Calif., Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. RARE today announced that the National Institute for Health and Care Excellence ( NICE ) has issued a final draft guidance recommending Evkeeza® ( evinacumab ) to NHS England.",REGN,0.029472,0.023335,Neutral
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼  ( evinacumab )  for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia  ( HoFH ) ,https://www.globenewswire.com/news-release/2024/01/04/2803980/20739/en/Ultragenyx-Receives-Positive-Recommendation-from-NICE-in-the-U-K-for-Evkeeza-evinacumab-for-Adolescents-and-Adults-Aged-12-Years-and-Older-with-Homozygous-Familial-Hypercholesterol.html,2024-01-04 13:00:00,"NOVATO, Calif., Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Ultragenyx Pharmaceutical Inc. ( NASDAQ: RARE ) today announced that the National Institute for Health and Care Excellence ( NICE ) has issued a final draft guidance recommending Evkeeza® ( evinacumab ) to NHS England.",REGN,0.029765,0.025274,Neutral
Antibody Therapeutics Market is Expected to Reach $479.0 Billion | MarketsandMarkets.,https://www.benzinga.com/pressreleases/24/01/g36487416/antibody-therapeutics-market-is-expected-to-reach-479-0-billion-marketsandmarkets,2024-01-04 12:30:00,"Chicago, Jan. 04, 2024 ( GLOBE NEWSWIRE ) -- Antibody Therapeutics market in terms of revenue was estimated to be worth $247.3 Billion in 2023 and is poised to reach $479.0 billion by 2028, growing at a CAGR of 14.1% from 2023 to 2028 according to a latest report published by MarketsandMarkets™.",REGN,0.079392,0.0,Neutral
Best Momentum Stocks to Buy for January 3rd,https://www.zacks.com/commentary/2204746/best-momentum-stocks-to-buy-for-january-3rd,2024-01-03 15:00:00,"SRPT, WING and REGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2024.",REGN,0.70749,0.0,Neutral
Top 5 Momentum Picks for January After a Fabulous 2023,https://www.zacks.com/stock/news/2204856/top-5-momentum-picks-for-january-after-a-fabulous-2023,2024-01-03 13:15:00,"We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.",REGN,0.16117,0.164297,Somewhat-Bullish
Buy These 4 Low-Beta Stocks to Counter Market Volatility,https://www.zacks.com/stock/news/2204825/buy-these-4-low-beta-stocks-to-counter-market-volatility,2024-01-03 12:50:00,"It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Otter Tail (OTTR), Regeneron (REGN), Kanzhun Limited (BZ) and Stride (LRN) are well-poised to gain.",REGN,0.16849,0.194426,Somewhat-Bullish
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea®  ( aflibercept ) ,https://www.globenewswire.com/news-release/2024/01/03/2803065/0/en/Alvotech-Clinical-Study-Results-Demonstrate-Therapeutic-Equivalence-between-Biosimilar-Candidate-AVT06-and-Reference-Product-Eylea-aflibercept.html,2024-01-03 08:30:00,"Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced positive top-line results from a confirmatory clinical study for AVT06, Alvotech's proposed biosimilar to Eylea® ( aflibercept ) .",REGN,0.025325,0.0,Neutral
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea®  ( aflibercept ) ,https://www.globenewswire.com/news-release/2024/01/03/2803066/0/en/Alvotech-Clinical-Study-Results-Demonstrate-Therapeutic-Equivalence-between-Biosimilar-Candidate-AVT06-and-Reference-Product-Eylea-aflibercept.html,2024-01-03 08:30:00,"The confirmatory clinical, safety and efficacy study for AVT06, biosimilar candidate to Eylea® ( aflibercept ) met its primary endpoint in patients with neovascular ( wet ) Age-related Macular Degeneration ...",REGN,0.025166,0.0,Neutral
"Why Regeneron Pharmaceuticals  ( REGN )  Stock Is Trading Lower Premarket Today? - Viatris  ( NASDAQ:VTRS ) , Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ",https://www.benzinga.com/general/biotech/23/12/36408741/regeneron-celebrates-legal-win-court-upholds-eylea-medication-patent,2023-12-28 13:46:57,"Wednesday, a court ruling that found Viatris Inc's VTRS replica of Regeneron Pharmaceuticals Inc's REGN eye drug, Eylea ( aflibercept ) , violated patent rights. The decision from the U.S.",REGN,0.359014,0.051145,Neutral
Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Upgraded at StockNews.com,https://www.defenseworld.net/2023/12/28/regeneron-pharmaceuticals-nasdaqregn-upgraded-at-stocknews-com.html,2023-12-28 06:30:48,"Regeneron Pharmaceuticals ( NASDAQ:REGN - Get Free Report ) was upgraded by investment analysts at StockNews.com from a ""buy"" rating to a ""strong-buy"" rating in a report issued on Thursday. REGN has been the topic of several other research reports.",REGN,0.769014,0.467612,Bullish
How Is The Market Feeling About Regeneron Pharmaceuticals? - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/short-sellers/23/12/36400246/how-is-the-market-feeling-about-regeneron-pharmaceuticals,2023-12-27 16:45:19,"Regeneron Pharmaceuticals's REGN short percent of float has fallen 12.42% since its last report. The company recently reported that it has 1.23 million shares sold short, which is 1.34% of all regular shares that are available for trading.",REGN,0.221819,0.083071,Neutral
"Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsight",https://www.prnewswire.com/news-releases/heart-failure-treatment-drug-market-to-accelerate-immensely-by-2032-predicts-delveinsight-302034593.html,2024-01-15 22:05:00,"The dynamics of the heart failure market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, and incremental healthcare spending across the world.",REGN,0.023441,0.03228,Neutral
Vir Biotechnology  ( VIR )  Gains 21.7% in 3 Months: Here's Why,https://www.zacks.com/stock/news/2210312/vir-biotechnology-vir-gains-217-in-3-months-heres-why,2024-01-15 16:32:00,"After a major pipeline setback, Vir Biotechnology (VIR) stock gains 21.7% in three months on its restructuring plan to cut operating expenses.",REGN,0.121037,0.0,Neutral
Merck  ( MRK )  Keytruda Ok'd by FDA for Expanded Cervical Cancer Use,https://www.zacks.com/stock/news/2210152/merck-mrk-keytruda-okd-by-fda-for-expanded-cervical-cancer-use,2024-01-15 14:30:00,FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.,REGN,0.129516,0.052545,Neutral
Virpax: A Promising Stock In A Sickly Biotech Market,https://www.forbes.com/sites/lawrencelight/2024/01/14/virpax-a-promising-stock-in-a-sickly-biotech-market/,2024-01-14 13:00:00,"Biotech always is a tough line of work, with a high failure rate because the research folks' ideas don't pan out, or even if they do, the Food and Drug Administration fails to approve their applications. Of the three FDA stages needed to greenlight a drug, the first has a mere 9% approval rate.",REGN,0.061949,0.165124,Somewhat-Bullish
Cytokinetics  ( CYTK )  Down on Report of Novartis Not Interested,https://www.zacks.com/stock/news/2209728/cytokinetics-cytk-down-on-report-of-novartis-not-interested,2024-01-12 19:47:00,Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.,REGN,0.149656,0.058089,Neutral
"Market Rebounds As Nvidia Leads; Bitcoin ETFs, Tesla Fall: Weekly Review",https://www.investors.com/news/stock-market-rally-rebounds-nvidia-tesla-jpmorgan-bitcoin-etfs-in-focus/,2024-01-12 19:13:00,"Market Rebounds As Nvidia Leads. Bitcoin ETFs, Tesla Fall: Weekly Review Investor's Business Daily ...",REGN,0.045612,-0.022883,Neutral
Here's Why Regeneron Just Hit A Record High - Again,https://www.investors.com/news/technology/regn-stock-hits-a-record-high-again-as-it-tacks-on-new-wins/,2024-01-12 18:22:00,REGN Stock Hits A Record High - Again - As It Tacks On New Wins Investor's Business Daily ...,REGN,0.303175,0.346108,Somewhat-Bullish
Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36611580/regeneron-pharmas-pipeline-makes-this-analyst-turn-bullish,2024-01-12 15:18:10,"Regeneron Pharmaceuticals Inc REGN won a lawsuit last month against Viatris Inc VTRS over its Eylea patent. While the performance of the company's Dupixent treatment is likely to be strong in the near term, chronic obstructive pulmonary disease ( COPD ) is likely to offer ""a meaningful ...",REGN,0.85246,0.321814,Somewhat-Bullish
There's A Paradigm Shift In Immunology; And Big Pharma Is Paying Richly For It,https://www.investors.com/news/technology/biotech-stocks-forge-a-paradigm-shift-in-immunology-and-big-pharma-pays-handsomely-for-it/,2024-01-12 14:00:00,There's A Paradigm Shift In Immunology. And Big Pharma Is Paying Richly For It Investor's Business Daily ...,REGN,0.047654,0.208731,Somewhat-Bullish
"Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results",https://www.zacks.com/stock/news/2208960/biotech-stock-roundup-regn-down-on-eylea-update-mrna-gains-on-preliminary-results,2024-01-11 15:28:00,Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.,REGN,0.074345,-0.034075,Neutral
Here's Why You Should Invest in Ocuphire Pharma  ( OCUP )  Now,https://www.zacks.com/stock/news/2208705/heres-why-you-should-invest-in-ocuphire-pharma-ocup-now,2024-01-11 12:41:00,"Here, we discuss some reasons why buying Ocuphire Pharma (OCUP) stock now may turn out to be a prudent move.",REGN,0.11894,0.0,Neutral
Acadia Healthcare  ( ACHC )  Inks JV to Better Serve Texas Residents,https://www.zacks.com/stock/news/2208468/acadia-healthcare-achc-inks-jv-to-better-serve-texas-residents,2024-01-10 17:56:00,"Acadia Healthcare (ACHC) enters into a JV with Ascension Seton to expand the availability of inpatient behavioral beds across Austin and thereby, establish a solid footprint in the region.",REGN,0.21258,0.171626,Somewhat-Bullish
Could Regeneron Stock Help You Retire a Millionaire?,https://www.fool.com/investing/2024/01/10/could-regeneron-stock-help-you-retire-millionaire/,2024-01-10 15:07:00,The blossoming biotech might give more than a nudge to investors in this project.,REGN,0.1172,0.251411,Somewhat-Bullish
"GSK to Buy Private Biotech, Strengthen Respiratory Pipeline",https://www.zacks.com/stock/news/2208092/gsk-to-buy-private-biotech-strengthen-respiratory-pipeline,2024-01-10 12:29:00,"GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.",REGN,0.170878,0.082617,Neutral
Regeneron  ( REGN )  Down as Q4 Eylea Preliminary Sales Disappoint,https://www.zacks.com/stock/news/2207560/regeneron-regn-down-as-q4-eylea-preliminary-sales-disappoint,2024-01-09 16:24:00,Regeneron (REGN) shares decline after it announces preliminary Q4 sales for the ophthalmology drug Eylea.,REGN,0.129168,-0.089639,Neutral
Bayer  ( BAYRY )  Elinzanetant Meets Goals in Late-Stage Studies,https://www.zacks.com/stock/news/2207070/bayer-bayry-elinzanetant-meets-goals-in-late-stage-studies,2024-01-08 16:26:00,"Bayer's (BAYRY) experimental candidate, elinzanetant, for the non-hormonal treatment of moderate to severe vasomotor symptoms, meets primary and secondary goals in phase III studies.",REGN,0.259037,0.191192,Somewhat-Bullish
5 Stocks in S&P 500 ETF That Braved the Worst Start Since 2016,https://www.zacks.com/stock/news/2207060/5-stocks-in-sp-500-etf-that-braved-the-worst-start-since-2016,2024-01-08 16:10:00,"The S&P 500 had the worst start to a year since 2016, reflecting a sharp reversal of the roaring rally in the final two months of 2023. Despite the losses, some stocks in the ETF stood tall.",REGN,0.098456,0.085644,Neutral
Regeneron Slumps As Its Biggest Moneymaker Falls Short,https://www.investors.com/news/technology/regn-stock-slumps-as-us-eylea-sales-disappoint-exel-stock-slammed-on-guidance/,2024-01-08 14:51:00,"REGN Stock Slumps As U.S. Eylea Sales Disappoint, EXEL Stock Slammed On Guidance Investor's Business Daily ...",REGN,0.615462,-0.308546,Somewhat-Bearish
Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo®  ( cemiplimab )  in Multiple Countries,https://www.prnewswire.com/news-releases/medison-pharma-announces--agreement-with-regeneron-pharmaceuticals-to-commercialize-libtayo-cemiplimab-in-multiple-countries-302028359.html,2024-01-08 12:30:00,Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® ( cemiplimab ) in ... PR ...,REGN,0.079524,0.139789,Neutral
Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo®  ( cemiplimab )  in Multiple Countries,https://www.prnewswire.com/news-releases/medison-pharma-announces--agreement-with-regeneron-pharmaceuticals-to-commercialize-libtayo-cemiplimab-in-multiple-countries-302028356.html,2024-01-08 12:30:00,Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® ( cemiplimab ) in ... PR ...,REGN,0.079524,0.139789,Neutral
Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo®  ( cemiplimab )  in Multiple Countries,https://www.prnewswire.com/apac/news-releases/medison-pharma-announces--agreement-with-regeneron-pharmaceuticals-to-commercialize-libtayo-cemiplimab-in-multiple-countries-302028440.html,2024-01-08 12:30:00,Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® ( cemiplimab ) in ... PR ...,REGN,0.079524,0.139789,Neutral
Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo®  ( cemiplimab )  in Multiple Countries,https://www.newswire.ca/news-releases/medison-pharma-announces-agreement-with-regeneron-pharmaceuticals-to-commercialize-libtayo-r-cemiplimab-in-multiple-countries-819240771.html,2024-01-08 12:30:00,Medison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® ( cemiplimab ) in ... Canada ...,REGN,0.079524,0.139789,Neutral
Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report,https://www.prnewswire.com/news-releases/clarivate-identifies-thirteen-potential-blockbuster-drugs-and-gamechangers-in-annual-drugs-to-watch-report-302027294.html,2024-01-08 08:00:00,"Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies",REGN,0.020266,0.0,Neutral
Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report,https://www.newswire.ca/news-releases/clarivate-identifies-thirteen-potential-blockbuster-drugs-and-gamechangers-in-annual-drugs-to-watch-report-802561925.html,2024-01-08 08:00:00,"Therapeutic advancements for sickle cell disease, RSV, breast cancer, Crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies",REGN,0.020266,0.0,Neutral
Regeneron Pharmaceuticals  ( NASDAQ:REGN )  Rating Lowered to Buy at StockNews.com,https://www.defenseworld.net/2024/01/06/regeneron-pharmaceuticals-nasdaqregn-rating-lowered-to-buy-at-stocknews-com.html,2024-01-06 09:48:45,StockNews.com lowered shares of Regeneron Pharmaceuticals ( NASDAQ:REGN - Free Report ) from a strong-buy rating to a buy rating in a research report sent to investors on Friday.,REGN,0.722944,0.385041,Bullish
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis  ( EoE )  - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/24/01/g36788272/press-release-dupixent-fda-approved-as-first-and-only-treatment-indicated-for-children-aged-1-year,2024-01-25 19:30:00,Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis ( EoE ) Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo,REGN,0.041755,0.039487,Neutral
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis  ( EoE ) ,https://www.globenewswire.com/news-release/2024/01/25/2817342/0/en/Press-Release-Dupixent-FDA-approved-as-first-and-only-treatment-indicated-for-children-aged-1-year-and-older-with-eosinophilic-esophagitis-EoE.html,2024-01-25 19:30:00,Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis ( EoE ) • Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo • Expanded ...,REGN,0.02892,0.037949,Neutral
Dupixent®  ( dupilumab )  FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis  ( EoE ) ,https://www.globenewswire.com/news-release/2024/01/25/2817340/0/en/Dupixent-dupilumab-FDA-Approved-as-First-and-Only-Treatment-Indicated-for-Children-Aged-1-Year-and-Older-with-Eosinophilic-Esophagitis-EoE.html,2024-01-25 19:29:00,Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo ...,REGN,0.039353,0.052084,Neutral
SpringWorks  ( SWTX )  Surges More Than 80% in 3 Months: Here's Why,https://www.zacks.com/stock/news/2215721/springworks-swtx-surges-more-than-80-in-3-months-heres-why,2024-01-25 14:19:00,SpringWorks (SWTX) receives a big boost with the FDA's approval for Ogsiveo (nirogacestat) to treat adult patients with progressing desmoid tumors.,REGN,0.271274,0.223434,Somewhat-Bullish
Should You Invest in the iShares Biotechnology ETF  ( IBB ) ?,https://www.zacks.com/stock/news/2215507/should-you-invest-in-the-ishares-biotechnology-etf-ibb,2024-01-25 11:20:04,Sector ETF report for ...,REGN,0.138066,0.072464,Neutral
Stocks Showing Rising Market Leadership: Revolution Medicines Earns 83 RS Rating,https://www.investors.com/ibd-data-stories/stocks-showing-rising-market-leadership-revolution-medicines-earns-83-rs-rating/,2024-01-25 08:00:00,"Revolution Medicines ( RVMD ) had its Relative Strength ( RS ) Rating upgraded from 79 to 83 Thursday. X As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength.",REGN,0.348103,0.0,Neutral
Experimental gene therapy allows kids with inherited deafness to hear,https://apnews.com/article/gene-therapy-deafness-hearing-6f38a9123a9cf7a0fd44d7e8402c9951,2024-01-24 23:34:26,"Gene therapy has allowed several children born with inherited deafness to hear. A small study documents significantly restored hearing in five of six kids treated in China. On Tuesday, the Children's Hospital of Philadelphia announced similar improvements in an 11-year-old boy treated there.",REGN,0.04823,0.095996,Neutral
"Drug-Eluting Balloons Global Market is Expected to Expand at a Healthy Growth Rate of ~8% by 2028, Predicts DelveInsight",https://www.prnewswire.com/news-releases/drug-eluting-balloons-global-market-is-expected-to-expand-at-a-healthy-growth-rate-of-8-by-2028-predicts-delveinsight-302042856.html,2024-01-24 22:01:00,"Drug-Eluting Balloons Global Market is Expected to Expand at a Healthy Growth Rate of ~8% by 2028, Predicts ... PR ...",REGN,0.025985,0.033663,Neutral
"Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts - Biogen  ( NASDAQ:BIIB ) ",https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36766392/slow-market-penetration-for-biogens-another-alzheimers-drug-ubs-highlights-risks-fo,2024-01-24 19:55:14,"UBS has downgraded Biogen Inc BIIB, noting inflection for its second Alzheimer's drug Leqembi ( lecanemab ) will take longer than anticipated.",REGN,0.214937,0.122634,Neutral
Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards,https://www.globenewswire.com/news-release/2024/01/24/2815766/0/en/Top-40-High-School-Scientists-in-Prestigious-Regeneron-Science-Talent-Search-to-Compete-for-1-8-Million-in-Awards.html,2024-01-24 17:00:00,"Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math ( STEM ) Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math ( STEM ...",REGN,0.09245,0.07054,Neutral
Travere  ( TVTX )  Stock Up More Than 30% in 3 Months: Here's Why,https://www.zacks.com/stock/news/2215121/travere-tvtx-stock-up-more-than-30-in-3-months-heres-why,2024-01-24 16:25:00,"Travere (TVTX) is on track to file an sNDA to the FDA to convert the accelerated approval for lead drug, Filspari, to full approval for IgAN in first-quarter 2024.",REGN,0.244109,0.203802,Somewhat-Bullish
Here's Why Investors May Bet on BioMarin  ( BMRN )  Stock Now,https://www.zacks.com/stock/news/2215118/heres-why-investors-may-bet-on-biomarin-bmrn-stock-now,2024-01-24 16:21:00,"Here, we discuss some reasons why investing in BioMarin (BMRN) stock now may turn out to be a more prudent move than ever.",REGN,0.198628,0.138377,Neutral
"Immunotherapy Drugs Market Size Anticipated to Surge to USD 237.4 billion at 7.1% CAGR by 2031 - Transparency Market Research, Inc.",https://www.benzinga.com/pressreleases/24/01/g36754138/immunotherapy-drugs-market-size-anticipated-to-surge-to-usd-237-4-billion-at-7-1-cagr-by-2031-tran,2024-01-24 11:14:00,"Wilmington, Delaware, United States, Jan. 24, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global immunotherapy drugs market is estimated to flourish at a CAGR of 7.1% from 2023 to 2031.",REGN,0.03399,0.0,Neutral
Lisata  ( LSTA )  Stock Up More Than 35% in 3 Months: Here's Why,https://www.zacks.com/stock/news/2214420/lisata-lsta-stock-up-more-than-35-in-3-months-heres-why,2024-01-23 17:12:00,"Lisata (LSTA) is progressing well with the development of its lead investigational product candidate, LSTA1, which targets several cancer indications.",REGN,0.272029,0.223923,Somewhat-Bullish
Mirum  ( MIRM )  Banks on Livmarli Sales Despite Recent Setback,https://www.zacks.com/stock/news/2214378/mirum-mirm-banks-on-livmarli-sales-despite-recent-setback,2024-01-23 16:44:00,"Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The company's efforts to expand the label of the drug are also encouraging. However, pipeline setback remains a concern.",REGN,0.208914,0.182071,Somewhat-Bullish
Gilead  ( GILD )  Down as NSCLC Study Fails to Meet Primary Goal,https://www.zacks.com/stock/news/2214367/gilead-gild-down-as-nsclc-study-fails-to-meet-primary-goal,2024-01-23 16:37:00,Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.,REGN,0.123526,0.085866,Neutral
"J&J's  ( JNJ )  Q4 Earnings Beat, Darzalex, Stelara Drive Sales",https://www.zacks.com/stock/news/2214342/jjs-jnj-q4-earnings-beat-darzalex-stelara-drive-sales,2024-01-23 16:03:00,"J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sales of several key drugs like Darzalex, Stelara and Tremfya beat estimates.",REGN,0.06623,0.067094,Neutral
What's Going On With Aclaris Therapeutics Stock Today? - Aclaris Therapeutics  ( NASDAQ:ACRS ) ,https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36723304/aclaris-therapeutics-ati-1777-faces-uphill-battle-in-atopic-dermatitis-treatment-la,2024-01-22 19:37:34,"HC Wainwright has downgraded Aclaris Therapeutics Inc ACRS. Earlier this month, the company released topline results from its Phase 2b study of ATI-1777, an investigational topical ""soft"" JAK 1/3 inhibitor, in patients with mild to severe atopic dermatitis ( eczema ) .",REGN,0.215894,0.358264,Bullish
Should You Add Marinus  ( MRNS )  Stock to Your Portfolio Now?,https://www.zacks.com/stock/news/2213480/should-you-add-marinus-mrns-stock-to-your-portfolio-now,2024-01-22 14:56:00,"Here, we discuss some reasons why investing in Marinus Pharmaceuticals' (MRNS) stock may turn out to be a prudent move.",REGN,0.148731,0.061665,Neutral
S&P 500 Index Hits All-Time High: 5 Must-Buy Stocks,https://www.zacks.com/stock/news/2213319/sp-500-index-hits-all-time-high-5-must-buy-stocks,2024-01-22 13:10:00,"We have narrowed our search to five S&P 500 stocks that have strong growth potential in 2024. These are: NVDA, REGN, ANET, IT, MLM.",REGN,0.142565,0.152506,Somewhat-Bullish
Edgewise Therapeutics Scores Relative Strength Rating Upgrade,https://www.investors.com/ibd-data-stories/edgewise-therapeutics-scores-relative-strength-rating-upgrade/,2024-01-22 08:00:00,"Edgewise Therapeutics ( EWTX ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Monday, with an upgrade from 88 to 97. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",REGN,0.374312,0.139473,Neutral
"USD 10.40 billion growth in Vascular Endothelial Market between 2022 and 2027, The strategic alliances and ... - PR Newswire",https://www.prnewswire.com/news-releases/usd-10-40-billion-growth-in-vascular-endothelial-market-between-2022-and-2027--the-strategic-alliances-and-collaborations-are-notably-driving-market-growth-17-000-technavio-research-reports-302039609.html,2024-01-22 04:35:00,"USD 10.40 billion growth in Vascular Endothelial Market between 2022 and 2027, The strategic alliances and ... PR ...",REGN,0.049939,0.083583,Neutral
2 Smart Growth Stocks to Buy Hand Over Fist in 2024,https://www.fool.com/investing/2024/01/21/2-smart-growth-stocks-to-buy-hand-over-fist/,2024-01-21 12:15:00,These businesses are on paths to extremely bright futures.,REGN,0.079,0.047636,Neutral
This Is What Whales Are Betting On Regeneron Pharmaceuticals - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/insights/options/24/01/36700984/this-is-what-whales-are-betting-on-regeneron-pharmaceuticals,2024-01-19 20:00:38,"Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals REGN. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.",REGN,0.731871,0.131413,Neutral
Mesoblast  ( MESO )  Up on Rare Pediatric Disease Tag for Heart Drug,https://www.zacks.com/stock/news/2212927/mesoblast-meso-up-on-rare-pediatric-disease-tag-for-heart-drug,2024-01-19 16:30:00,Mesoblast's (MESO) Revascor (rexlemestrocel-L) gets FDA's Rare Pediatric Disease designation for treating children with congenital heart disease. Shares rise in after-hours trading.,REGN,0.293214,0.235399,Somewhat-Bullish
Syros  ( SYRS )  Stock Surges 200% in 3 Months: Here's Why,https://www.zacks.com/stock/news/2212898/syros-syrs-stock-surges-200-in-3-months-heres-why,2024-01-19 15:43:00,"Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, targeting two different cancer indications.",REGN,0.276648,0.224951,Somewhat-Bullish
"The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker - Ansys  ( NASDAQ:ANSS ) , Advanced Micro Devices  ( NASDAQ:AMD ) ",https://www.benzinga.com/markets/equities/24/01/36685633/exclusive-the-buy-everything-market-is-over-synopsys-ansys-merger-provides-fertile-ground-for-th,2024-01-18 20:54:52,"The Federal Reserve is driving the market bus. Rate cut expectations have been re-drawn, and the ""buy everything"" sentiment that powered equity indices higher in the final quarter of 2023 is over. This is now a stock picker's market.",REGN,0.162802,0.114804,Neutral
Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83,https://www.investors.com/news/technology/ultragenyx-pharm-stock-earns-ibd-stock-upgrae-with-rs-rating-jump-to-83/,2024-01-18 19:41:00,"When building your watch list, look for stocks with an 80 or higher RS Rating. Ultragenyx Pharm ( RARE ) stock just cleared that benchmark with an upgrade from 75 to 83. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",REGN,0.306963,0.0,Neutral
Celularity Releases CEO Letter to Shareholders,https://www.globenewswire.com/news-release/2024/01/18/2811877/0/en/Celularity-Releases-CEO-Letter-to-Shareholders.html,2024-01-18 18:40:00,"FLORHAM PARK, N.J., Jan. 18, 2024 ( GLOBE NEWSWIRE ) -- Celularity Inc. ( Nasdaq: CELU ) has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Chairman, CEO, and Founder, which is included below and can also be accessed here.",REGN,0.027164,0.165451,Somewhat-Bullish
Instil  ( TIL )  Stock Rises More Than 20% in a Week: Here's Why,https://www.zacks.com/stock/news/2212365/instil-til-stock-rises-more-than-20-in-a-week-heres-why,2024-01-18 17:28:00,Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.,REGN,0.326283,0.25761,Somewhat-Bullish
"Novartis'  ( NVS )  Strong Portfolio, Pipeline to Fuel Growth in 2024",https://www.zacks.com/stock/news/2212312/novartis-nvs-strong-portfolio-pipeline-to-fuel-growth-in-2024,2024-01-18 17:11:00,"Novartis (NVS) is poised to outperform in 2024, backed by a diverse portfolio and a deep pipeline.",REGN,0.108222,0.067357,Neutral
Is it a Good Idea to Invest in Intellia  ( NTLA )  Stock Now?,https://www.zacks.com/stock/news/2212290/is-it-a-good-idea-to-invest-in-intellia-ntla-stock-now,2024-01-18 16:50:00,"Here, we discuss some reasons why investing in Intellia (NTLA) stock now may turn out to be a more prudent move than ever.",REGN,0.19117,0.311717,Somewhat-Bullish
Here's Why You Should Invest in Avadel  ( AVDL )  Stock Now,https://www.zacks.com/stock/news/2212231/heres-why-you-should-invest-in-avadel-avdl-stock-now,2024-01-18 15:35:00,"Here, we discuss some reasons why buying Avadel Pharmaceuticals (AVDL) stock now may turn out to be a prudent move.",REGN,0.158519,0.077285,Neutral
Buy These 4 Low-Beta Stocks to Counter Market Volatility,https://www.zacks.com/stock/news/2211917/buy-these-4-low-beta-stocks-to-counter-market-volatility,2024-01-18 12:36:00,"It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Otter Tail (OTTR), Regeneron (REGN), OraSure (OSUR) and BioMarin Pharmaceutical (BMRN) are well-poised to gain.",REGN,0.163909,0.234933,Somewhat-Bullish
89bio Shows Rising Relative Strength; Still Shy Of Key Threshold,https://www.investors.com/ibd-data-stories/89bio-shows-rising-relative-strength-still-shy-of-key-threshold/,2024-01-18 08:00:00,89bio Shows Rising Relative Strength. Still Shy Of Key Threshold Investor's Business Daily ...,REGN,0.348103,0.0,Neutral
Stock Upgrades: Ultragenyx Pharm Shows Rising Relative Strength,https://www.investors.com/ibd-data-stories/stock-upgrades-ultragenyx-pharm-shows-rising-relative-strength/,2024-01-18 08:00:00,"When building your watch list, look for stocks with an 80 or higher RS Rating. Ultragenyx Pharm ( RARE ) just cleared that benchmark with an upgrade from 75 to 83. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",REGN,0.343279,0.0,Neutral
Ironwood Pharm Cl A Reaches 80-Plus Relative Strength Rating Benchmark,https://www.investors.com/ibd-data-stories/ironwood-pharm-cl-a-reaches-80-plus-relative-strength-rating-benchmark/,2024-01-18 08:00:00,"The Relative Strength ( RS ) Rating for Ironwood Pharm Cl A ( IRWD ) entered a new percentile Thursday, with an increase from 79 to 86. X When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength.",REGN,0.329551,0.0,Neutral
Exelixis  ( EXEL )  Outperforms on Cabometyx and Pipeline Progress,https://www.zacks.com/stock/news/2211554/exelixis-exel-outperforms-on-cabometyx-and-pipeline-progress,2024-01-17 16:29:00,"Exelixis' (EXEL) lead drug, Cabometyx, maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.",REGN,0.108958,0.065325,Neutral
"Regeneron  ( REGN ) , Sanofi's Dupixent Gets Label Update in US",https://www.zacks.com/stock/news/2211552/regeneron-regn-sanofis-dupixent-gets-label-update-in-us,2024-01-17 16:21:00,The FDA updates Regeneron (REGN) and Sanofi's Dupixent label in the United States to include efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement.,REGN,0.108222,0.0,Neutral
Aclaris  ( ACRS )  Stock Rises on Appointment of New Interim CEO,https://www.zacks.com/stock/news/2211548/aclaris-acrs-stock-rises-on-appointment-of-new-interim-ceo,2024-01-17 16:14:00,"Aclaris (ACRS) appoints Neal Walker as interim CEO after current CEO, Douglas Manion, steps down from his role. Shares rise.",REGN,0.268294,0.2215,Somewhat-Bullish
Regeneron and Petco Health and Wellness have been highlighted as Zacks Bull and Bear of the Day,https://www.zacks.com/stock/news/2211296/regeneron-and-petco-health-and-wellness-have-been-highlighted-as-zacks-bull-and-bear-of-the-day,2024-01-17 13:18:00,"Chicago, IL - January 17, 2024 - Zacks Equity Research shares Regeneron Pharmaceuticals ( REGN Quick QuoteREGN - ) as the Bull of the Day and Petco Health and Wellness ( WOOF Quick QuoteWOOF - ) as the Bear of the Day.",REGN,0.12013,0.113842,Neutral
Bull of the Day: Regeneron Pharmaceuticals  ( REGN ) ,https://www.zacks.com/commentary/2211051/bull-of-the-day-regeneron-pharmaceuticals-regn,2024-01-17 09:30:00,The Biotechnology company enjoys a litany of bullish catalysts on the horizon ...,REGN,0.20698,0.231906,Somewhat-Bullish
Stocks With Rising Relative Price Strength: Apellis Pharmaceuticals,https://www.investors.com/ibd-data-stories/stocks-with-rising-relative-price-strength-apellis-pharmaceuticals-2/,2024-01-17 08:00:00,"Apellis Pharmaceuticals ( APLS ) saw a positive improvement to its Relative Strength ( RS ) Rating on Wednesday, with an increase from 84 to 92. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",REGN,0.345674,0.136121,Neutral
Stocks With Rising Relative Strength: Dynavax Technologies,https://www.investors.com/ibd-data-stories/stocks-with-rising-relative-strength-dynavax-technologies-2/,2024-01-17 08:00:00,"Dynavax Technologies ( DVAX ) had its Relative Strength ( RS ) Rating upgraded from 68 to 75 Wednesday -- a welcome improvement, but still short of the 80 or better score you look for. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",REGN,0.301315,0.0,Neutral
Roche's  ( RHHBY )  Tecentriq Subcutaneous Gets Approval in the EU,https://www.zacks.com/stock/news/2210990/roches-rhhby-tecentriq-subcutaneous-gets-approval-in-the-eu,2024-01-16 17:29:00,Roche's (RHHBY) subcutaneous formulation of immuno-oncology drug Tecentriq receives EC's approval for all approved indications.,REGN,0.130217,0.0,Neutral
Reasons to Add Blueprint  ( BPMC )  Stock to Your Portfolio Now,https://www.zacks.com/stock/news/2210923/reasons-to-add-blueprint-bpmc-stock-to-your-portfolio-now,2024-01-16 16:51:00,"Here, we discuss some reasons why investing in Blueprint (BPMC) stock now may turn out to be a more prudent move than ever.",REGN,0.211652,0.182292,Somewhat-Bullish
Basal Cell Carcinoma Treatment Market To Reach $10.7 Billion In 2028 At A CAGR Of More Than 9% As Per The Business Research Company's Basal Cell Carcinoma Treatment Global Market Report 2024,https://www.benzinga.com/pressreleases/24/01/g36645145/basal-cell-carcinoma-treatment-market-to-reach-10-7-billion-in-2028-at-a-cagr-of-more-than-9-as-pe,2024-01-16 16:30:00,"LONDON, Jan. 16, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Basal Cell Carcinoma Treatment Global Market Report 2024, the basal cell carcinoma treatment market is set to witness robust growth, expanding from $6.69 billion in 2023 to an estimated $7.42 billion in 2024, ...",REGN,0.05339,0.27599,Somewhat-Bullish
Dupixent®  ( dupilumab )  U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/24/01/g36636996/dupixent-dupilumab-u-s-label-updated-with-data-further-supporting-use-in-atopic-dermatitis-with-mo,2024-01-16 12:00:00,"TARRYTOWN, N.Y. and PARIS, Jan. 16, 2024 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. REGN and Sanofi today announced that the U.S.",REGN,0.054408,0.010001,Neutral
"Regeneron  ( REGN )  Q4 Earnings & Sales Top, Eylea Sales Decline",https://www.zacks.com/stock/news/2220525/regeneron-regn-q4-earnings-sales-top-eylea-sales-decline,2024-02-02 19:09:00,"Regeneron (REGN) beats earnings and sales estimates in fourth-quarter 2023, fueled by Dupixent. However, sales of the lead drug, Eylea, continue to fall.",REGN,0.229872,0.279897,Somewhat-Bullish
"Proliferative Diabetic Retinopathy Market Predicted to Grow at 8.5% CAGR, Reaching USD 5.2 billion by 2031: Transparency Market Research, Inc.",https://www.benzinga.com/pressreleases/24/02/g36914063/proliferative-diabetic-retinopathy-market-predicted-to-grow-at-8-5-cagr-reaching-usd-5-2-billion-b,2024-02-02 17:41:00,"Wilmington, Delaware, United States, Feb. 02, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The proliferative diabetic retinopathy market was valued at US$ 2.5 billion in 2022. A CAGR of 8.5% is expected between 2023 and 2031. The market is expected to reach US$ 5.2 billion by ...",REGN,0.070414,0.002017,Neutral
"Stocks Handle Huge Earnings, Fed, Jobs Report: Weekly Review",https://www.investors.com/news/stock-market-handles-huge-earnings-week-fed-powell-jobs-report-weekly-review/,2024-02-02 17:15:00,"Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review Investor's Business Daily ...",REGN,0.033236,-0.133526,Neutral
Why Is Regeneron Pharmaceuticals Stock Trading Higher Today? - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/general/biotech/24/02/36912319/why-is-sanofi-partner-regeneron-pharmaceuticals-stock-trading-higher-today,2024-02-02 16:08:14,"Regeneron Pharmaceuticals Inc REGN reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77. Revenues increased 1% to $3.43 billion, beating the consensus of $3.29 billion. Total revenues excluding Ronapreve ( COVID-19 treatment ) reached $3.44 billion, up 14% ...",REGN,0.366061,-0.056827,Neutral
The Two Surprising Sources Of Regeneron's Fourth-Quarter Beat,https://www.investors.com/news/technology/regn-stock-is-at-another-record-high-as-two-surprising-sources-drive-its-fourth-quarter-beat/,2024-02-02 14:13:00,REGN Stock Is At Another Record High As Two Surprising Sources Drive Its Fourth-Quarter Beat Investor's Business Daily ...,REGN,0.670742,0.181251,Somewhat-Bullish
"Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year - Invesco QQQ Trust, Series 1  ( NASDAQ:QQQ ) , SPDR S&P 500  ( ARCA:SPY ) ",https://www.benzinga.com/news/earnings/24/02/36907360/nasdaq-futures-climb-as-meta-amazon-gains-offset-apple-slide-analyst-points-to-2-factors-reinforcin,2024-02-02 12:24:06,"Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc. META, Amazon, Inc. AMZN, and Apple, Inc. AAPL. Earnings remain mixed, raising concerns about both the economy and corporate profit growth.",REGN,0.117486,0.0,Neutral
Bristol Myers Squibb results top expectations as newer drugs help fuel growth,https://www.marketwatch.com/story/bristol-myers-squibb-results-top-expectations-as-newer-drugs-help-fuel-growth-d8978299,2024-02-02 12:01:00,"Bristol Myers Squibb on Friday reported fourth-quarter results that beat analysts' expectations, helped by portfolio stalwarts as well as newer drugs.",REGN,0.188193,-0.02641,Neutral
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results,https://www.globenewswire.com/news-release/2024/02/02/2822727/0/en/Regeneron-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-and-Operating-Results.html,2024-02-02 11:30:00,"TARRYTOWN, N.Y., Feb. 02, 2024 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced financial results for the fourth quarter and full year 2023 and provided a business update.",REGN,0.044202,0.049492,Neutral
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma,https://www.globenewswire.com/news-release/2024/02/02/2822705/0/en/Linvoseltamab-Receives-EMA-Filing-Acceptance-for-Treatment-of-Relapsed-Refractory-Multiple-Myeloma.html,2024-02-02 11:00:00,"TARRYTOWN, N.Y., Feb. 02, 2024 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc. ( NASDAQ: REGN ) today announced that the European Medicines Agency ( EMA ) has accepted for review the Marketing Authorization Application ( MAA ) for linvoseltamab to treat adult patients with ...",REGN,0.097161,0.05891,Neutral
Two Titans Signal Strong End To Huge Week Of Earnings,https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-meta-amazon-fuel-techs-china-woes-hit-apple-jobs-report-looms/,2024-02-01 21:44:00,"Dow Jones Futures: Meta, Amazon Fuel Techs Late, China Woes Hit Apple. Jobs Report Looms Investor's Business Daily ...",REGN,0.061631,0.0,Neutral
"Biotech Stock Roundup: GSK's Q4 Results, VRTX Gains on Update, TSVT Up on REGN Deal",https://www.zacks.com/stock/news/2219523/biotech-stock-roundup-gsks-q4-results-vrtx-gains-on-update-tsvt-up-on-regn-deal,2024-02-01 14:45:00,Earnings from GSK and other updates from 2seventy bio (TSVT) were in focus in the biotech sector.,REGN,0.089462,0.174432,Somewhat-Bullish
Sanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't.,https://www.investors.com/news/technology/sanofi-stock-sanofi-earnings-q4-2023/,2024-02-01 13:50:00,Sanofi Stock Falls After Missing Fourth-Quarter Views Despite Dupixent Outperformance Investor's Business Daily ...,REGN,0.175221,-0.110807,Neutral
Is iShares Biotechnology ETF  ( IBB )  a Strong ETF Right Now?,https://www.zacks.com/stock/news/2219196/is-ishares-biotechnology-etf-ibb-a-strong-etf-right-now,2024-02-01 11:20:06,Smart Beta ETF report for ...,REGN,0.122894,0.06159,Neutral
Regeneron  ( REGN )  to Report Q4 Earnings: What's in the Cards?,https://www.zacks.com/stock/news/2218887/regeneron-regn-to-report-q4-earnings-whats-in-the-cards,2024-01-31 16:20:00,Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports its fourth-quarter 2023 results.,REGN,0.303175,0.274645,Somewhat-Bullish
"2seventy bio  ( TSVT )  Divests R&D Assets to Regeneron, Stock Up",https://www.zacks.com/stock/news/2218877/2seventy-bio-tsvt-divests-rd-assets-to-regeneron-stock-up,2024-01-31 16:11:00,2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.,REGN,0.205225,0.091365,Neutral
"Novartis  ( NVS )  Q4 Earnings Miss on Higher Costs, Sales Lag",https://www.zacks.com/stock/news/2218865/novartis-nvs-q4-earnings-miss-on-higher-costs-sales-lag,2024-01-31 15:48:00,Novartis' (NVS) earnings and sales miss estimates in the fourth quarter. The outlook for 2024 does not look promising as well.,REGN,0.123315,0.059389,Neutral
Stocks To Watch: Biomea Fusion Sees Relative Strength Rating Rise To 91,https://www.investors.com/ibd-data-stories/stocks-to-watch-biomea-fusion-sees-relative-strength-rating-rise-to-91/,2024-01-31 08:00:00,"When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is Biomea Fusion ( BMEA ) , which saw a positive improvement to its Relative Strength ( RS ) Rating on Wednesday, rising from 88 to 91.",REGN,0.310843,0.125315,Neutral
Regeneron Pharmaceuticals Unusual Options Activity For January 30 - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/insights/options/24/01/36852436/regeneron-pharmaceuticals-unusual-options-activity-for-january-30,2024-01-30 19:01:04,"Financial giants have made a conspicuous bearish move on Regeneron Pharmaceuticals. Our analysis of options history for Regeneron Pharmaceuticals REGN revealed 11 unusual trades. Delving into the details, we found 36% of traders were bullish, while 63% showed bearish tendencies.",REGN,0.636698,-0.236705,Somewhat-Bearish
"Pfizer  ( PFE )  Q4 Earnings Top, Revenues Miss on COVID Sales Slump",https://www.zacks.com/stock/news/2218064/pfizer-pfe-q4-earnings-top-revenues-miss-on-covid-sales-slump,2024-01-30 15:53:00,Pfizer (PFE) reports mixed fourth-quarter 2023 results. It re-affirms its 2024 sales and earnings guidance provided in December 2023.,REGN,0.051441,0.06656,Neutral
Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs - Regeneron Pharmaceuticals  ( NASDAQ:REGN ) ,https://www.benzinga.com/pressreleases/24/01/g36841055/regeneron-announces-formation-of-regeneron-cell-medicines-with-the-acquisition-of-2seventy-bio-pla,2024-01-30 12:00:41,"TARRYTOWN, N.Y., Jan. 30, 2024 ( GLOBE NEWSWIRE ) -- Regeneron Pharmaceuticals, Inc.",REGN,0.115453,0.063983,Neutral
Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs,https://www.globenewswire.com/news-release/2024/01/30/2819810/0/en/Regeneron-Announces-Formation-of-Regeneron-Cell-Medicines-with-the-Acquisition-of-2seventy-bio-Platforms-and-Preclinical-and-Clinical-Programs.html,2024-01-30 12:00:00,Regeneron to assume full development and commercialization rights for 2seventy bio's preclinical and clinical stage cell therapy pipeline Regeneron to assume full development and commercialization rights for 2seventy bio's preclinical and clinical stage cell therapy pipeline ...,REGN,0.117601,0.066876,Neutral
Stocks Flashing Renewed Technical Strength: CRISPR Therapeutics,https://www.investors.com/ibd-data-stories/stocks-flashing-renewed-technical-strength-crispr-therapeutics-4/,2024-01-30 08:00:00,"On Tuesday, CRISPR Therapeutics ( CRSP ) earned a positive adjustment to its Relative Strength ( RS ) Rating, from 89 to 93. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",REGN,0.329551,0.126618,Neutral
Stocks Generating Improved Relative Strength: Arrowhead Pharm,https://www.investors.com/ibd-data-stories/stocks-generating-improved-relative-strength-arrowhead-pharm-2/,2024-01-30 08:00:00,"The Relative Strength ( RS ) Rating for Arrowhead Pharm ( ARWR ) headed into a higher percentile Tuesday, as it got a lift from 69 to 79. X As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.",REGN,0.327366,0.0,Neutral
Stock Upgrades: Apellis Pharmaceuticals Shows Rising Relative Strength,https://www.investors.com/ibd-data-stories/stock-upgrades-apellis-pharmaceuticals-shows-rising-relative-strength-5/,2024-01-30 08:00:00,"When looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is Apellis Pharmaceuticals ( APLS ) , which saw a welcome improvement to its Relative Strength ( RS ) Rating on Tuesday, with an upgrade from 90 to 93.",REGN,0.31282,0.121543,Neutral
Stocks Showing Improved Relative Strength: Cassava Sciences,https://www.investors.com/ibd-data-stories/stocks-showing-improved-relative-strength-cassava-sciences/,2024-01-30 08:00:00,"The Relative Strength ( RS ) Rating for Cassava Sciences ( SAVA ) headed into a higher percentile Tuesday, as it got a lift from 61 to 74. When looking for the best stocks to buy and watch, keep a close on eye on relative price strength.",REGN,0.308891,0.0,Neutral
5 U.S. Corporate Giants to Buy on Solid Economic Data,https://www.zacks.com/stock/news/2216913/5-us-corporate-giants-to-buy-on-solid-economic-data,2024-01-29 13:22:00,"We have narrowed our search to five U.S. corporate giants that have strong potential for 2024. These are: NFLX, PGR, BK, ANET, REGN.",REGN,0.132004,0.146333,Neutral
Will New Drugs Drive Pfizer  ( PFE )  Sales in Q4 Earnings?,https://www.zacks.com/stock/news/2216911/will-new-drugs-drive-pfizer-pfe-sales-in-q4-earnings,2024-01-29 13:22:00,"Investor focus is likely to be on the sales numbers of Pfizer's (PFE) several newly launched drugs like Abrysvo, Velsipity, Penbraya as well as newly acquired products like Nurtec and Oxbryta on the fourth-quarter earnings call.",REGN,0.103554,0.071798,Neutral
"Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? - SPDR S&P 500  ( ARCA:SPY ) ",https://www.benzinga.com/news/earnings/24/01/36820476/tech-titans-microsoft-apple-lead-magnificent-seven-earnings-wave-this-week-can-mega-caps-ignite-mar,2024-01-29 10:51:00,"The past week's earnings were bordering on the negative, impacting trader sentiment, and the focus now shifts to the unfolding week that would see the release of a slew of tech earnings reports. The Week That Was: Tesla, Inc. TSLA, Intel, Inc. INTC, and Texas Instruments, Inc.",REGN,0.086713,0.0,Neutral
Stocks Showing Market Leadership: Avidity Biosciences Earns 95 RS Rating,https://www.investors.com/ibd-data-stories/stocks-showing-market-leadership-avidity-biosciences-earns-95-rs-rating/,2024-01-29 08:00:00,"On Monday, Avidity Biosciences ( RNA ) earned a positive adjustment to its Relative Strength ( RS ) Rating, from 86 to 95. X When looking for the best stocks to buy and watch, keep a close on eye on relative price strength.",REGN,0.331765,0.127279,Neutral
This week will make it clearer if the Fed will cut interest rates in March | Business,https://www.cnn.com/2024/01/28/business/stocks-week-ahead-economic-data-march-cut-fed/index.html,2024-01-28 12:30:00,This week will make it clearer if the Fed will cut interest rates in March ...,REGN,0.023169,0.039643,Neutral
3 Magnificent Stocks to Buy and Hold Forever,https://www.fool.com/investing/2024/01/27/3-magnificent-stocks-to-buy-and-hold-forever/,2024-01-27 12:54:00,Many investors will want to consider owning these stocks for a long time.,REGN,0.126784,0.228318,Somewhat-Bullish
Biomea Fusion Shows Rising Price Performance With Jump To 87 RS Rating,https://www.investors.com/ibd-data-stories/biomea-fusion-shows-rising-price-performance-with-jump-to-87-rs-rating/,2024-01-26 08:00:00,"On Friday, Biomea Fusion ( BMEA ) got a positive adjustment to its Relative Strength ( RS ) Rating, from 77 to 87. X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",REGN,0.374312,0.0,Neutral
Structure Therap ADR Shows Improved Relative Strength; Still Shy Of Benchmark,https://www.investors.com/ibd-data-stories/structure-therap-adr-shows-improved-relative-strength-still-shy-of-benchmark/,2024-01-26 08:00:00,Structure Therap ADR Shows Improved Relative Strength. Still Shy Of Benchmark Investor's Business Daily ...,REGN,0.31482,0.0,Neutral
Harmony Biosciences Earns RS Rating Upgrade,https://www.investors.com/ibd-data-stories/harmony-biosciences-earns-rs-rating-upgrade/,2024-01-26 08:00:00,"On Friday, Harmony Biosciences ( HRMY ) received an upgrade to its Relative Strength ( RS ) Rating, from 70 to 73. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.",REGN,0.310843,0.0,Neutral
